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Abstract 
Aerobic glycolysis is an inefficient metabolic phenotype displayed by many rapidly 
proliferating cells during growth. It is characterized by high glycolytic activity and only 
partial oxidation of glucose resulting in the production of high amounts of lactate. This 
phenotype was originally reported by Otto Warburg in 1927 as a hallmark of cancer and – 
while it is now known to occur in other fast growing cells as well – it remains an interesting 
target for cancer therapy. Aerobic glycolysis also has major implications for 
biopharmaceutical production, since lactate accumulation can be growth inhibiting, limiting 
the cell density that can be achieved in culture.  
Due to its association with various diseases and being an unfavorable metabolic 
phenotype in industrial applications, reducing the Warburg effect and analyzing 
accompanying effects on the cell as a whole are of great interest. Whereas in cancer 
therapy the objective is to kill cells relying on aerobic glycolysis, the aim in industrial 
applications is to reduce aerobic glycolysis without inducing cell death or inhibiting cell 
growth. Pyruvate dehydrogenase complex (PDC) is a mitochondrial gatekeeping enzyme 
determining how much pyruvate is converted to acetyl-CoA and subsequently enters the 
TCA cycle. PDC activity is regulated by reversible phosphorylation catalyzed by pyruvate 
dehydrogenase kinase (PDK) (phosphorylation → inactivation) and pyruvate 
dehydrogenase phosphatase (dephosphorylation → activation). PDC activity can be 
increased by inhibiting PDK using dichloroacetate (DCA) a known PDK inhibitor, hereby 
reducing aerobic glycolysis.  
The objective in this thesis was twofold; i) analyzing metabolic as well as growth inhibitory 
effects of DCA in human embryonic kidney 293 (HEK293) cells, and ii) investigating the 
effects of a non growth inhibiting DCA concentration using Chinese hamster ovary (CHO) 
cells in industrial relevant bioprocesses. In both studies aerobic glycolysis decreased with 
increasing DCA concentration characterized by reduced glucose consumption and lactate 
production. At lower DCA concentrations cell growth was unaffected. Furthermore, no 
increase in oxidative metabolism was detected at low DCA concentration indicating that 
the cells adopt a more energy efficient metabolism without directing more pyruvate into the 
TCA cycle. However, it appears that the cytoplasmic pyruvate fraction is reduced as not 
only less lactate but also less alanine is produced. The metabolic changes observed were 
mostly attributable to post-translational regulation since transcriptomics and proteomics 
analyses revealed only minor changes to metabolic enzymes. However, in the absence of 
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increased TCA cycle activity, allosteric regulation of glycolytic enzymes did not readily 
explain reduced glycolysis.  
Cell growth in HEK293 cells was reduced only at higher DCA concentration when 
increased cellular stress and TCA cycle activity were detected. Since DCA was found to 
depolarize mitochondria the increased TCA cycle activity may not result in higher ATP 
production and in fact the ATP yield may be insufficient leading to a “metabolic crisis” and 
reduced cell growth. Additionally, in the HEK293 study asparagine synthetase (ASNS) 
activity, amino acid transporter gene expression and mitochondrial one-carbon metabolism 
were increased in DCA cultures. Increased ASNS activity and one-carbon metabolism 
have been linked to various human diseases including cancer. However, further 
investigations are necessary to explain the upregulation of these reactions during 
increased PDC activity.  
With regard to industrial applications, reduced aerobic glycolysis induced by DCA led to 
longer cultivation periods and higher final antibody titers in CHO cell cultures due to lower 
lactate accumulation and slower increase in osmolality. Cell specific productivity and 
antibody quality in terms of charge variants, aggregation and glycan pattern were 
unaffected by DCA.  
In summary, we investigated the effects of increased PDC activity induced by DCA with 
regard to metabolic effects and growth inhibition. At lower DCA concentration the cells 
appear to have a more energy efficient metabolism and reduced aerobic glycolysis proved 
to be beneficial for culture performance and antibody production. However, the exact 
mechanisms leading to growth inhibition caused by DCA remain to be further investigated.  
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TWEAK TNF-Related Weak Inducer of Apoptosis  
UDPG UDP-glucose  
UDPGA  UDP-glucuronic acid  
UDPNAG UDP N-acetylglucosamine  
UPR  Unfolded protein response  
VCD  Viable cell density  
v/v Volume per volume 
w/v  Weight per volume  
XL99-Ab2 Chinese hamster ovary cell line producing IgG antibody Ab2 
Y  Yield  
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1.1. Mammalian cell metabolism and the Warburg effect 
Mammalian cell metabolism is highly structured, comprising of many pathways which are 
interlinked. Although strongly regulated mammalian metabolism provides the cell with a 
flexible metabolic structure to adapt to various energetic and biosynthetic demands and 
environmental conditions. The central metabolic pathways consist of glycolysis, pentose 
phosphate pathway, tricarboxylic acid (TCA) cycle, oxidative phosphorylation, 
glutaminolysis and metabolism of other amino acids. For  energy generation in form of 
ATP, mammalian cells mainly rely on glycolysis and TCA cycle. Both pathways are 
spatially separated; glycolysis taking place in the cytosol while the TCA cycle is located in 
the mitochondrion; and are connected via the pyruvate dehydrogenase complex (PDC). 
The metabolic phenotype is determined by a variety of factors, one major determinant 
being oxygen availability. Mammalian cells either use glycolysis and TCA cycle with 
oxidative phosphorylation or mainly rely on glycolysis. If oxygen supply is sufficient, normal 
cells use glycolysis, TCA cycle and oxidative phosphorylation. In hypoxic conditions, 
oxygen as the final electron acceptor during oxidative phosphorylation is not available. 
Cells cannot use the TCA cycle but rely on glycolysis alone for ATP generation converting 
the glycolytic end-product, pyruvate, into lactate. During anaerobic glycolysis, less ATP per 
molecule glucose is produced and cells usually show a higher glycolytic rate to 
compensate for the lower energy yield. A third metabolic phenotype is aerobic glycolysis, 
also known as the Warburg effect. Cells performing aerobic glycolysis mostly rely on 
glycolysis and only little TCA cycle and oxidative phosphorylation are performed despite 
the presence of sufficient oxygen (Warburg, Wind & Negelein 1927). Similar to cells using 
anaerobic glycolysis a higher glycolytic rate and high lactate production are observed in 
these cells. Despite the fact that this metabolic phenotype is energy inefficient, many rapid 
proliferating cell types including many cancer cells, cells of embryonic tissue and cells 
used as production hosts in industrial applications prefer aerobic glycolysis, indicating that 
their similar metabolic and biosynthetic demands play a role (Hanahan & Weinberg 2011). 
At the same time, aerobic glycolysis has been associated to other congenital and age-
related diseases in humans, such as congenital lactic acidosis or type-2 diabetes mellitus, 
and has been linked to impaired PDC activity (Stacpoole 2012). Due to its association with 
several diseases and being an unfavorable metabolic phenotype for industrial applications, 
reducing the Warburg effect and analyzing accompanying effects on the cell as a whole 
are of great interest. 
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Approaches to reduce the Warburg effect include reduction of glucose uptake, decrease of 
glycolytic rate as well as increase of pyruvate to acetyl-CoA conversion, latter being used 
in this work. PDC is the link between glycolysis and TCA cycle and its function plays a 
crucial role for the metabolism as it determines how much pyruvate enters the TCA cycle. 
PDC comprises of three components in multiple copies, pyruvate dehydrogenase (E1), 
dihydrolipoamide acetyltransferase (E2), and dihydrolipoamide dehydrogenase (E3), and 
is only active if unphosphorylated at three specific serine residues of E1-α subunit (Sale & 
Randle 1981; Teague et al. 1979; Yeaman et al. 1978). Phosphorylation (inactivation) and 
dephosphorylation (activation) are catalyzed by two enzymes, pyruvate dehydrogenase 
kinase (PDK) and pyruvate phosphatase, respectively.  
Here, we use dichloroacetate (DCA), a known PDK inhibitor (Whitehouse, Cooper & 
Randle 1974), to indirectly increase PDC activity and hereby reduce the Warburg effect in 
two mammalian cell lines. First, the effects of increased PDC activity on culture 
performance and antibody production were explored using Chinese hamster ovary cells, 
the predominant cell line in industrial applications (Chapter 4). This was followed by 
investigations using human embryonic kidney 293 (HEK293) cells, as an example of a 
human cell line. DCA was found to have growth inhibitory and apoptotic effects on some 
cancer cells and has been investigated as a potential anti cancer drug. Using HEK293 
cells the system wide effects of different DCA concentrations, metabolic effect with and 
without growth inhibition, were analyzed (Chapter 5). A systems biology approach was 
used to investigate the cellular changes during increased PDC activity using multiple 
omics technologies. A detailed literature review is provided in Chapter 2.  
1.2. Systems biology 
Cellular change in response to increased PDC activity can be at various functional levels 
(genes expression, protein abundance, or metabolite concentrations) and in order to 
investigate these changes various omics technologies (transcriptomics, proteomics, 
metabolomics, and fluxomics) can be used to obtain a detailed knowledge of the cell. 
Omics measurements and combining multiple omics technologies offer valuable 
information about the cell. Changes in transcriptome or proteome are not always reflected 
in the metabolic phenotype due to post-transcriptional or post-translational modifications 
as well as involvement of other regulators and degradation processes. Metabolite 
concentration and metabolic flux analysis are closer to the actual phenotype. However, 
changes in metabolite concentration may be the result of different metabolic activities and 
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transcriptomics and proteomics may be necessary to identify the corresponding enzyme 
activity. Therefore, the combination of transcriptomics and proteomics with metabolomics 
and fluxomics gives detailed information about the cell as a whole. 
Transcriptomics is readily available for human cells, capable of measuring the complete 
set of RNAs. Similarly, proteomics analysis is well established for human cells. The 
release of the CHO cell genome in 2011 (Xu et al. 2011) provides the option to perform 
transcriptomics as well as proteomics analysis of CHO cell lines. Additionally, protocols for 
analysis of intracellular metabolite concentrations are available. Finally, metabolic flux 
analysis (MFA) can be used to estimate fluxes through central metabolic pathways on the 
basis of limited number of extracellular measurements.  
Conventional MFA assumes a metabolic steady state, where intracellular fluxes are 
constant over time, and an average metabolic phenotype is estimated. This assumption 
though is only valid during mid exponential growth phase in batch cultures or continuous 
cultivations. In order to estimate intracellular fluxes over a complete cultivation or when 
variations in culture conditions occur, dynamic MFA (DMFA) approaches are necessary. 
An improved DMFA was developed based on current DMFA approaches by using B-
splines performing higher order fit (B-DMFA, Chapter 3) and was subsequently used to 
calculate metabolic fluxes in a temperature shift experiment (Chapter 3) and in CHO cell 
cultures treated with DCA (Chapter 4).A temperature shift experiment was used as it 
provides a readily available tool to generate the required cell culture and metabolic data 
with changing metabolic rates needed to develop B-DMFA. Furthermore, mild hypothermia 
is widely used in industry to reduce the negative effects of the Warburg effect by reducing 
metabolic activity and therefore accumulation of toxic metabolites and increase of 
osmolality.  
When specific enzyme activities in mammalian cells are investigated, genetic engineering 
is typically used to alter gene expression. The transfection is generally followed by 
selection for cells that have the introduced genomic modification. Genetic engineering can 
be time consuming and the clone obtained after single cell selection may not only have the 
desired genomic change but also may have other changes that were unknowingly selected 
(Dietmair et al. 2012). The obtained data from omics analysis would then not only give 
information about the effects of the intended but also of the unintentionally selected 
genomic modifications. In order to avoid this problem, either a cell line with an inducible 
expression system (Appendix H) can be generated or molecules that inhibit specific 
enzyme activity (if enzyme inhibition is pursued) can be used. Here, PDC activity was 
increased by using the small molecule PDK inhibitor DCA (Chapter 4 and 5).  
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1.3. Aims of this project 
1. Develop dynamic metabolic flux analysis using B-splines to estimate metabolic 
fluxes in dynamic cell cultures and analysis of temperature shifted cultures 
compared to cultures maintained at a constant temperature (Chapter 3) 
2. Analysis of increased PDC activity induced by DCA in CHO cells and its effect on 
culture performance and antibody production (Chapter 4) 
3. Analysis of increased PDC activity induced by DCA in HEK293F cells at a cellular 
system level using different DCA concentrations (Chapter 5) 
Chapter 2 provides a detailed literature review covering aerobic glycolysis, PDC and DCA. 
A contribution derived from research conducted during this thesis is the generation of a 
cell line with an inducible expression system as described in appendix H. However, this 
cell line was ultimately not used in the main investigations as DCA provided an easy and 
simple means to increase PDC activity. The cell line was subsequently used to investigate 
the effect of resistin-like molecule beta overexpression on glucose consumption in 
HEK293 cells. 
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2.1. Mammalian cell central metabolism and ATP generation 
Mammalian cell metabolism is highly complex and main metabolic pathways cannot be 
considered independent but rather as part of a complex and flexible structure. Additionally, 
mammalian cells are compartmentalized, particularly the cytosol and mitochondrion. The 
flexible network of metabolic pathways allows mammalian cells to adapt their metabolism 
to certain environmental conditions such as variations in nutrient or oxygen availability. 
The central metabolic pathways comprise of glycolysis, tricarboxylic acid (TCA) cycle, 
oxidative phosphorylation, pentose phosphate pathway (PPP), glutaminolysis and 
metabolism of other amino acids.  
The displayed metabolic phenotype of mammalian cells is the combined result of different 
factors including, nutrient availability, nutrient transport, particularly glucose and glutamine 
into the cell, glycolysis, glutaminolysis, TCA cycle, oxidative phosphorylation, generation of 
cellular energy and regeneration of reducing power as well as metabolic flexibility of the 
cell and compartmentalization including further transport steps. The extracellular 
environment is also crucial with regard to altered metabolic phenotypes as many transport 
processes are concentration dependent.  
In terms of energy generation in the form of ATP, glycolysis and TCA cycle are the two 
main sources. In glycolysis glucose is metabolized to pyruvate which can be further 
converted to CO2 in the TCA cycle. Under aerobic conditions, mammalian cells use both 
glycolysis and TCA cycle for ATP generation while under anaerobic conditions the final 
electron acceptor during oxidative phosphorylation, oxygen, is not available and cells only 
use glycolysis and convert the glycolytic derived pyruvate into lactate. This is usually 
characterized by an increased glycolytic rate as more ATP needs to be derived from 
glycolytic pathway alone. However, even under conditions of sufficient oxygen availability, 
some cells prefer to convert pyruvate to lactate over using TCA cycle and oxidative 
phosphorylation. This metabolic phenotype is called aerobic glycolysis, was first observed 
by Otto Warburg, and is also known as the Warburg effect today (Warburg, Wind & 
Negelein 1927).   
In this work we focused on glycolysis and TCA cycle as well as the connection between 
these two pathways with particular emphasis on aerobic glycolysis and possible 
approaches to reduce aerobic glycolysis in mammalian cells. 
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2.1.1. Glycolysis 
The glucose metabolism is highly regulated, not only by activity of glycolytic enzymes but 
also the glucose transport across the cell membrane. Uptake of glucose is achieved by 
means of transport proteins (GLUT1, GLUT2, GLUT3, GLUT4, GLUT5, GLUT7) located in 
the cytoplasmic membrane as it is otherwise impermeable for polar molecules such as 
glucose. In most mammalian cells the glucose transport is a bidirectional diffusion driven 
by the concentration gradient across the cell membrane. Normally, the transport takes 
place in the uptake direction as free intracellular glucose concentrations are low due to 
rapid phosphorylation by hexokinases.  
Once glucose is phosphorylated to glucose 6-phosphate it is further converted in three 
pathways: glycolysis, glycogen synthesis and PPP. In the main pathway glycolysis, 
glucose is converted to pyruvate via several intermediates some of which are also used for 
other biosynthetic pathways. Additionally, two ATP molecules and two NADH molecules 
are generated. Glucose 6-phosphate is also used for glycogen synthesis and can enter the 
PPP. In the PPP, NADPH molecules are generated required for cell anabolism and ribose 
5-phosphate molecules for nucleic acid synthesis. Alternatively, ribose 5-phosphate can be 
converted to fructose 6-phosphate and glyceraldehyde 3-phosphate, both intermediates of 
glycolysis, providing metabolic flexibility in order to balance fluxes through these pathways. 
Fructose 6-phosphate itself is also required for amino sugar compound synthesis. Other 
glycolytic intermediates needed as precursors for biosynthesis are dihydroxyacetone-
phosphate used for lipid synthesis via glycerol 3-phosphate and glycerate 3-phosphate 
used for serine and glycine synthesis.  
Glycolytic enzyme abundance and activity are crucial for overall glycolytic activity. 
Allosteric regulation of glycolysis plays an important role for fast modulation of the 
glycolytic rate; the three regulatory enzymes being hexokinase (HK), phosphofructokinase 
(PFK), and pyruvate kinase (PK). HK catalyzes the first glycolytic reaction from glucose to 
glucose 6-phosphate consuming ATP and it is allosterically inhibited by its product glucose 
6-phosphate (Regen et al. 1964). However, glucose 6-phosphate can also be generated 
from glycogen. Therefore, PFK rather than HK is considered the major regulatory glycolytic 
enzyme. PFK is also ATP-dependent and converts fructose 6-phosphate to fructose 1,6-
bisphosphate. It is activated by AMP, ADP, and fructose 2,6-bisphosphate, while ATP and 
citrate are allosteric inhibitors reducing glycolytic rate when sufficient ATP or citrate for 
oxidation in TCA cycle are available (Costa Leite et al. 2007; Marinho-Carvalho et al. 
2009; Zancan et al. 2007; Zancan et al. 2008). PK catalyzes the last step in glycolysis from 
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phosphoenolpyruvate to pyruvate producing ATP. It is activated by fructose 1,6-
bisphosphate (PFK product) and inhibited by ATP, acetyl coenzyme A (acetyl-CoA) and 
alanine (Bailey, Stirpe & Taylor 1968; Tanaka et al. 1967; Weber 1969; Weber, Lea & 
Stamm 1967). 
2.1.2. TCA cycle and oxidative phosphorylation 
The TCA cycle has two main functions: it generates most of the metabolic energy in form 
of ATP and provides precursors for cell anabolism. It is spatially separated from the 
glycolysis as it takes place in the mitochondria and also plays a role in balancing the rate 
of glycolysis and glutaminolysis. TCA cycle and glycolysis are connected via pyruvate 
which is transported into the mitochondria and further converted to acetyl-CoA. Only part 
of the pyruvate enters the mitochondria as pyruvate is also converted to lactate, alanine, 
oxoglutarate and malate in the cytosol. On the other hand, acetyl-CoA can also be partially 
generated from amino acids tyrosine, leucine, isoleucine and lysine. The percentage of 
pyruvate entering the mitochondria reported in literature are quite different ranging from 
very low values (Fitzpatrick, Jenkins & Butler 1993; Neermann & Wagner 1996; Petch & 
Butler 1994), even less than 1%, to up to 40% (Sharfstein et al. 1994). The acetyl-CoA 
then reacts with oxaloacetate to citrate which can either be converted to isocitrate via 
aconitate or leave the mitochondria to be used for lipid formation with concomitant 
pyruvate production in the cytosol. If inflow of pyruvate into mitochondria is low and outflow 
of citrate is high, the TCA cycle can become depleted. In order to maintain the energy 
generation function of the TCA cycle it must be replenished which is done at the level of α-
ketoglutarate using glutamine. Glutamine is converted to glutamate, generating ammonia, 
and further to α-ketoglutarate in the mitochondria. Therefore, glutamine’s main function is 
to supply TCA cycle intermediates explaining the importance of this compound as a main 
carbon and energy source. Similar to glycolysis, several other TCA cycle intermediates are 
connected to other pathways. Oxaloacetate is also used for the synthesis of aspartate and 
asparagine. On the other hand, several amino acids can contribute to the TCA cycle. 
There can be inflow in form of succinyl-CoA derived from degradation of isoleucine, 
threonine, valine and methionine. Similarly, degradation of leucine and tyrosine to 
succinate can contribute to the TCA cycle as well. At the level of malate there is an 
important outflow to relieve any malate in excess from the cycle necessary to balance the 
fluxes within the TCA cycle. Malate is transported into the cytosol and converted to 
pyruvate. The NADH generated in the TCA cycle is used by the respiratory system located 
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in the internal mitochondrial membrane to produce ATP. NADH molecules are oxidized 
with oxygen being the final electron acceptor making sufficient oxygen availability essential 
for oxidative phosphorylation to take place. 
Post-translational modulation of the TCA cycle is mainly determined by substrate 
availability and product inhibition. Availability of acetyl-CoA, citrate, and oxaloacetate as 
well as NAD+/NADH ratio are important for TCA cycle regulation. NADH is the product of 
all dehydrogenases (except succinate dehydrogenase) and inhibits isocitrate 
dehydrogenase, α-ketoglutarate dehydrogenase, and citrate synthase, thereby reducing 
TCA cycle rate. Furthermore, α-ketoglutarate dehydrogenase is inhibited by its product 
succinyl-CoA. Succinyl-CoA also inhibits citrate synthase. Additionally, ATP downregulates 
α-ketoglutarate dehydrogenase activity, thereby reducing TCA cycle activity when 
sufficient energy is available (reviewed in (Williamson & Cooper 1980)). 
2.1.3. Pyruvate dehydrogenase complex: connecting glycolysis and TCA cycle 
Glucose utilization is highly regulated at several levels. This includes glucose uptake, 
glycolytic rate and entry of pyruvate into the TCA cycle in form of acetyl-CoA (Sugden, MC 
& Holness 2006). Pyruvate dehydrogenase complex (PDC) links glycolysis to the TCA 
cycle and is a multi-enzyme complex situated in the inner mitochondrial membrane 
catalyzing the irreversible oxidation of pyruvate to acetyl-CoA, CO2 and NADH. There is no 
pathway in mammalian cells for the conversion of acetyl-CoA to pyruvate making PDC a 
key enzyme for the conversion of glucose to acetyl-CoA. Under aerobic conditions, activity 
of PDC is rate limiting for the oxidation of glucose and for metabolites, such as lactate and 
alanine, which are in equilibrium with pyruvate (Stacpoole et al. 1998). PDC also indirectly 
regulates the ATP yield from glucose by regulating the entry of acetyl-CoA into the TCA 
cycle, it controls the amount of malonyl-CoA available for fatty acid synthesis and plays an 
important role in the process of fuel selection in connection with the glucose fatty-acid 
cycle (Hue & Taegtmeyer 2009; Randle et al. 1963; Sugden, MC & Holness 2006). 
PDC consists of three components in multiple copies, pyruvate dehydrogenase (E1), 
dihydrolipoamide acetyltransferase (E2), and dihydrolipoamide dehydrogenase (E3). The 
E1 component is a heterotetramer of two alpha and two beta subunits (α2β2). PDC is only 
active if unphosphorylated at three serine residues of E1α, serine-293 (phosphorylation 
site 1), serine-300 (phosphorylation site 2), and serine-232 (phosphorylation site 3), 
catalyzed by pyruvate dehydrogenase phosphatases (PDP) (Sale & Randle 1981; Teague 
et al. 1979; Yeaman et al. 1978). Pyruvate dehydrogenase kinases (PDKs) phosphorylate 
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PDC at these three serine residues and thereby inactivate PDC (Figure 2.1). PDP and 
PDK are the two enzymes that regulate PDC activity post-transcriptionally and each PDC 
complex contains two or three PDKs and PDPs that are tightly bound to E2 (Linn et al. 
1972; Yang et al. 1998). PDC does not exist in a completely dephosphorylated (active) or 
phosphorylated (inactive) form but rather the relative activities of PDKs and PDPs 
determine the level of phosphorylation and therefore activity of PDC. Hence, changes in 
PDC phosphorylation and thereby its activity are determined by changes in PDK activity 
relative to PDP activity. PDKs phosphorylate the three serine residues however 
phosphorylation of any one site is sufficient to cause inactivation (Sugden, PH & Randle 
1978). Phosphorylation rate of the sites differ with phosphorylation of site 1 being the 
fastest and phosphorylation of site 3 being the slowest (Korotchkina & Patel 1995; Sale & 
Randle 1981). Therefore, phosphorylation of site 1 appears to be more important for acute 
modulation according to metabolic demands. In contrast, rates of dephosphorylation were 
nearly identical for all sites indicating a random mechanism of dephosphorylation 
(Korotchkina & Patel 1995). 
 
 
Figure 2.1: Regulation of pyruvate dehydrogenase complex (PDC) activity. PDC activity is regulated by 
pyruvate dehydrogenase kinases (PDKs) and pyruvate dehydrogenase phosphatases (PDPs). PDK activity 
is regulated by various factors and compounds; activators shown in green box and inhibitors shown in red 
box. The three phosphorylation sites are indicated by P1, P2 and P3. (Figure adapted from (Jeoung & Harris 
2008)). 
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Four PDK isozymes have been identified in humans and rodents (PDK1, PDK2, PDK3, 
and PDK4) (Bowker-Kinley et al. 1998; Popov, Hawes & Harris 1997). Different PDKs are 
expressed in a tissue specific manner and not all PDKs are able to phosphorylate each of 
the three serine residues. All PDKs phosphorylate site 1 and 2 of E1α whereas site 3 is 
only phosphorylated by PDK1 (Kolobova et al. 2001; Korotchkina & Patel 2001). PDK2 is 
the most widely distributed PDK with high expression levels in liver, heart and kidney 
(Bowker-Kinley et al. 1998). PDK4 is also expressed in heart, kidney, oxidative skeletal 
muscle and liver (Bowker-Kinley et al. 1998; Sugden, MC et al. 2001; Sugden, MC, 
Langdown, et al. 2000; Wu, P et al. 1999; Wu, P et al. 1997; Wu et al. 2000). PDK1 and 
PDK3 are less distributed (Bowker-Kinley et al. 1998; Huang et al. 1998; Peters et al. 
2001; Sugden, MC et al. 2001; Wu, F et al. 1997).  
All four PDKs are transcriptionally regulated with PDK1 and PDK3 stimulated by Hypoxia-
inducible factor 1-alpha (HIF1α) which is induced by low oxygen concentrations and often 
upregulated in cancer cells (Kim, JW et al. 2006; Lu et al. 2008; Papandreou et al. 2006) 
while PDK2 and PDK4 expression is controlled mostly by nutritional factors and hormones. 
Starvation, diabetes, fatty acids and glucocorticoids promote PDK activity (Abbot et al. 
2005; Peters et al. 2001; Sugden, MC, Kraus, et al. 2000; Wu, P et al. 1999; Wu, P et al. 
1997; Wu et al. 2000). The products of PDC (acetyl-CoA, NADH) increase PDK activity 
whereas PDC substrates (pyruvate, NAD+, ADP, and CoA) inhibit PDK (Jeoung & Harris 
2008; Roche & Hiromasa 2007). A high NADH/NAD+ ratio and a high acetyl-CoA/CoA 
ratio, both caused by fatty acid oxidation, reduce the lipoyl moieties of E2 and promote 
acetylation of the reduced lipoyl moieties, respectively. Binding of PDK to an E2 lipoyl 
domain in which the lipoyl group is reduced and acetylated results in maximum PDK 
activity (Baker et al. 2000). PDKs are also inhibited by insulin, lipoic acid and 
dichloroacetate. PDKs and PDPs have a unique tissue dependent expression, different 
kinetic properties and sensitivities to regulatory molecules.  
PDC has a crucial function in cell metabolism. Decreased PDC activity reduces glucose 
carbon flux into the TCA cycle and is linked to various age-related diseases such as 
glucose intolerance (Stacpoole, Moore & Kornhauser 1978), heart failure (Bersin & 
Stacpoole 1997), neurodegeneration (Stacpoole 1997), and cancer (reviewed in 
(Stacpoole 2012). An age-related decrease in glucose oxidation and oxygen consumption 
was observed in the brain (Kalpouzos et al. 2009; Martin et al. 1991) together with 
increased ketone body formation and aerobic glycolysis (Ross et al. 2010; Yao et al. 
2010). Many neurodegenerative diseases, such as Alzheimer’s disease, are associated 
with abnormal brain oxidative metabolism and data implicate up-regulated aerobic 
13 
 
glycolysis and reduced PDC activity (reviewed in (Coskun et al. 2012; Green, Galluzzi & 
Kroemer 2011). A decline in PDC activity may also contribute to the development of type 2 
diabetes mellitus and increasing PDC activity in patients had a glucose and lactate 
lowering effect (Stacpoole, Moore & Kornhauser 1978). Additionally, many cancer cells 
mostly rely on aerobic glycolysis for energy generation (Gatenby & Gillies 2004). 
Therefore, PDC is considered a therapeutic target for many age-related diseases 
(Stacpoole 2012) and numerous studies have investigated PDC for anti-cancer therapy in 
recent years described in more detail below.  
2.2. Aerobic glycolysis  
2.2.1. Aerobic glycolysis: a metabolic phenotype mostly observed in rapid 
proliferating cells  
More than 80 years ago, Otto Warburg observed that even under aerobic conditions 
cancer cells have an increased reliance on glycolysis for ATP generation and prefer 
lactate formation over oxidative phosphorylation (Warburg, Wind & Negelein 1927) (Figure 
2.2). This phenomenon is called aerobic glycolysis, also known as the Warburg effect, and 
is characterized by increased glucose consumption and lactate production. This seems to 
be counterproductive since aerobic glycolysis yields less ATP per consumed glucose 
molecule than oxidative phosphorylation. However, adjusting the metabolism towards 
aerobic glycolysis is observed for many continuously proliferating cells such as cancer 
cells, rapidly dividing cells of embryonic tissue and cells used as production hosts in 
industrial applications.  
In hypoxic environments, found in many solid tumors, increased glycolysis enables cancer 
cells to produce high amounts of ATP without the consumption of oxygen (Gatenby & 
Gillies 2004; Vander Heiden, Cantley & Thompson 2009). However, the fact that cancer 
cells under aerobic conditions and non-cancerous rapidly proliferating cells show a similar 
metabolic phenotype to hypoxic cancer cells indicate that their similar metabolic demands 
might play an important role as well (Hanahan & Weinberg 2011; Papandreou, Goliasova 
& Denko 2011). These cells must adjust their metabolism to meet the different energetic 
and biosynthetic requirements. Continuously dividing cells have a higher demand for 
nucleotides, amino acids and other cell components needed to assemble new cells and 
increased glycolysis allows the diversion of more glycolytic intermediates into other 
biosynthetic pathways to sustain rapid proliferation (Vander Heiden, Cantley & Thompson 
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2009). It was also shown in in vitro experiments using various cell lines that not only 
oxygen availability but also extracellular glucose concentration affects the glucose 
consumption rate (Altamirano et al. 2001; Cruz, Moreira & Carrondo 1999; Hayter et al. 
1992; Miller, Blanch & Wilke 2000; Miller, Wilke & Blanch 1988) indicating a deregulated 
metabolism as cells consume more glucose than needed for cell growth. Different authors 
proposed that the increased lactate production from pyruvate is used by the cell to reduce 
NADH to NAD+ in the cytosol for continued ATP production. High amounts of NADH are 
generated during increased glycolysis; however only NADH but not NAD+, can pass 
through the mitochondrial membrane via the malate-aspartate shuttle system, the usual 
place of NAD+ regeneration (Miller, Wilke & Blanch 1988; Sanfeliu et al. 1997; Wagner 
1997). Additionally, deficiencies in some key enzymes connecting glycolysis to TCA cycle, 
such as PDC, phosphoenolpyruvate carboxykinase, and pyruvate carboxylase (PC) may 
elevate lactate production (Fitzpatrick, Jenkins & Butler 1993; Neermann & Wagner 1996; 
Petch & Butler 1994).  
 
 
Figure 2.2: Differences between oxidative phosphorylation, anaerobic glycolysis and aerobic 
glycolysis. During oxidative phosphorylation cells first metabolize glucose to pyruvate in glycolysis followed 
by oxidation to CO2 in the mitochondria if sufficient oxygen is available as it is essential being the final 
electron acceptor. When oxygen supply is limited cells can redirect glycolytic derived pyruvate away from 
mitochondrial oxidative phosphorylation by converting it to lactate during anaerobic glycolysis with a 
considerably lower ATP yield when compared to oxidative phosphorylation. During aerobic glycolysis, cells 
convert most glucose to lactate independent of oxygen availability. Mitochondria remain functional but only a 
smaller amount of pyruvate is oxidized making aerobic glycolysis less efficient for generating ATP than 
oxidative phosphorylation. (Figure adapted from (Vander Heiden, Cantley & Thompson 2009)) 
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In order to compensate for the decrease in ATP yield per molecule glucose and for the 
increased need of glycolytic intermediates, cells activate a cellular response system, 
including regulation of glucose transporter and multiple enzymes of the glycolytic pathway 
(DeBerardinis et al. 2008; Hsu & Sabatini 2008; Jones & Thompson 2009; Kroemer & 
Pouyssegur 2008; Semenza 2010a, 2010b). PDK1 overexpression has been found in 
cancers such as head and neck, breast and lung cancers (Koukourakis et al. 2005; Lin, HJ 
et al. 2005). This is often associated with altered signaling pathways that involve 
oncogenes and tumor suppressor genes. Oncogenes that affect the central carbon 
metabolism are Akt1, cMyc, PKM2, and HIF1α. HIF1α is known to activate PDKs and 
thereby supporting pyruvate to lactate conversion observed in hypoxic cancer cells (Kim, 
JW et al. 2006; Lu et al. 2008; Wigfield et al. 2008). Overexprssion of PDKs is also 
associated with chemoresistance and PDK knockdown increased cytotoxicity of anticancer 
drugs  (Lu et al. 2008) making PDC inactivation by PDK overexpression an important pro-
survival pathway used by cancer cells.  
Cancer cells and rapid proliferating non-cancerous cells share several characteristics and 
show a similar metabolic phenotype. However, the contribution and interplay of several 
factors, such as demand for biosynthetic precursors, extracellular environment, oncogene 
expression, and flexible structure between pathways, are very complex and many 
questions still remain. Due to the complex nature of the metabolic network several targets 
to affect the metabolic phenotype and lower the Warburg effect exist. Increasing PDC 
activity is promising as it directly links glycolysis to the TCA cycle and indirectly influences 
lactate production as well. 
2.2.2. The Warburg effect in industrial relevant cell lines 
Mammalian cell lines are the preferred production host for therapeutic proteins and the 
market of biopharmaceuticals is growing rapidly with annual sales exceeding USD 110 
billion in 2011 (Ecker DM 2013). A great range of biologics, including vaccines, hormones, 
blood factors and monoclonal antibodies (mAbs) are produced in mammalian cell culture 
systems. As of December 2012, 154 biopharmaceuticals products have been approved for 
the US and EU market whereof 89 are produced in mammalian cell lines (Ecker DM 2013). 
There is a continuing need to develop technologies and approaches to achieve higher 
productivity and final antibody titers due to the increasing demand for biopharmaceuticals.  
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Despite their cost, difficulties and lower productivity, mammalian cells are the preferred 
production system for complex proteins, e.g. mAbs, because of their ability to correctly 
perform protein folding, assembly and post-translational modifications (e.g. glycosylation 
and phosphorylation) essential for safety and biologic efficacy (Durocher & Butler 2009; 
Walsh 2010; Wurm 2004). Those modifications are generally not correctly performed by 
microbial systems. 
During the development of a production cell line the metabolic patterns of mammalian cell 
metabolism are altered considerably due to genetic changes during the immortalization 
process and stressful in vitro culture conditions leading to mammalian cell lines that exhibit 
a highly deregulated metabolism when cultured in vitro (Godia & Cairo 2006). Mammalian 
cell lines used as production hosts show a similar metabolic phenotype, aerobic glycolysis, 
to cancer cells, despite the fact that these cells are cultured in an environment very 
different from the environment in tumors, e.g. higher glucose concentration, higher oxygen 
concentration and all substrates in excess. They exhibit aerobic glycolysis resulting in an 
undesired high glucose and glutamine consumption in combination with high lactate and 
ammonia production leading to shorter culture periods and possible negative effects on 
cell growth, productivity, and product quality (Dietmair, Nielsen & Timmins 2011; Lim et al. 
2010). Lactate is the main waste product that highly accumulates in both, batch and fed-
batch processes, which can inhibit cell growth and protein production (Glacken, Huang & 
Sinskey 1989; Lao & Toth 1997). Additionally, to keep the pH constant, at high lactate 
production a large amount of base has to be added to the culture resulting in an increased 
osmolality which can inhibit cell growth and in turn can lead to lower productivity as well 
(Cruz et al. 2000; Irani et al. 1999; Langheinrich & Nienow 1999).  
Intracellular pyruvate concentration influences the production of lactate and decreasing the 
available amount of cytoplasmic pyruvate by directing more pyruvate towards the TCA 
cycle could decrease lactate formation (Liu et al. 2009; Samuvel et al. 2009). Furthermore, 
enhancing the energy metabolism by increasing the ATP yield per glucose molecule 
consumed is promising because protein production is an extremely energy consuming 
process. A more efficient central carbon metabolism could also result in a decreased 
glucose and glutamine consumption as well as reduced ammonia production. The 
characterization, understanding and finally redistribution of the cellular metabolic behavior 
are essential to optimize the production systems and improve culture performance. 
Different approaches were tested to obtain modified cells with a more efficient metabolism 
such as alteration of culture conditions (e.g. media formulation, culture strategy) or 
metabolic engineering. Reduced lactate production was observed using optimized culture 
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conditions such as changing the balance of glucose and other nutrients (Nahapetian, 
Thomas & Thilly 1986) or exchanging glucose by other sugars such as galactose also in 
combination with replacing glutamine with glutamate (Altamirano, Illanes, Becerra, Cairó, 
et al. 2006; Altamirano et al. 2000; Altamirano et al. 2004). Strategic process control is 
another option keeping glucose concentrations low (Glacken, Fleischaker & Sinskey 1986) 
or lowering the culture pH (Gagnon et al. 2011).  
Genetic engineering approaches either aim at reducing lactate production and glucose 
consumption or increase lactate consumption. Reduction of lactate dehydrogenase 
expression either by gene knock-out, siRNA or antisense RNA of lactate dehydrogenase 
(LDH) (Chen et al. 2001; Kim, SH & Lee 2007), knocking down glucose transporter 
(GLUT1) (Paredes et al. 1999), or transfection of fructose transporter (GLUT5) to enable 
growth on fructose (Wlaschin & Hu 2007) were used with varying results. Alternatively, 
directing more pyruvate into the TCA cycle by over-expression of yeast pyruvate 
carboxylase resulted in a reduced lactate production and glucose consumption (Fogolin et 
al. 2004; Irani et al. 1999) or simultaneous reduction of LDH and PDK using siRNA (Zhou, 
M et al. 2011). Inhibiting PDK activity and thereby increasing PDC activity is a promising 
target to reduce lactate production and to increase productivity in mammalian cell culture.  
2.3. Dichloroacetate 
2.3.1. Dichloroacetate indirectly increases PDC activity 
Dichloroacetate (DCA) is an organohalide that is considered both, a potential 
environmental hazard and potential drug for the treatment of several metabolic, 
cardiovascular and cerebrovascular disorders (Stacpoole et al. 2008), as well as cancer 
(Michelakis et al. 2010). DCA is found in municipal drinking water as a by-product of water 
chlorination and the metabolism of chlorinated solvents, e.g. trichloroethylene, and 
pharmaceuticals, e.g. chloramphenicol, can result in in vivo formation of DCA (Stacpoole 
et al. 1998). In studies with in bred rodents it was shown that DCA has multiple organ 
toxicities and hepatocarcinogenicity after chronic exposure of doses in the range of 10 to 
50 mg/kg/day (Stacpoole et al. 1998). However, similar doses were used for decades from 
the late 1970th onwards for short term or chronic treatment of diabetes, hyper 
lipoproteinemia, coronary heart diseases, congestive heart failure, or various acquired or 
congenital lactic acidosis, like PDC deficiency (Stacpoole, Nagaraja & Hutson 2003). It has 
mostly been used to lower blood lactate levels in children with different inborn 
18 
 
mitochondrial dysfunctions which lead to accumulation of lactate in the body (Stacpoole et 
al. 1998). Exposure to such high doses of DCA caused several reversible side effects in 
humans, such as mild increases in serum transaminases and mild to severe peripheral 
neuropathy (Kaufmann et al. 1999; Stacpoole et al. 1998; Stacpoole et al. 2008).  
DCA is a pyruvate analog and the mitochondrion is considered the primary cellular site of 
DCA action. DCA enters the cell via the monocarboxylate transporter system that is 
located in the cell membrane and it enters the mitochondrial matrix via the mitochondrial 
pyruvate transporter (Stacpoole et al. 1998). Within the mitochondrial matrix, DCA inhibits 
PDK and thereby indirectly activates PDC. It was identified as a PDK inhibitor in 1973 
using perfused rat heart (Whitehouse, Cooper & Randle 1974) and DCA occupies the 
pyruvate binding site in PDK2 (Roche et al. 2001). The PDK isozymes, identified in 
humans and rodents (PDK1, PDK2, PDK3, and PDK4), have different sensitivities to DCA; 
PDK2 is most sensitive to DCA, whereas PDK1 and PDK4 are relative sensitive and PDK3 
is most resistant (Baker et al. 2000; Bowker-Kinley et al. 1998). Inside the cell, DCA can 
be dechlorinated to glyoxylate by glutathione S-transferase ζ1 (GSTZ1) the only enzyme 
known to metabolize DCA (Lantum et al. 2003; Li, WJ et al. 2011). GSTZ1 belongs to the 
cytosolic GST superfamily and is present in cytosol and mitochondria. Glyoxylate is then 
further metabolized in multiple pathways. DCA is also able to inhibit GSTZ1 activity in a 
broad range of doses in rats within days of continuous administration and thereby DCA 
can prevent its own degradation (Guo et al. 2006; Li, WJ et al. 2011).  
Due to its effect on PDC activity, DCA has been coming into focus of cancer research and 
is considered a potential treatment. It was observed that DCA treatment increased PDC 
activity in tumors resulting in reduces glucose consumption and lactate production 
(Michelakis, Webster & Mackey 2008; Niewisch et al. 2012). However, DCA’s lactate 
lowering activity can also be useful in other systems in which high lactate production is 
undesirable. In industrial applications where mammalian cells are used as production 
hosts, reducing lactate production is desirable as high lactate production can have 
negative effects on culture performance or product yield and it was shown that DCA can 
reduce lactate production in CHO cells (Follstat 2002). 
2.3.2. Dichloroacetate in the focus of cancer research 
In recent years, cancer research began to focus on the distinctive metabolism of glycolytic 
cancer cells as their metabolism is considered a new target for anti-cancer therapy 
(Hanahan & Weinberg 2011). Due to its lactate lowering activity, DCA has been receiving 
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attention as a potential anti-cancer drug and the majority of literature published in recent 
years regarding DCA is within the area of cancer research. Bonnet et al. published in 2007 
that DCA inhibited the growth of A549 lung tumor xenocrafts in rats (Bonnet et al. 2007) 
and since then, numerous studies investigated the effect of DCA in vitro on mammalian 
cancer and non-cancerous cell lines and in vivo. The main focus in these studies has been 
cell survival and cause of cell death during DCA treatment. In addition, it was observed 
that DCA reduced lactate formation and aerobic glycolysis in non-cancerous and cancer 
cells (Bonnet et al. 2007; Michelakis et al. 2010; Stacpoole et al. 2008). However, DCA’s 
affect on TCA cycle activity, measured by oxygen consumption, varied and appears to 
depend on factors such as cell line or HIF1α expression (Cairns et al. 2007; Niewisch et al. 
2012). Additionally, DCA decreased E1α phosphorylation in UM-22A cells with increasing 
DCA concentration but had no effect on E1α phosphorylation in UM-22B cells (both are 
human neck squamous carcinoma cell lines) (McFate et al. 2008). Similarly, studies 
reported cytotoxic effects in different cancer cell lines but a broad range of concentration 
was necessary to induce toxicity, ranging from 0.5 mM to 100 mM affirming that different 
cell lines can respond very differently to DCA (Bonnet et al. 2007; Hanberry, Berger & 
Zastre 2014; Heshe et al. 2010; Stockwin et al. 2010).  
Mitochondrial dysfunction contributes to apoptotic resistance in cancer cells and is 
believed to contribute to aerobic glycolysis (Kim, JW & Dang 2006). High mitochondrial 
membrane potential and low expression of K+ channel Kv1.5, both characteristics of many 
cancer cells but not normal cells, were reported to be a selection criterion for the effect of 
DCA (Bonnet et al. 2007). Hyperpolarization of the mitochondrial membrane prevents the 
release of pro-apoptotic mediators from the mitochondria to the cytoplasm and thereby 
mediates apoptotic resistance. It was proposed that DCA is selective for cancer cells and 
“normalizes” the hyperpolarized mitochondrial membrane potential (MMP) which 
eventually leads to release of pro-apoptotic proteins and activation of apoptosis (Bonnet et 
al. 2007). More recently, an alternative mechanism as cause of cell death was reported. 
Several normal and cancerous cell lines of various tissues were investigated and the 
results indicated that DCA is not selective for cancer cells and the effect of DCA on MMP 
is the same for non-cancerous and cancer cells with a rather low influence of Kv1.5. 
Instead, DCA selectively targets cells with defects in their mitochondrial electron transport 
chain (ETC) (Stockwin et al. 2010). DCA inhibited cell growth of cells with impaired ETC 
and promoted oxidative phosphorylation. As a result ROS generation is increased; leading 
to increased cytochrome C release which ultimately leads to apoptosis (Garber 2006; 
Papandreou, Goliasova & Denko 2011).  
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However, the exact mechanisms that result in the tumoricidal effect of DCA need further 
investigation as DCA can inhibit tumor progression in several ways: i) increasing apoptosis 
without effect on cell proliferation was observed in endometrial cancer cells (Wong et al. 
2008), ii) inhibiting cell proliferation without apoptosis induction or cell death was observed 
in lung, prostate and breast cancer (Stockwin et al. 2010; Sun et al. 2010), and iii) 
induction of apoptosis and inhibition of proliferation such as in lung and colorectal cancer 
(Bonnet et al. 2007; Madhok et al. 2010). Several studies reported an anti-tumor effect of 
DCA and decreased MMP and lactate production and increased production of reactive 
oxygen species (ROS) associated with induction of apoptosis and/or declined tumor cell 
proliferation were observed (Bonnet et al. 2007; Cao et al. 2008; Madhok et al. 2010; 
Michelakis et al. 2010; Niewisch et al. 2012; Ohashi et al. 2013; Shahrzad et al. 2010; 
Sorokina et al. 2011; Sun, Board & Blackburn 2011; Vella et al. 2012; Wong et al. 2008). 
However, reduced MMP and increased ROS were observed in several cancer cell lines 
without an apoptotic response (Stockwin et al. 2010). Others observed a decreased MMP 
and reduced cell proliferation without increased ROS production (Hanberry, Berger & 
Zastre 2014). Similarly, JNK1 activation and apoptosis was observed in A549 cancer cells 
without increase in ROS production (Ayyanathan et al. 2012). Induction of apoptosis 
together with alterations in expression of pro- and anti-apoptotic proteins such as p53 
activation and HIF1α inhibition was reported as well (Kumar, A, Kant & Singh 2012, 2013; 
Michelakis et al. 2010; Sun, Board & Blackburn 2011). 
While an increasing number of publications investigated DCA as an anti-cancer drug as 
sole treatment, it has also been considered for combination with established and novel 
cancer treatments (Ayyanathan et al. 2012; Fiebiger et al. 2011; Hur et al. 2013; Ishiguro 
et al. 2012; Kumar, K et al. 2013; Shen et al. 2013; Stockwin et al. 2010; Xie et al. 2011). 
Case studies of DCA treatment (Flavin 2010; Michelakis et al. 2010) as well as a phase I 
trial were published (Dunbar et al. 2013). A table summarizing the studies cited here can 
be found in Appendix I. 
The metabolic effect of DCA, namely reduction of aerobic glycolysis, is well established. 
However, the exact mechanism by which increased PDC activity reduces the glycolytic 
rate needs further exploration. At the same time, the proliferation inhibiting and apoptotic 
effects are highly cell line dependent and it is still not fully understood what factors and 
mechanisms are responsible for apoptotic and anti-proliferating effects.  
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3.1. Abstract 
Metabolic flux analysis (MFA) is widely used to estimate intracellular fluxes. Conventional 
MFA, however, is limited to continuous cultures and the mid-exponential growth phase of 
batch cultures. Dynamic MFA (DMFA) has emerged to characterize time-resolved 
metabolic fluxes for the entire culture period. Here, the linear DMFA approach was 
extended using B-spline fitting (B-DMFA) to estimate mass balanced fluxes. Smoother fits 
were achieved using reduced number of knots and parameters. Additionally, computation 
time was greatly reduced using a new heuristic algorithm for knot placement. B-DMFA 
revealed that Chinese hamster ovary cells shifted from 37C to 32C maintained a 
constant IgG volume-specific productivity, whereas the productivity for the controls peaked 
during mid-exponential growth phase and declined afterward. The observed 42% increase 
in product titer at 32C was explained by a prolonged cell growth with high cell viability, a 
larger cell volume and a more stable volume-specific productivity. 
3.2. Introduction 
For over 20 years, metabolic flux analysis (MFA) has proven a powerful tool to 
quantitatively characterize cell metabolic phenotypes (Bonarius et al., 1996; Nielsen, 2003; 
Vallino and Stephanopoulos, 1993). MFA estimates intracellular fluxes using experimental 
measurements and mass balances. The quantification of metabolic fluxes has facilitated a 
better understanding of biological systems (Boghigian et al., 2010), including the 
identification of bottlenecks in product formation (Burleigh et al., 2011; Nyberg et al., 1999) 
and metabolic regulation (Fendt and Sauer, 2010). MFA is routinely used in media design 
(Altamirano et al., 2006; Martínez et al., 2010; Xing et al., 2011) and metabolic engineering 
(Becker et al., 2005) in order to improve metabolic phenotypes. 
Conventional MFA assumes constant intracellular fluxes, a condition only satisfied by 
continuous cultures at steady state and during the mid-exponential phase of batch 
cultures. Most industrial cultures display dynamic metabolic changes (Matasci et al., 2008; 
Meadows et al., 2010), such as a gradual decline in cell-specific growth rate during batch 
and fed batch (Antoniewicz et al., 2007; Niklas et al., 2011) or diauxic growth (Mahadevan 
et al., 2002). Frequently, the most relevant metabolic behaviour occurs during transient 
conditions, where conventional MFA is no longer applicable. 
Monoclonal antibody production by CHO cells illustrates the point. Conventional MFA has 
been used to study the Warburg effect observed during the initial growth phase, yet all 
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cultures display this phenotype during the initial exponential phase. What distinguishes 
successful cultures is the transition from exponential to stationary growth phase, whether 
the transition is invoked naturally (Ahn and Antoniewicz, 2011; Martínez et al., 2013), 
caused by medium design (Altamirano et al., 2006) or deliberate manipulation of culture 
conditions, such as a temperature shift (Bollati-Fogolin et al., 2005). A metabolic shift from 
lactate production to lactate consumption during this transition aids longevity and 
productivity of the culture (Altamirano et al., 2006; Ma et al., 2009; Martínez et al., 2013; 
Niklas et al., 2011; Young, 2013). 
Several approaches have been used to estimate dynamic flux distributions (Antoniewicz, 
2013). While all approaches assume pseudo-steady state for intracellular metabolism, i.e. 
the changes in internal metabolite concentrations are trivial compared to the fluxes (Varma 
and Palsson, 1994), they differ in terms of how dynamics in the data are captured. The 
simplest approach is to manually divide the time series data into distinct metabolic phases 
and estimate the flux profile of each phase by MFA (Ahn and Antoniewicz, 2011; 
Altamirano et al., 2006; Martínez et al., 2013; Niklas et al., 2011). This approach produces 
an average flux estimate for each phase but fails to capture the temporal evolution of 
metabolic fluxes. It is also difficult to maintain a homogenous precision among determined 
rates, which are dependent on the consistency and frequency of data points contained in 
each phase. Newer approaches overcome these limitations by first generating smooth 
functions to fit the measured metabolite concentrations and subsequently estimating 
instantaneous rates based on the functions’ slope (Lequeux et al., 2010; Llaneras and 
Pico, 2007; Niklas et al., 2011). Then MFA is applied to each time point to generate a 
continuous flux distribution profile. The independent smoothing of individual concentration 
profiles followed by differentiation ignores mass conservation, potentially introducing 
significant bias into the flux estimates. Dynamic MFA (DMFA) overcomes this issue by 
using free fluxes as bases for the fitting functions and a least-square approach to fit the full 
dataset simultaneously (Leighty and Antoniewicz, 2011). 
The original DMFA implementation uses piecewise linear functions to describe the time 
profile of free fluxes (Leighty and Antoniewicz, 2011). While simple in form, the linear 
assumption creates rates with unnatural, non-smooth breakpoints and struggle to fit 
higher-order dynamics, which do commonly occur since the time profile of absolute rates 
tend to trace a sigmoid curve (e.g., Monod model). In this study, we have extended the 
linear method by using B-spline functions when performing DMFA (B-DMFA), bringing in 
capabilities for higher order fit and the use of knot multiplicity. Knots are equivalent to the 
so-called DMFA time points (Leighty and Antoniewicz, 2011). 
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B-splines, or basis splines, are often used in computer-aided geometrical design and 
software packages to approximate data due to their rich mathematical structure and the 
robust numerical algorithms available (Prautzsch et al., 2002). B-splines and their integrals 
can be formulated such that they are linear with respect to the model parameters, and 
therefore all statistical and computational advantages shown in the linear DMFA (L-DMFA) 
implementation are retained (Leighty and Antoniewicz, 2011). Moreover, by exploiting the 
local support property of B-splines, a fast heuristic algorithm was developed for knot 
placement, which is by far the most time consuming task when performing DMFA. The 
performance of the B-DMFA algorithm was compared to the current L-DMFA approach 
(Leighty and Antoniewicz, 2011) using a simulated diauxic growth dataset of yeast 
fermentation (Sonnleitner and Kappeli, 1986). Demonstrating application to real data, B-
DMFA was used to determine flux profiles of CHO cultures in order to investigate the 
effects of temperature shift on CHO metabolism. 
3.3. Materials and Methods 
3.3.1. Dynamic metabolic flux analysis (DMFA) using B-Spline fitting  
Metabolic fluxes (v(t)) are calculated by performing mass balance around each metabolite 
in a metabolic network, which is represented by a stoichiometric matrix (S) for the internal 
metabolites (cint) and a matrix R for the external metabolites (cext): 
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]  ( )                                                          (1) 
 
Eq. (1) can be divided in balanced (internal) and not balanced (external) metabolites. It is 
assumed that internal metabolites are at pseudo steady-state, i.e., the fluxes to and away 
from any internal metabolite are far greater than the net accumulation of the metabolite 
itself (Varma & Palsson 1994a):  
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In conventional MFA, metabolic fluxes are assumed to be constant, and the internal 
metabolite balances are mathematically formulated by Eq. (3) with constant  . In DMFA, 
metabolic fluxes are allowed to change over time to reflect the dynamics of the measured 
concentrations and rates.  
The vector of fluxes (v(t)) can be expressed as a function of the null space of the balanced 
stoichiometric matrix S and a set of free fluxes (u(t)): 
 
 ( )     ( );    where K = null(S)                                                (4) 
 
Leighty and Antoniewicz calculated internal fluxes using a time-dependent  ( ) formulated 
as a linear spline function (Leighty and Antoniewicz, 2011). A smoother fit, however, can 
be achieved by formulating  ( ) using higher order B-splines as shown in Eq. (5) (Curry, 
H. B. & Schoenberg 1947; Curry, Haskell B & Schoenberg 1966). 
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Under B-spline terminology, m is the number of time points (called knots), k is the order of 
the polynomial segments of the B-spline (order k means that the curve is made of 
polynomial segments of degree k-1),    is the i
th control point, and    ( ) is the i
th 
normalized B-spline blending function of order k. The control points and blending functions 
define the shape of the B-spline (Prautzsch, Boehm & Paluszny 2002). The normalized 
blending functions are estimated by the Cox-de Boor recurrence relation (Cox 1972; De 
Boor 1972): 
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In this study, a quadratic B-spline (k=3) was used to fit the free-flux vector, thus the 
metabolic fluxes were expressed as: 
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The time profiles of metabolite concentrations are described using the integral of Eq. (2), 
thus the integral of Eq. (8) is required. The indefinite integral of B-spline function of 3rd 
order is: 
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The B-spline functions for metabolite concentrations, after the rearrangement of ej, can 
subsequently be expressed in matrix form as: 
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For a pre-determined knot series, the control points (matrix  ) and the initial metabolite 
concentrations (vector   ) are linear with respect to the model. The complete time-series of 
metabolic fluxes can be estimated by solving a single optimization problem (Antoniewicz 
2013a). The optimization estimates free fluxes and initial metabolite concentrations by 
minimizing the variance-weighted sum of squared residuals (SSR) between estimated and 
measured external metabolite concentrations (   and    ) and external rates (          ) if 
available (Leighty & Antoniewicz 2011):  
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where Wi and Wrj are diagonal matrices containing the inverse of measurement variances 
of metabolite i and external rates j for every time point, respectively. 
The optimization is linear with respect to P and    (                  ), thus the solution 
to the problem can be solved explicitly using the equation (Leighty & Antoniewicz 2011): 
 
(
  
 )   
                                                                   (14) 
 
where H and J are the Hessian and Jacobian  matrixes, respectively. From this point 
onwards, the formulation is identical to the L-DMFA approach (Leighty & Antoniewicz 
2011), namely the method used to estimate standard deviations for the estimated 
metabolic fluxes. The B-DMFA algorithm was scripted in MATLAB, and is available from 
the corresponding author upon request. 
3.3.2.   Heuristic algorithm to determine the placement and number of knots 
Finding the least-square solution of B-splines is a simple linear problem once the knots 
sequence has been specified, otherwise the problem is non-linear and difficult to solve. 
There are various parameterization approaches to specify the knot sequence, such as 
uniformly spaced or chord length (Prautzsch, Boehm & Paluszny 2002), however, these 
approaches are mainly designed to fit one curve at a time. Since we are simultaneously 
fitting a large number of curves using a single knot sequence, we developed a heuristic 
algorithm that uses the SSR within knot spans to guide the placement of knots (Appendix 
A). The algorithm was conceived based on the fact that the shape of B-splines can be 
controlled locally, i.e. adjusting positions of proximal knots have limited distal effects. 
Generally there are more time series data points than there are piecewise polynomials 
required to fit the experimental data. As such, the algorithm starts from no internal knots 
and progressively adds knots until the SSR is reduced to an acceptable threshold. A 
region of data with greater dynamic behaviour will correspondingly have higher density of 
knots. This avoids issues related to over-fitting and oscillation. 
Briefly, the algorithm places a knot into the time span that has the largest contribution to 
the overall SSR (Figure 3.1A). The position of each added knot is determined by a greedy 
trial-and-error approach, guided by SSR trial calculations, the SSR of placing a knot in 
either the middle of the time span or the middle of the half right or left of the defined time 
interval is compared (Figure 3.1B).  
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Figure 3.1: A. Selecting knot placement time interval. The time interval that has the greatest contribution 
to the total SSR is selected for placing a knot. B. Placing knot i within the selected time interval. The 
position of the knot i is determined by an iterative process. First, the SSRs of placing the knot in the middle 
of the knot placement time interval, or the middle of the left or right half of the knot placement time interval 
are compared. The process is stopped if placing the knot in the middle of the knot placement time interval 
gives the smallest SSR. Otherwise the knot placement time interval is updated to the right or left half of the 
initial time interval, depending on which knot position gives the smallest SSR. Then the process is repeated 
on the new reduced knot placement time interval. 
 
If the smallest SSR is given by placing the knot in the middle position, then it is kept as 
part of the final knot sequence. Otherwise, the focus is shifted to the right or left half of the 
current time span, chosen based on the knot position that gives the smallest SSR. The 
previous smallest SSR is compared again with the options of placing the new knot in the 
middle of the right or left half of the new time span (half of the previous time interval), and 
the knot position that generates the smallest SSR is selected. The process is repeated, 
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with the time span segment becoming narrower, until the best knot position is found to be 
placed at the middle of the last defined time span. The algorithm starts again for the next 
knot. After the placement of the second and subsequent knots, the position of all knots are 
adjusted again to minimize SSR in order to account for the effects of other knots, whereby 
a better position for the ith knot is checked between the time interval defined by i-1th knot 
and i+1th knot. The whole process terminates when the minimum SSR is below the chi-
square threshold. 
3.3.3.   Metabolic model  
The metabolic model was derived from the Mus musculus GeM (Quek & Nielsen 2008a) 
as previously described (Quek et al. 2010). The metabolic model contains the TCA cycle, 
non-oxidative pentose phosphate pathway (PPP) and pathways for the synthesis of 
essential biomass precursors (e.g., fatty acids, steroids, glycogen, and nucleotides). The 
mitochondrial malic enzyme and the oxidative PPP were removed such that NADPH is 
only produced by NADP+ dependant malic enzyme. Further modifications were made to 
the model to reflect differences in substrate consumption and by-product formation: (1) the 
uptake of hypoxanthine, choline, myo-inositol and ethanolamine were removed; (2) proline 
degradation pathway was replaced by its biosynthetic pathway; and (3) an IgG1 antibody 
production reaction was added (IgG1 composition shown in Appendix B). L-alanyl-L-
glutamine dipeptide was treated as free glutamine and alanine, and the decomposition of 
glutamine was assumed to be negligible since its extracellular accumulation is low. A 
biomass equation was used, with the precursor compositions obtained from a previous 
CHO cell culture study (Martínez, VS et al. 2013). The average dry weight for control cells 
at exponential growth phase was measured to be 350 [pg/cell]. 
3.3.4.   Cell culture 
The CHO cell line CHO-XL99, producing an IgG1 antibody (Ab2), is a derivative of CHO-
K1 (ATCC 61-CCL) adapted from adherent growth in serum containing medium to 
suspension growth in EX-CELL302 serum free medium at the University of New South 
Wales. The CHO-XL99 cell line was further adapted to EX-CELL CD CHO Fusion (Sigma-
Aldrich, Castle Hill, Australia) medium supplemented with 8 mM GlutaMAX (L-alanyl-L-
glutamine; LifeTechnologies Australia, Mulgrave, Australia), 400 μg/ml Geneticin 
(LifeTechnologies Australia) and 0.2% v/v Anti-Clumping Agent (LifeTechnologies 
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Australia). CHO-XL99 cells were cultivated in four 1L shake flasks with a working volume 
of 200 ml in humidified Infors shaking incubators set at 37°C, 7.5% CO2 and 130 rpm. 
After 72.5 hours two shake flasks were transferred to a humidified incubator set at 32°C 
with otherwise identical settings. Samples for viable cell density and cell diameter 
measurements as well as antibody and metabolite concentration analysis were taken twice 
a day. Cell number, viability and cell diameter were determined using a CedeX cell counter 
(Innovatis, Bielefeld, Germany). Ammonia concentrations were measured using a Nova 
Bioprofiler FLEX (Nova Biomedical, Waltham, USA). For extracellular metabolites and 
antibody analysis, 500 μl of cell suspension was removed from the cell cultures, 
centrifuged at 200 g for 5 min and supernatants were frozen on dry ice and stored at -80°C 
until further processing. 
3.3.5.   Extracellular metabolites and antibody concentration analysis 
Glucose, lactate, L-alanyl-L-glutamine and amino acid concentrations were measured 
using HPLC as described previously (Dietmair, Timmins, Gray, Nielsen & Krömer 2010). 
Antibody concentrations were determined using surface plasmon resonance with a 
Biacore T-100 system (GE Healthcare, Mansfield, Australia) and the human antibody 
capture kit (GE Healthcare) was used for the immobilization of an Ab2 binding α-Hu IgG 
FC-specific antibody onto the CM5 sensor chips. Samples were diluted 5-10 times in a 96 
well plate and protein-A purified Ab2 was used to obtain a standard curve for 
quantification.  
3.4. Results and discussion 
3.4.1. Comparing B-DMFA against L-DMFA  
The implementation of L-DMFA is formally identical to B-DMFA with order (k) 2, except 
that L-DMFA uses an optimization algorithm to specify knot sequence (Leighty & 
Antoniewicz 2011). A diauxic growth model of yeast on glucose (Nielsen, Jens & Villadsen 
2003; Sonnleitner & Kappeli 1986) was used to compare their performances (Figure 3.2). 
In the simulated batch culture, S. cerevisiae initially metabolize glucose by an 
oxidoreductive metabolism. While the uptake rate of glucose is described by Monod 
kinetics, the oxidation of glucose is additionally limited by the respiratory capacity. Excess 
pyruvate therefore overflows to ethanol. As glucose is consumed, its consumption rate 
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decreases to a point where spare respiratory capacity allows the reconsumption of 
ethanol. The uptake rate of ethanol is described by Monod kinetics that includes glucose 
inhibition. The complex dynamics of the oxygen consumption rate is shown in Figure 3.2. 
 
 
Figure 3.2: Simulated data of yeast diauxic growth in batch culture. Initially, cells metabolize glucose 
and produce ethanol and CO2. Ethanol is consumed when glucose is depleted. Transients in the oxygen 
consumption rate and CO2 production rate around the depletion of glucose and ethanol are shown. 
 
The goodness of fit by L-DMFA (Leighty & Antoniewicz 2011) and by B-DMFA were 
compared using the described simulated dataset. The dataset consisted of concentrations 
of glucose, ethanol, biomass, and rates of oxygen and carbon dioxide at 30 minutes 
intervals from 0 to 15 hours. Initial glucose and biomass concentrations were set to 2 g/L 
and 0.1 g/L. Measurement errors were assumed to be 5% (Figure 3.3). 
The two approaches were comparable in terms of the ability to fit concentration datasets 
(Figure 3.3 A, B and C). B-DMFA, however, gave a smoother fit for the oxygen and CO2 
rates, particularly at time points when glucose and ethanol approached depletion (Figure 
3.3 D and E). Unlike L-DMFA, B-DMFA was able to trace the spike in the rates by allowing 
insertion of multiple knots at the same time point. Therefore, B-DMFA generates a better 
fitting for dynamic experimental rates that contain drastic changes in a short period of time. 
A quantitative comparison of the fitting between both approaches was carried out (Table 
3.1). Particularly, we examined how sampling frequency would affect performance. B-
DMFA and L-DMFA were performed on ten datasets for each sampling frequency (15, 30 
and 60 minutes sampling intervals). Each dataset was generated by corrupting the 
simulated concentrations and rates with normally distributed random noise (5% standard 
deviation). Since the upper limit of SSR in DMFA vary depending on the number of knots, 
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a proxy for goodness-of-fit (SSRo) was used, which measures the discrepancy between 
the fitted and the noise-free models. This allows us to compare the goodness-of-fit for the 
various fitted models using the simulated noise-free dataset as a common basis. SSRo 
was found to be similar for both B-DMFA and L-DMFA. However, B-DMFA achieved this 
with a smaller number of internal knots (time points) and parameters than L-DMFA, 
demonstrating the higher fitting power achieved using B-spline fitting. 
 
 
 
Figure 3.3: Fitting of simulated dataset of yeast diauxic growth by L-DMFA and B-DMFA, and 
simulations computation time. In A to E the simulated data points are represented by ◊, and the fitting of 
L-DMFA and B-DFMA are represented by black and red lines, respectively. In F, the computation time (in an 
Intel® Core™ i5 CPU with 8GB RAM) by L-DMFA and B-DMFA with increasing number of sampling points is 
shown. 
 
B-DMFA was found to be significantly faster than L-DMFA (Table 3.1). We attributed this 
to the heuristic algorithm for knots placement. L-DMFA uses an optimization approach, 
which begins with a maximum potential DMFA time points (e.g., 29 in the 15 minute case) 
and removes one by one until the fit is still within the 95% confidence intervals (CI) 
(Leighty & Antoniewicz 2011),  while the B-DMFA heuristic algorithm adds knots starting 
from zero. This was verified when the knot placement heuristic algorithm was implemented 
in the original L-DMFA approach, and as a consequence, the computation times were 
significantly improved. Interestingly the B-DMFA approach remains the fastest (Table 3.1). 
SSRo indicates that the resulting fits were similar to the original L-DFMA implementation. 
Nonetheless, B-DMFA remained the faster approach compared to the original L-DMFA 
with or without the heuristic algorithm, especially for datasets presenting in higher 
sampling frequency (Table 3.1). 
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Table 3.1: Comparison of B-DMFA, L-DMFA and L-DMFA using the knot insertion heuristic. For each 
sampling frequency ten datasets with noise (5% standard deviation) were simulated,  for sampling every 15, 
30 and 60 minutes. The datasets were analyzed with B-DMFA, L-DMFA and L-DMFA using the heuristic 
algorithm for knots placement. The SSR with respect to a dataset without noise (SSRo), the computation 
time (in an Intel® Core™ i5 CPU with 8GB RAM), the number of internal knots required for fitting and the 
number of parameters were determined. The goodness of fit was similar between the three approaches, 
however, B-DMFA required less parameters. B-DMFA is also a much faster approach than L-DMFA, mainly 
due to the knots placement heuristic algorithm. 
  
B-DMFA L-DMFA 
L-DMFA + heuristic 
algorithm 
 15 min 94.8 ± 24.2 125.9 ± 32.8 97.1 ± 22.5 
SSRo 30 min 65.1 ± 14.3 75.7 ± 18.0 65.5 ± 15.9 
  1 hour 49.0 ± 12.6 * 51.1 ± 11.5 * 50.2 ± 12.2# 
  15 min 23.2 ± 13.2 3,543 ± 3,119 36.3 ± 12.3 
Time (sec) 30 min 9.5 ± 2.9 826.2 ± 413.4 22.5 ± 13.5 
  1 hour 5.6 ± 3.0 * 140.5 ± 40.1 * 10.1 ± 8.0 # 
  15 min 7 ± 2 15 ± 15 9 ± 1 
N° Internal knots 30 min 6 ± 1 11 ± 7 9 ± 3 
  1 hour 6 ± 1 * 8 ± 4 * 9 ± 4 # 
  15 min 40 ± 6 69 ± 61 45 ± 6 
N° Parameters 30 min 37 ± 4 51 ± 27 46 ± 12 
  1 hour 36 ± 5 * 40 ± 14 * 46 ± 17 # 
* One out of ten datasets did not converge with a 95% CI, thus the dataset was omitted from the analysis.  
#
 Two out of ten datasets did not converge with a 95% CI, thus the datasets were omitted from the analysis. 
 
Figure 3.3F shows that the B-DMFA approach is significantly less sensitive to the number 
of sampling time points than L-DMFA. At 16 time points, B-DMFA algorithm took 7 
seconds to generate a statistically acceptable flux distribution, while L-DMFA took 115 
seconds; at 91 sampling points, B-DMFA was two orders of magnitude faster (Figure 
3.3F). The longest computation time using L-DMFA was approximately one hour. This 
computation time can be considered reasonable, however, when dealing with large models 
that describe the full cell metabolism (more than 100 reactions), and more experimental 
measurement (the full set of amino acids concentrations for a ten days cell culture) the 
computation time could be in  the order of days. 
The heuristic algorithm for knot placement was validated to be sound by a Monte Carlo 
approach. By randomly sampling 10,000 sets of knot sequences with a fixed number of 
knots, the best SSR was still 37% greater despite the Monte Carlo approach requiring 8.5 
minutes to complete compared to the 12 seconds required by the heuristic algorithm. 
When sample size was increased to 100,000, the best SSR was 25% less than the 
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heuristic algorithm, but only four instances returned SSR better than the algorithm 
(Appendix A). The sets of statistically acceptable knot sequences randomly generated 
were not very different compared to the knot sequence determined by the algorithm. The 
largest difference was 6% of the full time span when compared to the best set. However, 
the Monte Carlo approach took 1.4 hours to completion. 
3.4.2.   Effects of temperature shift on cell size and productivity of CHO-XL99 cells 
Growth profile, antibody concentration, mean cell diameter and cell specific productivity for 
the two control cultures (37°C) and two temperature-shifted cultures (32°C) are shown in 
Figure 3.4. The log plot of cell number (Figure 3.4A) showed that cell-specific growth rates 
for all four cultures were constant at about 0.025 to 0.029 h-1 during early exponential 
phase, but began to decline after 96 hours. This is expected for shake flask cultures as pH 
is not controlled. At 100 hours, the cell-specific growth rates for the temperature-shifted 
and control cultures were between 0.012 – 0.016 hr-1 and 0.020 – 0.023 hr-1, respectively, 
suggesting a reduced growth rate and slower metabolism for the temperature-shifted 
cultures. A lower peak cell density was also observed for the temperature-shifted cultures. 
Both observations are consistent with the literature (Kumar, N, Gammell & Clynes 2007; 
Moore et al. 1997). Cultures reached peak cell density at 168 hours and 192 hours for the 
control and temperature-shifted cultures, respectively. Cell viabilities for all four cultures 
were above 90% for the remaining culture duration up to 240 hours. Cell viability was 
slightly higher for the temperature-shifted cultures than the control cultures. The reduction 
of culture temperature from 37°C to 32°C appears to have reduced the cell growth rate 
and overall metabolism. 
The final antibody titer was on average 42% higher in the temperature-shifted cultures 
compared to the controls. As a consequence of a smaller integral viable cell density and a 
higher antibody titer, the average cell-specific productivity (Qp) appeared to be larger for 
the temperature-shifted cultures (Figure 3.4D). Cells in the temperature-shifted cultures, 
however, showed a significant increase in cell diameter compared to the controls despite 
all cultures showing similar cell sizes before the temperature shift (Figure 3.4C). Metabolic 
fluxes and antibody yields were therefore normalized to cell volume instead of cell number 
due to the observed differences in cell sizes. Since cell volume is proportional to cell mass 
(Frame & Hu 1990), it is more accurate to express metabolic fluxes and antibody yields in 
terms of cell volume instead of cell number when cell size varies (Nielsen, LK, Reid & 
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Greenfield 1997). The difference in average Qp was eliminated once Qp was normalized 
against cell volume (Figure 3.4D). 
 
 
Figure 3.4: Viable cell density, antibody concentration, cell size and specific productivity. A: CHO-
XL99 cells were cultivated in four shake flasks, two cultures were temperature-shifted at 72.5 hours (32°C-1 
and 32°C-2) and the other two were maintained at 37°C throughout the whole experiment (37°C-1 and 37°C 
-2). Approximately 24 hours after the temperature shift the growth rate decreased and peak viable cell 
density was lower in temperature shifted cells compared to cells at 37°C. B: Final antibody titer was higher in 
temperature shifted cells by about 42%. C: An increase in cell diameter was observed for cells at 32°C on 
day 5, approximately two days after the temperature shift. D: Cell specific productivity (Qp) based on cell 
number increased for cells cultivated at 32°C while cell volume normalized Qp did not show an increased 
productivity for temperature shifted cells. Qp after 72.5 h was estimated until cells entered stationary phase.  
 
Several studies of CHO cultures have reported an enhanced Qp when temperature was 
reduced from 37°C to mild hypothermia (Al-Fageeh et al. 2006; Bollati-Fogolin et al. 2005; 
Fox et al. 2004; Furukawa & Ohsuye 1998; Kumar, N, Gammell & Clynes 2007; Yoon, 
Song & Lee 2003), but none of these studies accounted for the role of cell size. 
Temperature-shifted CHO cells typically accumulate in the G1 phase (Kumar, N, Gammell 
& Clynes 2007; Moore et al. 1997), and might therefore be expected to be smaller in size 
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than cells in S or G2 phases. However, an increase in size has been observed for cells 
arrested in G1 phase by means other than temperature shift (Al-Rubeai et al. 1992; Bi, 
Shuttleworth & Ai-Rubeai 2004; Carvalhal, Marcelino & Carrondo 2003; Lloyd et al. 2000). 
It has previously been found that cell-specific productivity correlates with cell size (Bi, 
Shuttleworth & Ai-Rubeai 2004; Lloyd et al. 2000) and our data similarly showed that 
volumetric productivity was largely constant even with an almost 40% increase in observed 
cell volume. 
3.4.3.   B-DMFA captures dynamic metabolic changes caused by temperature shift 
Dynamic flux analysis of CHO cell cultures was performed using the B-DMFA framework. 
The experimentally measured metabolite concentrations (amino acids, glucose, lactate 
and ammonia), antibody concentration and cell volume were used as input. Cell number 
was not used due to differences in cell diameter observed between the control and the 
temperature-shifted cultures (Figure 3.4C). The second control culture (37 °C-2) had a 
smaller inoculum concentration than the first (37 °C-2), thus the 37 °C-2 dataset was 
shifted back by 8.5 hours. A total of 408 measurements (24 concentrations  17 time 
points) per culture were fitted (Figure 3.5). Since oxygen uptake was not measured, the 
measurement set has only one degree of redundancy with respect to the model inputs and 
outputs (Quek et al. 2010). The calculated residual error therefore reflects the consistency 
of nitrogen balance among the measurements. 
The B-splines were generally able to accurately trace all of the measured concentrations 
for both control and temperature-shifted cultures (Figure 3.5). The number of internal knots 
used and parameters fitted ranged from 0 to 2 and 93 to 141, respectively, for the four 
cultures; computation times were less than 11 seconds. The knot selection was validated 
by a Monte Carlo approach using 100,000 random samples of knot sequence; SSR was 
improved by only 3% at most.  
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Figure 3.5: Fitted concentrations from CHO-XL99 cell cultures by B-DMFA. The experimental data are 
presented by points and the B-spline fit by lines. Data for cell cultures at constant 37°C are shown in pink 
(37°C-1) and red (37°C-2), and for temperature-shifted cultures in cyan (32°C-1) and blue (32°C-2). 
Measurements before 24 hours were omitted from the analysis due to their high uncertainty. 
 
Compared to the temperature-shifted cultures, the control cultures displayed faster 
depletion of glucose, glutamine and serine, and accumulation of lactate, ammonia and 
glycine (Figure 3.5). The time-resolved absolute fluxes estimated by B-DMFA were 
consistent with these general observations (Figures 3.6). The biomass precursor 
(glycogen, steroids, fatty acids and nucleotides) reactions presented the biggest difference 
in flux between control and temperature-shifted cultures, particularly between 80 and 180 
hours a higher flux was observed for the cells at 37°C. The fluxes for serine aldolase 
(glycine production from serine) and glutaminase (glutamate production from glutamine) 
were also higher in a similar fashion to the biomass precursor reactions, but glycolytic 
fluxes were only marginally higher. Lactate dehydrogenase flux was higher for the control 
cultures; in agreement with the lactate concentration profile (Figures 3.5 and 3.7). TCA 
cycle flux was similar under both culture conditions. The absolute fluxes clearly showed 
the transient changes in metabolism as the cultures progress (Figure 3.6). Particularly in 
the control cultures, the glutamine consumption flux was elevated when cell-specific 
growth rate was beginning to decline at 100 hours, which coincided with the switch from 
lactate production to consumption (Figure 3.7). 
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Figure 3.6: Absolute intracellular fluxes over time for control and temperature shifted cultures. Fluxes 
in [mM/h], time scale in hours. The figure shows the estimated dynamic fluxes from 40 to 200 h (Full time 
scale of the estimated fluxes in Appendix Figure A3). The CHO-XL99 cultures at constant 37°C are in pink 
(37°C-1) and red (37°C-2), the temperature shifted cultures in cyan (32°C-1) and blue (32°C-2). The fluxes 
calculated by B-DMFA are shown with solid lines and the 95% CIs are shown with dashed lines. Clear flux 
differences were observed between the control and temperature-shifted cultures. Especially for the biomass 
precursor reactions, control cultures showed higher fluxes than temperature-shifted cultures between 80 to 
180 hours. 
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Figure 3.7: Concentration, absolute fluxes and volume specific fluxes for glucose, lactate and 
glutamine. Concentration in [mM], absolute fluxes in [mM/h], volume specific fluxes in [mmol/gDW/cell] and 
time scale in hours. The data for the control cultures are shown in pink (37°C-1) and red (37°C-2), and the 
temperature-shifted cultures in cyan (32°C-1) and blue (32°C-2). The glucose and glutamine consumption 
fluxes were higher for the control cultures, whereas they were more stable over time for the temperature-
shifted cultures. Similarly, the lactate flux was higher for the control cultures until 168 hours. At stationary 
phase cells began to consume lactate. Differences in fluxes between the control and temperature-shifted 
cultures were reduced when fluxes were expressed as specific fluxes. 
The differences in absolute fluxes between the two conditions can partially be attributed to 
differences in cell density, as cultures at 37°C grew faster than temperature-shifted cells 
and concomitantly accumulated more biomass. Volume-specific fluxes were therefore 
estimated to check if normalized fluxes were still different. While fluxes still showed 
transient behaviors, flux differences between the two culture conditions were diminished in 
general (Figure appendix A3). Glutaminase and lactate dehydrogenase fluxes for the 
control cultures were still significantly higher compared to the temperature-shifted cultures 
(Figure 3.8), but glycolytic fluxes were only marginally higher. The disparity between 
glycolytic and lactate fluxes suggests that, for the control cultures, a larger fraction of 
pyruvate was derived from other carbon sources in addition to glucose compared to 
temperature-shifted cultures. Biomass precursor reactions were kept at higher fluxes 
between 95 and 168 hours for the control cultures, which is proportional to the higher cell-
specific growth rate of the control cultures during that period of time. Cells entered 
stationary phase at 168 hours, showing a reduction in their biomass precursor 
requirements and concomitantly most intracellular fluxes. An interesting exception are the 
TCA cycle fluxes, which appeared to be similar and constant throughout the whole culture 
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for both conditions. Yoon et al. (2003) showed no change in cell-specific glucose, 
glutamine and lactate fluxes when temperature of CHO cell culture was reduced from 37°C 
to 33°C, but a significant increase in all three fluxes when temperature was reduced to 
30°C (Yoon, Song & Lee 2003). 
 
 
Figure 3.8: Volume specific productivity (Qp) over time for control and temperature-shifted cultures. 
The figure shows the estimated volume specific Qp from 40 to 200 h. The data for the control cultures are 
shown in pink (37°C-1) and red (37°C-2), and the temperature-shifted cultures in cyan (32°C-1) and blue 
(32°C-2). The cell number was normalized by cell volume. The temperature-shifted cultures have an almost 
constant volumetric Qp over the full culture. On the other hand, cells at constant temperature have a peak in 
volumetric Qp around 90 hours and then a decline. However, on average volumetric Qp is comparable in 
both conditions from 72.5 hours to 168 hours. Note that the 95% CIs of the Qp estimated by B-DMFA were 
large before the temperature shift due to the low cell number. 
Although the average volumetric Qp was the same for the two conditions (Figure 3.4D) 
during exponential phase, the time-resolved volumetric Qp prolife revealed by B-DMFA 
was very different (Figure 3.7). The volumetric Qp for the temperature-shifted cultures was 
largely constant at about 6 - 7 pg cell-1day-1 for the entire culture duration, despite the 
decline in cell-specific growth rate. In contrast, volumetric Qp for the control cultures 
peaked between 8 – 10 pg cell-1 day-1 at 90 hours, before gradually declining to 0. The 
higher titer achieved in the temperature-shifted cultures could be attributed to a more 
stable volumetric Qp (Figure 3.8). 
Overall, B-DFMA was able to quantify changes in cell metabolism for the whole cell culture 
duration. While we expect the temperature shift to induce transient metabolic behaviors in 
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the cell cultures, B-DFMA was able to account for the gradual decline in cell-specific 
growth rate and dynamic consumption and production profiles. The changes observed in 
the latter were not expected for the control cultures. None of the metabolic fluxes were 
constant over time for any of the culture conditions (Figures 3.6, 3.7, A2 and A3). The 
gradual decline in cell-specific growth rate may be pH-related, and possibly due to the 
accumulation of lactate and ammonia. While B-DMFA was designed for resolving transient 
metabolic behaviors, it was crucial in showing that volume-specific productivity of IgG1 
was significantly more stable in the temperature-shifted cultures compared to the controls. 
These observations would have been missed if average fluxes were used, highlighting the 
benefit of B-DMFA compared to conventional MFA. 
3.5. Conclusions  
We have demonstrated the usefulness of applying conventional B-spline notation and 
formulation to calculate dynamic fluxes without being restricted to any specific order of 
fitting. B-DMFA is capable of generating smooth fit for complete time series experimental 
data, as well as incorporating statistical estimation of dynamic metabolic fluxes in one step 
using redundant datasets. Using a higher-order fit, B-DMFA was shown to perform better 
in fitting dynamic external rates compared to L-DMFA. The heuristic algorithm developed 
to determine the knots sequence was validated to be accurate and was demonstrated to 
be much faster than the optimization method used in the L-DMFA approach (Leighty & 
Antoniewicz 2011). By resolving the dynamic changes in metabolic fluxes in temperature-
shifted CHO-XL99 culture, we showed that the reduction of growth and overall metabolic 
rates by inducing mild hypothermia may have benefited the CHO cell culture in terms of 
enhancing the stability of recombinant protein production, leading to an observed increase 
in final antibody titer by 42%. This leaves room to speculate whether the slower cell 
metabolism and the reduced accumulation of lactate and ammonia have a positive effect 
on the stability of recombinant protein productivity. 
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Chapter 4 
 
Improving Culture Performance and Antibody 
Production in CHO Cell Culture Processes by Reducing 
the Warburg Effect 
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4.1. Abstract 
Lactate is one of the key waste metabolites of mammalian cell culture. High lactate levels 
are caused by high aerobic glycolysis, also known as the Warburg effect, and are usually 
associated with adverse culture performance. Therefore, reducing lactate accumulation 
has been an ongoing challenge in cell culture development in order to improve growth, 
productivity and process robustness. The pyruvate dehydrogenase complex (PDC) plays a 
crucial role for the fate of pyruvate, as it converts pyruvate to acetyl-CoA. PDC activity can 
be indirectly increased by inhibiting the PDC inhibitor, pyruvate dehydrogenase kinase, 
using dichloroacetate (DCA); resulting in less pyruvate being available for lactate 
formation. Here, Chinese hamster ovary cells were cultivated either with 5 mM DCA or 
without DCA in various batch and fed-batch bioreactor processes. In all cultures, DCA 
increased peak viable cell density (VCD), culture length and final antibody titer. The 
strongest effect was observed in a fed-batch with media and glucose feeding in which 
peak VCD was increased by more than 50%, culture length was extended by over three 
days and final antibody titer increased by more than 2-fold. In cultures with DCA, lactate 
production and glucose consumption during exponential growth were on average reduced 
by about 40% and 35%, respectively. Reduced lactate production rate also reduced 
osmolality increase in DCA cultures due to smaller amount of base being added to the 
system. Metabolic flux analysis showed reduced glycolytic fluxes while fluxes in TCA cycle 
were not affected suggesting that cultures with DCA use glucose more efficiently. In 
proteomics analysis only few proteins were identified as being differentially expressed 
indicating that DCA acts on a post-translational level. Antibody quality in terms of 
aggregation, charge variant and glycosylation pattern was unaffected. Subsequent 
bioreactor experiments with sodium lactate and sodium chloride feeding indicated that 
lower osmolality, rather than lower lactate concentration itself, improved culture 
performance in DCA cultures. In conclusion, the addition of DCA to the cell culture 
improved culture performance and increased antibody titers without any disadvantages for 
cell specific productivity or antibody quality.  
4.2. Introduction 
Mammalian cells are the preferred production host for therapeutic proteins such as 
monoclonal antibodies due to their ability to perform post-translational modifications, which 
are essential for biological efficacy and safety (Durocher & Butler 2009; Wurm 2004). Most 
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cultured mammalian cells display aerobic glycolysis also known as the Warburg effect, i.e. 
inefficient energy metabolism, characterized by increased glucose consumption and 
lactate production (Warburg, Wind & Negelein 1927). Rapid lactate accumulation 
adversely effects culture performance and productivity (Dietmair, Nielsen & Timmins 2011; 
Gambhir et al. 2003; Lao & Toth 1997; Lim et al. 2010). In fermentation, pH is controlled 
and growth inhibition has been attributed to the concomitant osmolality increase (Cruz et 
al. 2000). Increased osmolality can also affect antibody quality (Li, J et al. 2012; Pacis et 
al. 2011). 
Many strategies involving process optimization (Altamirano et al. 2004; Gagnon et al. 
2011; Glacken, Fleischaker & Sinskey 1986; Kuwae et al. 2005) or genetic engineering 
(Fogolin et al. 2004; Irani et al. 1999; Wlaschin & Hu 2007; Zhou, M et al. 2011) have been 
explored to reduce lactate production and hereby improving cell growth, productivity and 
process robustness. Interestingly, while a knock-down of lactate dehydrogenase (LDH) 
reduces glucose consumption and lactate production (Kim, SH & Lee 2007), our attempt to 
perform a double knock-out of LDH failed presumably due to lethality; one allele was 
readily interrupted by a zing finger nuclease, but no double knock-out could be produced 
(unpublished). Correspondingly, Sanfeliu et al. concluded from experiments using 
oxamate, an LDH inhibitor, in hybridoma cells that LDH activity is essential for cell survival 
as LDH activity is necessary to reoxidise large amounts of NADH produced in glycolysis 
(Sanfeliu et al. 1997). It is possible that the TCA cycle is unable to absorb additional 
carbon. Consistent herewith, the glucose consumption declined in knock-down study and 
no additional carbon was redirected into the TCA cycle as lactate to glucose yield was 
unaltered.  
The pyruvate dehydrogenase complex (PDC) plays a crucial role in glucose metabolism 
linking glycolysis to the TCA cycle as it converts pyruvate to acetyl-CoA. PDC activity is 
regulated by reversible phosphorylation of three serine residues; phosphorylation being 
catalyzed by pyruvate dehydrogenase kinase (PDK) which inactivates PDC (Yeaman et al. 
1978). PDC activity can be indirectly increased by inhibiting PDK using dichloroacetate 
(DCA) (Whitehouse, Cooper & Randle 1974). DCA has been used for decades in the 
treatment of human diseases such as acquired or congenital lactic acidosis, congestive 
heart failure and ischemic heart disease due to its ability to lower blood lactate levels 
(Stacpoole et al. 1998). DCA has also been explored to improve mammalian cell culture. 
In hybridoma cell cultures without pH control, DCA improved peak viable cell density and 
final antibody titer by delaying glutamine depletion without any effect on glucose 
consumption or lactate production (Murray, Gull & Dickson 1996). In Chinese hamster 
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ovary (CHO) cultures without pH control, DCA reduced lactate production leading to higher 
viable cell density (Follstat 2002). However, no improvements in culture performance were 
observed in pH controlled bioreactor fermentations. 
In this study, we successfully used DCA to reduce lactate production and glucose 
consumption in commercially relevant, pH controlled CHO fed batch cultures, in which no 
essential macronutrients were depleted. We compared cell growth as well as nutrient 
consumption and metabolite production, productivity and antibody quality. Proteomics, 
metabolomics and fluxomics were used to explore the system-wide effect of DCA. Finally, 
sodium lactate and sodium chloride feed experiments were performed to establish if lower 
lactate accumulation itself or lower osmolality levels are responsible for improvements in 
culture performance.  
4.3. Material and Methods 
4.3.1. Cell line and medium  
CHO-XL99 is a derivative of CHO-K1 (ATCC 61-CCL) and expresses a full IgG1 antibody 
(Ab2). It was adapted to CD CHO medium supplemented with 8mM GlutaMAX, 400ug/ml 
Geneticin and 0.2% v/v Anti-Clumping Agent (all Invitrogen). Cells were routinely 
maintained in shake flask in humidified incubators set to 37°C, 7.5% CO2 and 130 rpm. 
Sodium dichloroacetate (Sigma-Aldrich) was added to respective pre-cultures two days 
before transfer to the bioreactor. Two ml/l Pluronic F-68 (Invitrogen) was added to the 
medium used for bioreactor cultures. Separate shake flask experiments were performed 
for Western blot, DCA response curve and DCA stability in cell culture analysis.  
4.3.2. Western blot 
CHO-XL99 cells were cultivated using different DCA concentrations (0 – 10 mM DCA) for 
48 hours. Approximately, 2 x 107 cells were collected, washed with 0.9% sodium chloride 
and lysed in RIPA buffer (0.1% SDS, 1% Triton-X100, 5 mM ethylenediaminetetraacetic 
acid, 0.5% sodium deoxycholate, 150 mM NaCl, 50 mM Tris-HCl, 2 mM dithiothreitol, 
supplemented with 1ug/mL leupeptin (Roche), 1ug/mL aprotinin (Roche), 1 mM sodium 
orthovanadate, 10 mM sodium fluoride). Cell lysates were incubated for 60 min on ice 
followed by centrifugation at 16,000 rcf, 4°C for 10 min. Protein concentration of the 
supernatant was determined using a 2D Quant Kit (GE Healthcare). Cell extracts 
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equivalent to 10 µg of protein were run on a 4-12% SDS-polyacrylamide gel and 
transferred to nitrocellulose membranes by standard procedures. Membranes were 
blocked with 5% nonfat milk in PBS/Tween for 1 hour followed by incubation with anti-
human PDC E1-α subunit (phospho S293) (abcam) and anti-β-tubulin (Cell Signalling 
Technology) antibodies for 2 hours at RT. Immunoreactive bands were visualized using 
horseradish peroxidase-conjugated anti-rabbit antibody (Life Technologies) and 
Amersham ECL Western Blotting Detection Reagents (GE Healthcare Bio-Sciences). 
Densitometry was performed using a BIORAD ChemiDoc MP Imaging System (Bio-Rad 
Laboratories) and Image Lab 4.0.1 software (Bio-Rad Laboratories).  
4.3.3. HPLC method for DCA quantification in cell culture 
CHO-XL99 cells were cultivated with different DCA concentrations (0 – 10 mM DCA). 
Every two days, a 500 μl sample was collected, centrifuged at 500 rcf and supernatants 
were frozen and stored at -20°C until analysis. DCA concentrations were determined by 
reverse phase HPLC on an Agilent 1200 system equipped with a Kinetex C18-XB column 
(100 Å, 2.6 µm, 100 × 2.1 mm, Phenomenex) and a diode array detector. The column 
temperature was set at 30°C and the flow rate was 0.2 ml/min. Mobile phase A consisted 
of 10 mM tetrabutylammonium bisulfate (Sigma-Aldrich) in water and mobile phase B was 
100% acetonitrile (Merck). The gradient started with 5% mobile phase B and was 
increased linear to 30% in 3 min followed by a hold at 30% for 5 min. Next, the 
concentration of mobile phase B was increased linear from 30% to 60% in 1 min followed 
by a hold of 60% mobile phase B for 5 min. Afterwards, the gradient was reversed from 
60% to 5% mobile phase B in 1 min, followed by a hold at 5% mobile phase B for 5 min.  
4.3.4. Bioreactor cell culture 
A total of 12 bioreactor cultures were performed (Table 4.1). All cultures were carried out 
in a 3L sparged bioreactor (Applikon) with 1L initial working volume at 37°C, pO2 at 50% 
air saturation, stirrer speed at 200 rpm, and pH 7.0 controlled by CO2 sparging and 
addition of 1 M sodium bicarbonate. Oxygen uptake rate (OUR) was determined using the 
dynamic method (Singh 1996). In fed-batch cultivations, a 1:1 mixture of CHO CD 
EfficientFeed A and CHO CD EfficientFeed B (FeedAB) (Life Technologies) was fed four 
times: prior to inoculation (15% of volume) and after approximately 90 h (15%), 109 h 
(10%) and 118 h (10%) after inoculation. In the “fed-batch plus glucose” cultures 
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concentrated glucose (450g/l, Sigma) was added to the cell culture as needed to keep 
glucose concentration above 11 mM after the last FeedAB feed and until the end of the 
culture.  
Sodium lactate (Ajax finechem) and sodium chloride (Sigma-Aldrich) feeding experiments 
were carried out, starting the bioreactor cultivation as the fed-batch cultures. One day after 
inoculation, sodium lactate (40 mM/day) or sodium chloride (30 mM/day) was fed 
continuously until the end of culture. 
 
Table 4.1: Overview of experiments presented in this work. 
Study Conditions* Cultures No. of runs 
Batch CD CHO medium 
No feeding 
5mM DCA 
No DCA (control) 
2 
2 
Fed-batch CD CHO medium 
FeedAB 
5mM DCA 
No DCA (control) 
1 
1 
Fed-batch plus glucose CD CHO medium 
FeedAB + glucose feed 
5mM DCA 
No DCA (control) 
2 
2 
Sodium lactate feed CD CHO medium 
FeedAB + sodium lactate 
No DCA 1 
Sodium chloride feed CD CHO medium 
FeedAB + sodium chloride 
No DCA 1 
* FeedAB = CHO CD Efficient Feed A & B (1:1) 
4.3.5. Cell count, metabolite and IgG measurements 
Viable cell density, viability and cell diameter were measured using a CedeX cell counter 
(Innovatis AG). Ammonia, Na+, and glucose concentrations used to determine time points 
of glucose feeding were quantified using a Nova Bioprofiler FLEX (Nova Biomedical). 
Extracellular glucose, lactate, GlutaMAXTM and amino acid concentrations were measured 
by HPLC as described previously (Dietmair, Timmins, Gray, Nielsen & Kromer 2010), 
while antibody titers were determined using surface plasmon resonance with a Biacore T-
100 (GE Healthcare). A human antibody capture kit (GE Healthcare) was used for the 
immobilization of an Ab2 binding α-Hu IgG FC-specific antibody onto the CM5 sensor 
chips. Samples were diluted 5-10 times in HBS-EP buffer (GE healthcare) and protein-A 
purified Ab2 was used to obtain a standard curve for quantification. Selected intracellular 
metabolites from glycolysis, TCA cycle and pentose phosphate pathway were measured 
by HPLC-MS/MS (Dietmair, Timmins, Gray, Nielsen & Kromer 2010) in mid-exponential 
growth phase of fed-batch and fed-batch plus glucose cultivations (Figure 4.2).  
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4.3.6. Metabolic flux analysis 
Metabolic fluxes during exponential growth were estimated using a metabolic model 
derived from Mus musculus GeM (Quek & Nielsen 2008b) as previously described (Quek 
et al. 2010). The average cell dry weight was measured to be 350 pg/cell and precursor 
compositions obtained from previous CHO cell studies (Martínez, VS et al. 2013) were 
used for the biomass equation. An Ab2 antibody production reaction was added (Ab2 
amino acid composition shown Appendix B). GlutaMAXTM (L-alanyl-L-glutamine dipeptide) 
was treated as free glutamine and alanine. Constrained weighted quadratic programming 
was used for consistency checking and flux variability analysis (Antoniewicz, Kelleher & 
Stephanopoulos 2006), while a Monte-Carlo approach was used to propagate errors in the 
primary concentration data into the calculated cell-specific rates (Goudar et al. 2009, Quek 
et al. 2014) (see also Appendix C). Estimated fluxes were also used for calculation of ATP 
production (Martínez, VS et al. 2013).  
Dynamic metabolic flux analysis (DMFA) was used to determine metabolic fluxes over the 
complete culture period and is described in chapter 3 in detail. Briefly, metabolic fluxes are 
allowed to change over time to reflect the dynamics of the measured concentrations and 
rates. The complete time-series of metabolic fluxes can be estimated by solving a single 
optimization problem (Antoniewicz 2013b). Higher-order B-spline fitting was used to 
estimate mass balanced fluxes for the entire culture time and a fast heuristic algorithm was 
used to determine the position of the knots (time points) of the B-spline.  
4.3.7. Proteomics 
4.3.7.1. Sample preparation 
Approximately 3 x 107 cells were collected during the mid-exponential growth phase of fed-
batch and fed-batch plus glucose cultures (Figure 4.2). Cells were centrifuged at 500 rcf 
for 3 min, washed with 0.9% sodium chloride and cell pellets frozen on dry ice and stored 
at -80°C. Cells were lysed in 500 μl cell lysis buffer (8 M urea, 50 mM ammonium 
bicarbonate, 5 mM sodium orthovanadate, 10 mM sodium fluoride, 2.5 μg/ml leupeptin 
(Roche), 1.5 μg/ml aprotinin (Roche)) and disrupted using a 25G needle followed by 3 x 1 
min sonication. 5 μl RNaseA (Thermo Fisher Scientific Inc.) and 5 μl DNaseI (Thermo 
Fisher Scientific Inc.) were added to the cell lysate followed by incubation at RT for 15 min. 
Cell lysate was centrifuged for 10 min at 16.000 rcf, 0°C and supernatant was collected, 
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frozen on dry ice and stored at -80°C. Protein concentration was determined using a 2D 
Quant Kit (GE Healthcare) according the manufacturer’s instructions. To 100 μg of protein, 
six times the volume of -20°C cold acetone was added and incubated at -20°C for three 
hours. Samples were centrifuged for 2 min at 1000 rcf, 0°C and supernatant was removed 
from the tubes. 20 μl of Dissolution Buffer (iTRAQ reagents, Sciex) and 1 μl of Denaturant 
(iTRAQ reagents) were added to dissolve the sample. 2 μl of Reducing Reagent (iTRAQ 
reagents) were added and the samples were incubated at 60°C for one hour. 1 μl of 
Cysteine Blocking Reagent (iTRAQ reagents) was added to the sample and incubated for 
10 min at RT followed by adding 10 μg of trypsin (Trypsin Gold, Promega) and incubation 
at 37°C overnight. Digested peptide samples were cleaned using ZipTip C18 (Millipore) 
and eluted with 70% (v/v) acetonitrile. Residual acetonitrile was removed using vacuum 
centrifugation (Eppendorf) and samples were resuspended in 0.1% formic acid.  
4.3.7.2. LC-MS/MS analysis and quantification 
Peptides were separated on a Shimadzu Prominence Nano-LC system equipped with a 
Vydec Everest C18 column (300 Å, 5 μm, 150 mm x 150 μm) at a flow rate of 1 μl/min 
using a gradient of 10-60% mobile phase B over 90 min; mobile phase A = 1% 
acetonitrile/0.1% formic acid and mobile phase B = 80% acetonitrile/ 0.1% formic acid. 
Eluted peptides were analyzed on a QSTAR-Elite (ABSciex) equipped with a nano-spray 
ESI source operated in positive mode. Analyst® software was used to scan for masses 
between 300 to 1800 Da followed by high sensitivity product ion scan. ProteinPilot v4.5 
(ABSciex) and the Paragon Algorithm were used to analyze MS/MS data. The protein 
sequences for CHO-K1 were downloaded from the Chinese hamster genome database 
(http://www.chogenome.org). A false discovery rate of 5% was used. Only proteins 
identified with at least 2 peptides at 95% confidence were included in the statistical 
analysis. For SWATH-MS, MS/MS data was analyzed with the SWATH-MS processing 
script in PeakView v 1.2 (ABSciex) using discovery data as the spectra library for protein 
identification and fragment ion peak areas were used for quantification. Summed protein 
peak areas were used for statistical analysis. Raw data was first log2 transformed and 
quantile normalized. Data was then analyzed for statistically differentially expressed 
proteins using limma (Smyth 2005) in R (R Core Team 2013). Proteins with an adjusted p-
value of < 0.05 were considered statistically significant different.  
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4.3.8. Antibody product quality analysis 
Samples were collected during early stationary phase of fed-batch plus glucose 
cultivations (Figure 4.2).  Cell culture was centrifuged at 500 rcf, RT for 5 min, followed by 
a 0.22 μm filtration. Supernatant was stored at -80°C until purification. Antibody was 
protein-A purified using an ÄKTA avant 150 (GE Healthcare) with a HiTrap Map Select 1 
mL column (GE Healthcare). Antibody was eluted in 0.1 M glycine, pH 3.0. The purified 
antibody was then desalted using a HiTrap 5 mL column (GE Healthcare) and eluted in 1x 
Dulbecco's Phosphate-Buffered Saline (Dulbecco). A LabChip GXII (Caliper) was used to 
analyze charged variants (HT Protein Charge Variant Kit, Caliper) and various glycoforms 
(ProfilerPro Glycan Profiling Kit, Caliper). Except for a longer PNGase digestion step of 3 
hours, the kits were used according to manufacturer’s instructions. Antibody aggregation, 
monomer and fragment levels were determined using standard size exclusion 
chromatography on an Agilent HPLC system.  
4.4. Results 
4.4.1. DCA is stable in CHO cell culture, decreases PDC phosphorylation and 
reduces lactate formation 
Shake flask experiments with different DCA concentrations were performed to analyze the 
effects of DCA on cell growth, lactate production and PDC phosphorylation. DCA can be 
degraded by glutathione S-transferase ζ1 (Lantum et al. 2003; Li, WJ et al. 2011) and we 
first established that DCA concentration in CHO culture decreased less than 5% of its 
initial concentration over a period of 12 days and no additional DCA supplementation is 
required (Figure 4.1C). Lactate production decreased with increasing DCA concentration, 
while the growth rate was unaffected up to a concentration of 5 mM DCA, and this 
concentration was chosen for subsequent bioreactor cultures. Western blot analysis 
confirmed a decrease in PDC E1α phosphorylation with increasing DCA concentration with 
a 17% reduction observed at 5 mM DCA (Figure 4.1D).  
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Figure 4.1: Growth curve, lactate and DCA concentration profile, and Western blot analysis. CHO cells 
were cultured in shake flask with different DCA concentrations. Growth rate was unaffected by DCA up to 5 
mM and decreased at higher DCA concentrations (A). Lactate production decreased with increasing DCA 
concentration during exponential growth (B). DCA concentration decreased less than 5% in CHO cell culture 
over a 12 day culture period (C) and with increasing DCA concentration PDC E1α phosphorylation 
decreased (D). 
4.4.2. Growth, glucose consumption, lactate production, and antibody titer profiles 
in different bioreactor culture processes 
In batch fermentations, both control and 5 mM DCA, cell growth stopped once glucose 
was depleted (Figure 4.2, top panel). DCA delayed depletion, maintained high viability for 
an additional day and enhanced Ab2 titer (Table 4.2). Depletion can be avoided using fed-
batch and we first used a rich feed to the maximum recommended total of 50% of culture 
volume (Figure 4.2, middle panel). While feeding extended the culture, cell growth stopped 
due to glucose depletion and DCA again extended the culture and increased titer (Table 
4.2). Glucose depletion was avoided in the subsequent fed batch cultures by feeding 
glucose as required after completion of the rich medium feed (Figure 4.2, bottom panel). 
Surprisingly, glucose feeding had a greater benefit in DCA cultures extending these by 2.5 
days compared to 1 day without DCA. The Ab2 titer improvement further increased to 
105% (Table 4.2). 
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Figure 4.2: Impact of DCA on cell growth, glucose consumption, lactate production and antibody 
titer. CHO-XL99 cells were cultivated in a bioreactor with 1L initial working volume in batch, fed-batch and 
fed-batch plus glucose processes either with 5 mM dichloroacetate (DCA) or no DCA as control cultures. In 
fed-batch and fed-batch plus glucose the feeding medium (FeedAB) was added before inoculation followed 
by three more feedings during the cultivation. In fed-batch plus glucose cultures, glucose feeding started on 
day 6 and continued until the end of the culture as needed to keep glucose concentration above 11 mM. In 
all processes, DCA extended the culture time, led to a higher peak VCD, decreased glucose consumption 
and lactate production and increased final antibody titer. VCD = viable cell density. 
 
During exponential growth, DCA reduced glucose consumption and lactate production by 
about 35.4 ± 3.4% and 40.2 ± 3.4%, respectively, resulting in a decrease in molar lactate 
to glucose yield of 7.43% (Table 4.2). The growth rate during exponential growth for all ten 
cultures was the same (0.0333 ± 0.0004 h-1, p = 0.30, t-test). Similarly, there was no 
difference in the cell specific productivity (8.81 ± 0.05 pg/(cell*day), p = 0.65, t-test). Thus, 
the improved titers seen with DCA are exclusively attributable to maintaining cultures 
viable for longer.  
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Table 4.2: Culture length, peak viable cell density, lactate to glucose yield, and final antibody titer of 
cultures with DCA and control cultures in different processes. 
 Culture 
time [days] 
Peak VCD 
[*10
5
 
cells/ml]  
Ylactate/glucose Final Ab2 
conc. [ug/ml]  
Ab2 conc. increase 
compared to control 
culture  
Batch, no DCA  ~4 62.52 1.75 77.15  
Batch, 5 mM DCA  ~5 74.66 1.62 137.79 ~78% 
Fed-batch, no DCA  ~7 108.52 1.74 167.27  
Fed-batch, 5 mM DCA  ~8.5 172.85 1.61 311.54 ~86% 
Fed-batch + glucose, 
no DCA  
~8 117.97 1.68 215.56  
Fed-batch + glucose, 
5 mM DCA  
~11 181.51 1.56 442.94 ~105% 
VCD = viable cell density 
4.4.3. DCA does not affect antibody quality 
The CHO-XL99 cell line expresses a full IgG1 antibody (Ab2). Change in culture conditions 
and cell metabolism can influence the antibody quality. DCA had no major impact on 
aggregation level, acidic and basic variants or glycoform pattern (Table 4.3). The 
percentage of monomers was slightly lower, while the percentage of dimers and multimers 
was higher. Similarly, a slight shift from basic to acidic variants was observed in DCA 
cultures. The glycan profile analysis was similar for both cultures and showed no change 
in % Man5, a variable previously found to be affected by osmolality (Pacis et al. 2011).  
 
Table 4.3: Aggregation, charge variant and glycan profiles of control and DCA cultures. Samples (n=3 
for each condition) were collected in early stationary phase (Figure 4.2) and analyzed for aggregation using 
SEC-HPLC, charge variants (HT Protein Charge Variant Kit, LabChip GX2) and glycoforms (ProfilerPro 
Glycan Profiling Kit, LabChip GX2). 
 
4.4.4. Growth cessation is caused by high osmolality 
During fed-batch plus glucose cultures, cell growth slowed down and cultures entered 
stationary phase despite neither glucose nor any of the essential amino acids being 
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depleted. While depletion of a micronutrient is a possibility, a more likely explanation, 
given the effect of DCA, is the accumulation of growth inhibiting by-products. Comparing 
growth curves and lactate concentrations of control and DCA cultures showed that in both 
conditions growth started to slow down once lactate concentration reached about 90 mM 
(Figure 4.3, blue circle).  
 
Figure 4.3: Viable cell density and lactate concentration of fed-batch plus glucose cultures. Viable cell 
density (VCD) and lactate concentration profile of fed-batch plus glucose control cultures (A) and with 5 mM 
DCA (B). Circles indicate start of growth rate reduction. 
 
A sodium lactate feeding experiment was performed to confirm that high lactate 
concentration was responsible for growth inhibition (Figure 4.4A). Sodium lactate was fed 
at 40 mM/day, which is higher than the maximum volumetric lactate production rate 
observed in DCA cultures (~24 mM/day) but slightly lower than in control cultures (~42 
mM/day).  
 
Figure 4.4: Impact of sodium lactate and sodium chloride feeding on cell growth. Culture had same 
starting conditions as fed-batch without DCA. One day after inoculation sodium lactate feeding (A, 40 
mM/day) or sodium chloride feeding (B, 30 mM/day) started.  
 
Early on day four during sodium lactate feed experiment, the lactate concentration reached 
90 mM and cell growth slowed down, followed by stationary phase and entering death 
phase late on day four (Figure 4.4A). Na+ concentration was around 180 mM when cell 
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growth rate decreased. Cells entered stationary phase at a Na+ concentration of about 220 
mM. Feeding sodium lactate to the culture not only increased the lactate concentration but 
also increased osmolality. Therefore it is not clear whether lactate itself or the increased 
osmolality caused growth inhibition.  
A sodium chloride feeding experiment in which osmolality is increased at a higher rate 
while lactate concentration only increases at the rate produced by the cells was carried out 
to determine which factor is growth inhibitory (Figure 4.4B). The growth rate declined on 
day four at around 180 mM Na+ however cell growth continued until day five. Cells started 
to die once Na+ concentration reached about 220 mM. The Na+ concentration were similar 
to concentrations observed in sodium lactate feeding experiment at time point of growth 
rate reduction, however lactate concentration was significantly lower (final lactate 
concentration was 49 mM) indicating that high osmolality, rather than the lactate 
concentration per se, was growth inhibitory in fed-batch plus glucose fermentations. 
4.4.5. DCA significantly decreases lactate production without affecting oxidative 
metabolism 
In order to understand global effects of DCA, a comprehensive omics comparison was 
performed during the exponential phase of fed batch cultures. Since this precedes post-
inoculation feeding, data from fed batch cultures with and without glucose were used as 
biological replicates. Samples for proteomics and metabolomics were obtained on Day 3. 
Metabolic rates were determined between day ~1 and ~3.5 (Table 4.4) which were 
subsequently used for metabolic flux analysis (MFA) (Figure 4.5). Additionally, B-DMFA 
was performed for the complete cultivation period of fed-batch plus glucose fermentations 
(Figure 4.7).  Samples for intracellular metabolite analysis were collected in triplicate from 
fed-batch plus glucose cultures. One of the DCA samples had varying results without a 
clear trend and was omitted from the analysis, leaving n = 5 for DCA cultures and n = 6 for 
control cultures. A total of 43 metabolites were measured whereof 14 were either not 
detected or below the lower limit of quantification in at least one of the samples (Figure 
4.6). Using SWATH for quantitative proteomics, less than 1% (20) of 2016 identified 
proteins were differentially expressed (Appendix D) with the highest fold change being 
2.31. None of the genes in central carbon metabolism appeared in the differentially 
expressed list, nor did gene enrichment analysis identify central metabolic processes such 
as glycolysis. Evidently both the direct and indirect effects of DCA are at a post-
56 
 
translational level and observed metabolic changes are the result of post-translational 
regulation.  
Table 4.4: Metabolic rates of CHO-XL99 cultures treated with 5 mM DCA and control cultures during 
exponential growth. Mean (n=3, fed-batch and fed-batch plus glucose) metabolic uptake and production 
rates of cultures with 5 mM DCA and control cultures during exponential growth. Rates are in µM/(gDW*h), 
growth rate is in h
-1
, antibody (Ab2) production rate is in pg/(cell*day). Negative rates represent consumption 
while positive rates are production of the corresponding metabolite. The asterisks indicate rates which were 
statistically significantly different (p < 0.05, t-test) in cultures with DCA compared to control cultures. OUR = 
oxygen uptake rate, SE = standard error, Y = yield. 
 
  No DCA 5mM DCA 
Metabolite Rate ± SE Rate ± SE 
Glucose* -575.0 9.6 -371.6 8.7 
Lactate* 1005 15 600 14 
Ylactate/glucose* 1.749 0.004 1.616 0.001 
NH4
+* 27.04 0.25 30.03 0.70 
OUR -291.4 3.5 -289.2 3.5 
Consumed amino acids 
    Asp* -4.83 0.041 -3.83 0.087 
Glu -4.04 0.044 -3.82 0.17 
Asn -43.02 0.38 -42.30 0.54 
Ser* -47.95 0.23 -44.30 0.76 
Arg* -10.03 0.21 -8.44 0.13 
Essential amino acids 
    His -4.45 0.13 -4.16 0.033 
Thr -10.70 0.25 -10.10 0.21 
Tyr -4.56 0.11 -4.76 0.21 
Val -13.89 0.23 -13.18 0.38 
Met  -4.90 0.15 -4.79 0.065 
Trp* -3.67 0.090 -3.26 0.090 
Phe* -6.77 0.098 -5.52 0.12 
Ile* -11.43 0.12 -10.55 0.26 
Leu -17.79 0.23 -16.62 0.45 
Lys* -13.94 0.11 -13.05 0.25 
Pro  -11.16 0.28 -11.88 0.31 
Produced amino acids 
    Gly* 23.73 0.30 16.61 0.24 
Ala 97.4 1.4 95.0 1.9 
Gln* 22.77 0.27 19.05 0.53 
Glutamax* -56.8 1.1 -50.8 1.4 
  
    Growth rate 0.0328 0.0004 0.0322 0.0007 
Productivity 8.86 0.037 8.77 0.095 
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The metabolic rates for glucose consumption and lactate production were significantly 
reduced in DCA cultures, while the oxygen uptake rate (OUR) was unchanged indicating 
similar TCA cycle activity during exponential growth (Table 4.4). Several of the amino acid 
production and consumption rates as well as ammonia production were different between 
the two conditions (p < 0.05, t-test) with rates being lower in DCA cultures. The largest 
difference was observed for glycine production which was 30% lower in DCA cultures. 
Intracellular metabolic fluxes (Figure 4.5) were estimated using total cell number, amino 
acids, glucose, lactate, ammonia measurements and Ab2 concentration as input data for 
MFA. As expected from reduced glucose consumption and lactate production (Table 4.4), 
glycolytic fluxes and flux through LDH were significantly lower in cultures with DCA (Figure 
4.5). The concentration of glycolytic intermediates downstream of phosphofructokinase 
(PFK) and aldolase were lower in DCA culture compared to control cultures as were 
lactate. In contrast, glucose 6-phosphate, glucose 1-phosphate and fructose 6-phosphate 
were similar. MFA cannot resolve fluxes in the oxidative pentose phosphate pathway as 
the need for NADPH can also be met by the cytosolic malic enzyme (Quek et al. 2010). 
The concentrations of ribose 5-phosphate and ribulose 5-phosphate were higher in DCA 
cultures, suggesting a more active pentose phosphate pathway. 
Apart from glycolysis, the only significant flux change was reduced flux in DCA cultures 
through the serine transhydroxymethyltransferase enzyme that converts serine and 
tetrahydrofolate (THF) to glycine and 5,10-methylene-THF, which is consistent with the 
reduced production of glycine observed in Table 4.4. 
In both cultures, the majority of glycolytic derived pyruvate was converted to lactate though 
the percentage was lower for cultures with DCA (68% and 78% for DCA and control 
cultures, respectively). DCA reduces phosphorylation of PDC (Figure 4.1) and data does 
support a small shift in concentrations with lower pyruvate and higher acetyl-CoA (Figure 
4.6). However, fluxes for pyruvate transport into the mitochondrion and the PDC reaction 
were unchanged (Figure 4.5), indicating that DCA cultures did not direct more pyruvate 
into the TCA cycle but rather reduced the flux to pyruvate and the fraction of pyruvate 
converted to lactate. Consistent herewith, the concentration of TCA cycle intermediates 
(citrate, aconitate, fumarate, and malate) were similar between the two conditions (Figure 
4.6).  
58 
 
 
Figure 4.5: Metabolic flux analysis of CHO-XL99 cultures with 5 mM DCA and control cultures during 
exponential growth. Intracellular fluxes were estimated using metabolic flux analysis. Rates are shown as 
solid bars with 95% confidence intervals shown as vertical lines. While glycolytic fluxes, fluxes through 
lactate dehydrogenase and one carbon metabolism reaction were significantly lower in cultures with 5 mM 
DCA (DCA) compared to control cultures (C); fluxes through the TCA cycle, pentose phosphate pathway, 
and fatty acid and steroid production pathways were very similar. Rates are in µM/(gDW*h). THF = 
Tetrahydrofolate, 5,10MTHF = 5,10 Methylenetetrahydrofolate. 
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ATP production was calculated using the estimated optimum fluxes. ATP production via 
the TCA cycle was similar in both conditions. 1284 μmol/(gDW*h) and 1256  
μmol/(gDW*h) for control and DCA cultures respectively, which is consistent with the 
unchanged OUR (Table 4.4). However, the amount of ATP generated in glycolysis is about 
35% lower in DCA cultures, 1155 µM/(gDW*h)  and 741 µM/(gDW*h) for control and DCA 
cultures, respectively. Accordingly, cultures with DCA produced 18% less ATP overall, 
2440 μmol/(gDW*h) for control cultures and 1997 μmol/(gDW*h) for DCA cultures, despite 
having similar growth rates and cell specific productivity. 
ATP concentration was lower in DCA cultures, however the adenylate energy charge 
(Atkinson & Walton 1967) was similar for control and DCA cultures with 0.91 ± 0.03 and 
0.92 ± 0.01, respectively, indicating no lack of energy in either condition (Figure 4.6). Other 
nucleotides and nucleotide sugars were also elevated. NADP+ concentrations were similar, 
while NAD+ concentration was slightly reduced in DCA cultures (Figure 4.6). The latter 
may be attributed to reduced LDH activity in DCA cultures. 
Similar to MFA, glucose, lactate, amino acids, ammonia measurements and Ab2 
concentration data were used for B-DMFA (Figure 4.7). However, instead of cell number, 
cell volume was used as the cell diameter increased during the cultivation in both cultures. 
Since OUR was only measured once during the exponential growth, it was not used and 
the measurement set had only one degree of freedom (Quek et al. 2010). Therefore, the 
calculated residual error represents the consistency of the nitrogen balance among the 
measurements. The number of knots in control culture was two while three knots were 
necessary in DCA cultures. Data before 50 hours is not shown as the 95% CIs were very 
large due to low cell density increasing the error. However, MFA can be used during that 
period to estimate fluxes as steady state can be assumed during exponential growth.  
The B-splines were mostly able to accurately trace the measured concentrations 
(Appendix Figure A1). The only difference was observed in stationary growth phase of 5 
mM DCA cultures where the fitted biomass was lower than the measured values, meaning 
that more cells were generated than possible according to the nutrients consumed. This 
can be due to measurement errors of VCD at high cell densities, also indicated by the 
spreading of the measurements. Alternatively, another compound which was not 
measured was used as a nutrient by the cells.  
Correlating with results from MFA, DCA cultures have a reduced flux in lactate production 
from pyruvate compared to control cultures. In control cultures, lactate production 
decreased over time for the whole cultivation period; while in DCA cultures, lactate 
production was constantly low after 150 hours when the cells entered stationary phase 
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which correlates with the reduced lactate production rate after day six (Figure 4.2). The 
fluxes from serine to glycine and glycolytic fluxes were also lower in DCA cultures, 
although the 95% CI overlap and the difference is only present until ~120 hours, when 
control cultures enter stationary phase. Interestingly, in both conditions TCA cycle fluxes 
were constant and similar, indicating a constant TCA cycle activity in 5 mM DCA and 
control cultures over the complete cultivation period.   
 
 
Figure 4.6: Comparison of intracellular metabolite concentrations. Concentrations are in fmol/cell. N=5 
for DCA cultures, n=6 for control cultures. 3PG and 2PG = 3-phosphoglycerate and 2-phosphoglycerate, CIT 
+ ISO = citrate and isocitrate, DHAP = dihydroxyacetone phosphate, F6P = fructose 6-phosphate, G1P = 
glucose 1-phosphate, G6P = glucose 6-phosphate, GA3P = glyceraldehyde 3-phosphate, PEP = 
phosphoenolpyruvate, PYR = pyruvate, R5P = ribose 5-phosphate, PL5P = ribulose 5-phosphate, UDPG = 
UDP-glucose, UDPGA = UDP-glucuronic acid, UDPNAG = UDP N-acetylglucosamine, 0 = control, 5 = 5 mM 
DCA. 
61 
 
 
Figure 4.7: Intracellular fluxes over time for CHO-XL99 with 5mM DCA and control cultures. Fluxes are 
shown in [mM/(gDW*h)] and time scale is in hours. The estimated fluxes from 50 hours until 180 hours for 
control cultures and until 260 hours for DCA cultures are shown. The CHO-XL99 control cultures are shown 
in cyan and blue and the 5 mM DCA cultures are in pink and red. The calculated fluxes are shown as solid 
lines and the 95% confidence interval are shown as dashed lines. While most of the fluxes overlap, a 
difference can be observed for conversion of pyruvate to lactate and serine to glycine until ~120 hours. 
During that time, glycolytic fluxes of DCA cultures are also slightly lower however 95% CI overlap.  
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4.5. Discussion 
4.5.1. DCA improves culture performance without affecting productivity and product 
quality 
Cultured mammalian cells, such as CHO cells, consume glucose and glutamine beyond 
their stoichiometric needs and produce large amounts of waste products, such as lactate 
and ammonia (Altamirano et al. 2000; DeBerardinis et al. 2007; Warburg 1956). Lactate 
negatively impacts cell growth as well as antibody production and quality (Lao & Toth 
1997; Ozturk et al. 1992; Cruz et al. 2000; Li, J et al. 2012; Pacis et al. 2011). In this study, 
we investigated the effects of a DCA-mediated increase of PDC activity on culture 
performance, cell metabolism as well as antibody production and antibody quality in a 
CHO cell line. 
DCA inhibits PDK and thereby indirectly activates PDC. DCA reduced PDC 
phosphorylation in CHO-XL99 cells and cells were unable to degrade DCA ensuring 
exposure of the cells to a constant DCA concentration throughout the cultivation (Figure 
4.1). PDC phosphorylation and lactate production were reduced in a dose-dependent 
manner, while cell growth was only affected at concentrations above 5 mM DCA, which 
was used in subsequent studies. 
In all bioreactor fermentations, aerobic glycolysis was reduced and the lactate to glucose 
yield was about 7.4% lower in DCA cultures (Figure 4.2). DCA increased peak viable cell 
density, culture duration and final antibody titer. The largest effect was observed in fed-
batch plus glucose cultures in which culture duration was extended by three days and final 
antibody titer doubled.  
Culture conditions can impact productivity and antibody quality (Lao & Toth 1997; Li, J et 
al. 2012; Lim et al. 2010; Pacis et al. 2011). The cell specific productivity during 
exponential growth was the same in control and DCA cultures with 8.81 ± 0.05 
pg/(cell*day) (p > 0.05, t-test). The differences seen between the two conditions regarding 
antibody quality were minor and within expected run-to-run variability (Table 4.3). We 
observed a small decrease in monomers, a slight reduction in basic charge variants and 
no change in glycan pattern (Table 4.3). In particular, no increase was observed in the 
Man5 fraction, a fraction that is readily cleared in the body (Goetze et al. 2011) and has 
previously been reported to increase in high osmolality conditions (Pacis et al. 2011). 
Reduced aerobic glycolysis induced by DCA does not affect cell specific productivity or 
antibody quality in CHO-XL99 cells.  
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4.5.2. Lactate inhibition mechanism on cell growth 
Using fed batch, we demonstrated that the benefit of DCA is not merely to prevent 
depletion of glucose and amino acids. Indeed, the greatest improvement was observed in 
the fed-batch plus glucose culture. In both DCA and control cultures, the reduction of 
growth rate was observed around 90 mM lactate concentration (Figure 4.3), which is 
higher than previously reported growth inhibitory lactate concentrations (Lao & Toth 1997; 
Ozturk, Riley & Palsson 1992). Deliberately feeding sodium lactate, we confirmed that 90 
mM lactate inhibits cell growth (Figure 4.4A). Sodium lactate was fed at a rate (40 
mM/day) just below the maximum rate of lactate production observed in the culture, in 
order to prevent stress responses related to the rate of change (Newland et al. 1994). 
Growth inhibition may be a direct effect of lactate itself or a result of the increased 
osmolality due to the lactic acid as well as the addition of base to neutralize the produced 
lactate (Cruz et al. 2000; Irani et al. 1999; Langheinrich & Nienow 1999). Feeding sodium 
lactate has the same effect on lactate and osmolality as cells producing lactic acid, which 
is neutralized by sodium bicarbonate addition. Feeding NaCl, we can separate the two 
effects and the Na+ concentration is a surrogate measure for the culture osmolality. 
Deliberately feeding NaCl at 30 mM/day, growth inhibition commenced at about 180 mM 
Na+ concentration with complete arrest around 220 mM Na+ before onset of cell death 
(Figure 4.4B). These numbers are similar to those observed in the sodium lactate feeding 
experiment (Figure 4.4A), while the final lactate concentration was only 49 mM, about half 
observed in sodium lactate feeding experiments. It appears that high osmolality rather than 
lactate per se is the cause of growth inhibition and arrest. As DCA reduces lactate 
production and associated base addition, it delays growth inhibiting osmolality levels and 
increased antibody titer is a direct result of the extended cultures. 
4.5.3. Warburg revisited 
DCA reduces the production of lactate under aerobic conditions and may therefore provide 
insights into the Warburg effect. SWATH proteomics revealed only few differentially 
expressed proteins (20 out 2016 identified proteins) and none in central carbon 
metabolism. This indicates that at 5 mM, where DCA does not affect growth, both DCA 
and follow-on effects are at a post-translational level.  
PFK is considered the major regulatory glycolytic enzyme (Schöneberg et al. 2013) and 
our data are consistent with control at the PFK node. Intracellular concentrations of 
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glycolytic intermediates before PFK were similar or slightly higher, while concentrations of 
glycolytic intermediates downstream of PFK were significantly lower in DCA treated 
cultures (Figure 4.6). Reduced PFK activity causes an accumulation of fructose 6-
phosphate and glucose 6-phosphate, which inhibits hexokinase and reduces glucose 
assimilation. 
Inhibition of PFK is normally attributed to high ATP and citrate levels reducing PFK activity 
when cells contain sufficient storage of ATP and oxidisable substrates (Costa Leite et al. 
2007; Marinho-Carvalho et al. 2009; Zancan et al. 2007; Zancan et al. 2008). However, the 
ATP and citrate levels were lower under DCA conditions and there was no change the 
adenylate energy charge (Figure 4.6). Arguably, control is very tight and metabolomics is 
not sensitive enough to pick up the subtle concentration changes required for control. 
However, even at the most basic level the regulatory logic does not work; there is no 
evidence of increased PDC flux leading to more pyruvate through the TCA cycle (Figure 
4.5) nor is there an increase in oxidative metabolism as measured by OUR (Table 4.4). 
The molecular link between de-repressed PDC and reduced glycolytic flux remains to be 
resolved. 
The data does highlight that energy metabolism is inefficient under normal conditions. 
Without increasing oxidative metabolism, DCA caused a 35% reduction in glucose uptake, 
a 40% reduction in lactate production, a 30% reduction in glycine production and an 18% 
reduction in ATP production all without affecting adenylate energy charge, growth rate, or 
productivity. It is possible that the impact of DCA on cell growth at concentration greater 
than 5 mM (Figure 4.1) represents the limit of reduction possible given that aerobic 
metabolism apparently does not increase. 
4.6. Conclusions 
Lactate metabolism is one of the most important characteristics of industrial mammalian 
cell culture and due to its adverse effects on cell culture performance and productivity, 
reducing lactate production is a major focus in cell line and process development. 
Decreasing PDK activity using DCA is an easy and simple approach to increase PDC 
activity and thereby reduce aerobic glycolysis and decrease lactate production in an 
industrial relevant setting. Reduction in aerobic glycolysis had positive effects on cell 
culture performance and final antibody titer, while cell specific productivity and antibody 
quality were unaffected. The increase in final antibody titer in DCA cultures was the result 
of higher cell density and longer cultivation periods. DCA extended the culture duration by 
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reducing the lactate production rate, thereby the growth inhibiting osmolality level was 
reached later in DCA cultures. Additionally, the data demonstrate that the DCA 
concentration used here decreased glycolytic fluxes while the TCA cycle activity was 
unaffected and DCA mainly acted on a post-translational level.  
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5.1. Abstract 
Aerobic glycolysis, also known as the Warburg effect, is a metabolic phenotype 
characterized by cells preferring glycolysis and conversion of pyruvate to lactate over 
oxidative phosphorylation despite the presence of oxygen. This is observed not only in 
many cancer cells but also in other rapidly proliferating cells such as cell lines used as 
production hosts in industrial applications. Pyruvate dehydrogenase complex (PDC) plays 
a crucial role because it controls how much pyruvate derived from glycolysis enters the 
tricarboxylic acid cycle. PDC activity is inhibited by the enzyme pyruvate dehydrogenase 
kinase (PDK). Dichloroacetate is a known PDK inhibitor and thereby indirectly increases 
PDC activity.  Here we analyzed the effects of increased PDC activity induced by DCA 
using multiple omics technologies. Human embryonic kidney 293 cells were cultivated with 
different DCA concentrations, 5mM and 10mM, and data for growth profile, nutrient 
consumption, metabolite production, gene expression, protein abundance and intracellular 
metabolite concentrations were obtained and metabolic flux analysis was performed. We 
observed a DCA concentration dependent reduction in aerobic glycolysis characterized by 
decreased glucose consumption and lactate production. An effect on cell growth was only 
observed at 10mM DCA. Further analysis revealed that the reduced aerobic glycolysis was 
mainly caused by post-translational effects of DCA. Additionally, an increased asparagine 
synthetase activity and increased mitochondrial one-carbon metabolism were observed. 
Metabolic flux analysis showed an increased TCA cycle activity in 10 mM DCA cultures 
and various genes linked to cellular stress were upregulated. 
5.2. Introduction 
In mammalian cells energy in the form of ATP is mainly derived from two sources, 
glycolysis in which glucose is metabolized to pyruvate and the tricarboxylic acid (TCA) 
cycle which converts pyruvate to CO2. Under aerobic conditions normal cells use both 
glycolysis and TCA cycle for ATP generation. Under anaerobic conditions cells only use 
glycolysis and convert pyruvate to lactate as oxygen, the final electron acceptor in the 
electron transport chain, is not available. This is usually characterized by an elevated 
glycolytic rate resulting in increased glucose consumption and lactate production. Over 80 
years ago, Warburg observed that even under aerobic conditions cancer cells prefer 
glycolysis and lactate formation over oxidative phosphorylation (OXPHOS) (Warburg, 
Wind & Negelein 1927). Aerobic glycolysis seems counterproductive because of its lower 
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ATP yield per glucose molecule compared to cells using OXPHOS however it enables 
hypoxic tumor cells to generate ATP without oxygen consumption. In order to counteract 
the lower ATP yield, cells often have a higher glycolytic rate during aerobic glycolysis. 
Additionally, a high glycolytic rate may allow cells to direct glycolytic intermediates into 
other biosynthetic pathways needed to assemble new cells (Vander Heiden, Cantley & 
Thompson 2009). Aerobic glycolysis is not only observed in many cancer cells but also in 
other rapid proliferating cells such as cell lines used as production hosts in industrial 
applications and cells of embryonic tissue, suggesting that similar energetic and 
biosynthetic demands play an important role (Hanahan & Weinberg 2011; Papandreou, 
Goliasova & Denko 2011). 
Whether pyruvate derived from glycolysis enters the TCA cycle in the mitochondria or is 
available for lactate production in the cytosol is largely determined by the activity of 
pyruvate dehydrogenase complex (PDC). PDC is a key enzyme complex distributed 
heterogeneously within the mitochondrial matrix (Margineantu et al. 2002). It catalyzes the 
irreversible oxidation of pyruvate to acetyl-CoA and under aerobic conditions is rate-
limiting for the elimination of pyruvate as well as alanine and lactate which are in 
equilibrium with pyruvate (Stacpoole et al. 1998). Hence, PDC deficiency or inhibition may 
lead to lactate accumulation and mitochondrial energy failure. PDC also indirectly 
regulates the ATP yield from glucose, controls the amount of malonyl-CoA available for 
fatty acid synthesis and plays an important role in the process of fuel selection in 
connection with the glucose fatty-acid cycle (Hue & Taegtmeyer 2009; Randle et al. 1963; 
Sugden, MC & Holness 2006).  
PDC deficiency has been linked to various diseases and has been studied as a 
therapeutic target for  cancer (Archer et al. 2008) and other age-related diseases such as 
glucose intolerance (Stacpoole, Moore & Kornhauser 1978), heart failure (Bersin & 
Stacpoole 1997) and neurodegeneration (Stacpoole 1997) (reviewed in (Stacpoole 2012)). 
A decline of PDC activity with increasing age was observed in several tissues (Gurd et al. 
2008; Zhou, Q et al. 2009). This may contribute to development of type 2 diabetes mellitus 
as insulin secretion requires a coupled PDC-OXPHOS system and increasing PDC activity 
in patients had a glucose and lactate lowering effect  (Stacpoole, Moore & Kornhauser 
1978). In brain, an age-related decrease in glucose oxidation and oxygen consumption 
was observed (Kalpouzos et al. 2009; Martin et al. 1991) together with an increase of 
aerobic glycolysis and ketone body oxidation (Ross et al. 2010; Yao et al. 2010). Many 
neurodegenerative diseases, particularly Alzheimer’s disease, are associated with 
abnormal brain oxidative metabolism and data implicate a reduced PDC activity and up-
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regulation of aerobic glycolysis (reviewed in (Coskun et al. 2012; Green, Galluzzi & 
Kroemer 2011)). Furthermore, despite the differences between many cancers, they mostly 
rely on aerobic glycolysis for energy generation (Gatenby & Gillies 2004).  
PDC activity is regulated by reversible phosphorylation of three serine residues by PDC 
kinases (PDKs) and PDC phosphatases (PDPs) (Sale & Randle 1981; Teague et al. 1979; 
Yeaman et al. 1978). Four PDK and two PDP isoforms were identified in humans and 
rodents with different tissue specific distributions (Bowker-Kinley et al. 1998; Linn, Pettit & 
Reed 1969; Popov, Hawes & Harris 1997). Acetyl-CoA and NADH, both end-products of 
the PDC reaction, as well as increase in intramitochondrial ATP increase PDK activity, 
resulting in phosphorylation and inhibition of PDC (reviewed in (Patel & Korotchkina 2006; 
Sugden, MC & Holness 2006). Inhibitors of PDK are pyruvate as well as dichloroacetate 
(DCA) which is a halogenated xenobiotic structurally similar to pyruvate (Li, J, Kato & 
Chuang 2009; Roche & Hiromasa 2007; Whitehouse, Cooper & Randle 1974). DCA 
occupies the pyruvate binding site and inhibits PDK thereby indirectly increasing PDC 
activity redirecting pyruvate towards the TCA cycle (Roche et al. 2001; Stacpoole et al. 
1998). DCA has been explored for decades as a lactate lowering drug in treatment of 
various human diseases such as acquired or congenital lactic acidosis, diabetes, hypoxic 
pulmonary hypertension and congestive heart failure (Michelakis et al. 2002; Stacpoole, 
Moore & Kornhauser 1978; Stacpoole, Nagaraja & Hutson 2003).  
In 2007, Bonnet et al. reported that DCA specifically induces apoptosis in cancer cells and 
since then numerous studies evaluated DCA’s potential as an anti-cancer drug (reviewed 
in (Papandreou, Goliasova & Denko 2011)) and proof-of-concept was demonstrated in 
patients and a phase I trial was conducted (Dunbar et al. 2013; Flavin 2010; Michelakis et 
al. 2010). Bonnet et al. attributed the effect to the restoration of a normal mitochondrial 
membrane potential (ΔΨm) in previously hyperpolarized mitochondria leading to increased 
H2O2 production, efflux of mitochondrial pro-apoptotic factors and activation of plasma 
membrane Kv1.5 potassium transporters, all together inducing apoptosis (Bonnet et al. 
2007). However, a later study found that DCA has low activity and is not selective for 
cancer cells, but rather depolarizes mitochondria of both normal and cancer cells without 
induction of apoptosis (Stockwin et al. 2010). Growth suppression was greater in cells with 
defects in the mitochondrial electron transport chain (ETC) and DCA displayed synergistic 
effects with agents known to target mitochondria or interfere with glucose metabolism. 
They concluded that in cells with a defective ETC, DCA treatment results in “metabolic 
crisis” whereby cells are forced to generate ATP using a deficient pathway, resulting in a 
failure to meet metabolic demands. Interestingly, in some studies DCA reduces lactate 
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production without an increase in oxygen consumption, an indicator for TCA cycle activity. 
Oxygen consumption in response to DCA appears to depend on other factors such as cell 
line and HIF1α activity (Cairns et al. 2007; Niewisch et al. 2012). 
In this study, a comprehensive evaluation of the metabolic effects of DCA was performed. 
Human embryonic kidney 293 (HEK293) cells were cultivated with different concentrations 
of DCA and a multi-omics approach was used to characterize the effects of increased PDC 
activity on gene expression, protein abundance, intracellular metabolite concentrations 
and metabolic fluxes. 
5.3. Material and methods 
5.3.1. Cell culture and extracellular metabolite analysis 
HEK293F cells (Invitrogen) were cultivated in CD 293 medium (Invitrogen) supplemented 
with 4.5 mM glutamine (Invitrogen), 50 μg/ml dextran sulfate (Mw=5000Da, Sigma-Aldrich) 
and sodium dichloroacetate (DCA) (Sigma-Aldrich) at indicated concentrations. Cells were 
cultivated in vented shake flasks (Corning) with a working volume of 200 ml at 37°C, 5% 
CO2, and 130 rpm. Single shake flask experiments were performed to analyze effects on 
growth, lactate production and PDC phosphorylation as well as DCA stability in HEK293F 
culture. Duplicate shake flasks experiments were performed for 14 days to obtain growth 
curve and extracellular metabolite concentration data. Samples were collected twice daily 
during the first seven days and at least once a day for the remaining culture period. Cell 
number and viability were measured using a CedeX cell counter (Roche Innovatis AG). 
Ammonia concentrations were determined using a Nova Bioprofiler FLEX (Nova 
Biomedical). Glucose, lactate and extracellular amino acid concentrations in culture 
supernatant were determined using HPLC as described in Dietmair et al. (Dietmair, 
Timmins, Gray, Nielsen & Kromer 2010). Additional shake flask cultures were cultivated in 
triplicates for 3 days and samples for transcriptomics, protein abundance and intracellular 
metabolite analysis were obtained.  
5.3.2. Western blot  
HEK293F cells (Invitrogen) were cultivated for 24 hours with different DCA concentrations 
(0 – 15 mM DCA). Approximately, 2 x 107 cells were collected, washed with 0.9% sodium 
chloride and lysed in RIPA buffer (0.1% SDS, 1% Triton-X100, 5 mM 
71 
 
ethylenediaminetetraacetic acid, 0.5% sodium deoxycholate, 150 mM NaCl, 50 mM Tris-
HCl, 2 mM dithiothreitol, supplemented with 1ug/mL leupeptin (Roche), 1ug/mL aprotinin 
(Roche), 1 mM sodium orthovanadate, 10 mM sodium fluoride). Cell lysates were 
incubated for 60 min on ice followed by centrifugation at 16,000 rcf, 4°C for 10 min. Protein 
concentration of the supernatant was determined using a 2D Quant Kit (GE Healthcare). 
Cell extracts equivalent to 10 µg of protein were run on a 4-12% SDS-polyacrylamide gel 
and transferred to nitrocellulose membranes by standard procedures. Membranes were 
blocked with 5% nonfat milk in PBS/Tween for 1 hour followed by incubation with anti-PDC 
E1-α subunit (phospho S293) (abcam) and anti-β-tubulin (Cell Signalling Technology) 
antibodies for 2 hours at RT. Immunoreactive bands were visualized using horseradish 
peroxidase-conjugated anti-rabbit antibody (Life Technologies) and Amersham ECL 
Western Blotting Detection Reagents (GE Healthcare Bio-Sciences). Densitometry was 
performed using a BIORAD ChemiDoc MP Imaging System (Bio-Rad Laboratories) and 
Image Lab 4.0.1 software (Bio-Rad Laboratories).  
5.3.3. DCA concentration in culture 
HEK293F cells (Invitrogen) were cultivated in different DCA concentrations ranging from 0 
– 20 mM DCA. Every two days, a sample of 500 μl was collected from the culture, 
centrifuged at 500 rcf and supernatants were frozen and stored at -20°C until further 
processing. An Agilent 1200 HPLC system (Agilent Technologies) equipped with a Kinetex 
C18-XB column (100 Å, 2.6 µm, 100 × 2.1 mm, Phenomenex) and a diode array detector 
was used to measure DCA concentrations. The column temperature was set at 30°C and 
the flow rate was 0.2 ml/min. Mobile phase A was of 10 mM tetrabutylammonium bisulfate 
in water and mobile phase B consisted of 100% acetonitrile far UV. The gradient began 
with 5% mobile phase B and was increased linear to 30% in 3 min followed by a hold at 
30% for 5 min. The concentration of mobile phase B was then increased linear from 30% 
to 60% in 1 min followed by a hold of 60% mobile phase B for 5 min. Afterwards, the 
gradient was reversed from 60% to 5% mobile phase B in 1 min, followed by a hold at 5% 
mobile phase B for 5 min.  
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5.3.4. Transcriptomics analysis 
5.3.4.1. Sample preparation 
Cells were collected after three days and centrifuged at 200 rcf for 3 min. The supernatant 
was discarded and the pellet frozen on dry ice and stored at -80°C Total RNA from 
collected cells was extracted using an RNA Mini Kit (Qiagen) according to manufacturer’s 
instructions including on-column DNA digestion using an RNase-Free DNase Set 
(Qiagen). RNA amount and purity were determined using an Agilent Bioanalyzer 2100 
(Agilent Technologies). One sample per shake flask (n = 3 for each DCA concentration) 
was submitted to AGRF, Melbourne, Australia for gene expression analysis using Illumina 
HT12v4 chips (Illumina).  
5.3.4.2. Data analysis 
Background subtracted data from GenomeStudio was analyzed using lumi (Du, Kibbe & 
Lin 2008), a package for processing Illumina data in R (R Core Team 2012). A variance-
stabilizing transformation and quantile normalization were performed (Lin, SM et al. 2008). 
Unexpressed genes were removed to reduce false positives and a nucleotide universal 
identifier (nuID) annotation system was used (Du, Kibbe & Lin 2007). Genes with a false 
discovery rate adjusted p-value of less than 0.01 were considered differentially expressed. 
The differentially expressed genes were analyzed manually and using HumanCyc Omics 
Viewer (http://humancyc.org/). 
5.3.5. Targeted proteomics analysis 
5.3.5.1. Sample preparation 
Cells were collected after three days and centrifuged at 200 rcf for 3 min, washed with 
0.9% sodium chloride and cell pellets stored at -80°C. Cell pellets were lysed in 8 M 
urea/50 mM ammonium bicarbonate (AMBIC) supplemented with 1 μg/ml aprotinin 
(Roche), 2.5 μg/ml leupeptin (Roche), 5 mM sodium orthovanadate, and 10 mM sodium 
fluoride. Cells were disrupted using a 22G needle and sonicated three times for 1 min. 
RNaseA (Thermo Fisher Scientific Inc.) and DNaseI (Thermo Fisher Scientific Inc.) were 
added to the samples according to manufacturer’s instructions. After 15 min incubation at 
RT, samples were centrifuged at 16,000 rcf for 10 min at 0°C. Protein concentration of the 
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supernatant was determined using a 2D Quant kit (GE Healthcare Life Sciences) 
according to manufacturer’s instructions. Dithiothreitol was added to 5 mM and samples 
were incubated at RT for 45 min, followed by addition of iodoacetamide to 25mM and 
incubation for 30 min at RT in the dark. Samples were diluted with 7 volumes of 50 mM 
AMBIC to obtain a final concentration of < 1M urea. Trypsin (Trypsin Gold, Promega) was 
added in a 1:50 enzyme:protein ratio and samples were incubated overnight at 37°C. The 
next morning samples were centrifuged at 16,000 rcf, 0°C for 10 min and 5% trifluoroacetic 
acid (TFA) was added to the sample until pH was below pH 4. Samples were desalted 
using Sep-Pak cartridges (Waters) equilibrated first with 100% acetonitrile (ACN), then 
70% ACN/0.1%TFA, and finally 0.1% TFA. Equal volume of 0.1% TFA was added to the 
samples before loading them onto the column. The column was washed twice with 0.1% 
TFA and proteins were eluted with 70%ACN/0.1%TFA. Residual acetonitrile was removed 
by vacuum centrifugation (Eppendorf Group) and the sample was resuspended in 0.1% 
TFA and stored at -80°C until analysis. 
5.3.5.2. HPLC-MS/MS 
Mass spectrometry was performed as described elsewhere (Chang, RYK et al. 2014) with 
modified HPLC flow rate and gradient profile. Briefly, peptide samples were analyzed 
using an Agilent 1100/1200 HPLC system (Agilent Technologies) coupled to an ABSciex 
QTRAP 5500 mass spectrometer (ABSciex). Chromatographic separation was performed 
on an Agilent ZORBAX 300SB-C18, 5μm, 150 x 0.3 mm column (Agilent Technologies). 
Mobile phase A consisted of 5% ACN/0.1% formic acid (FA), mobile phase B was 99.9% 
ACN/0.1% FA (v/v) and the flow rate was set to 10 μl/min. The gradient elution profile was 
10% buffer B 0-5 min, 10-40% buffer B 5-75 min, 40-90% buffer B 75-77 min, 90% buffer 
B 77-83 min, 90-10% buffer B 83-85 min, 10% buffer B 85-90 min.  
The Agilent QTRAP 5500 was equipped with a TurboSpray ion source and set to Multiple 
Reaction Monitoring (MRM) scan type at unit resolution and peptide ionization was 
performed in positive mode. Skyline software (MacCross Lab Software) and SRM Atlas 
(http://www.srmatlas.org/) were used to build MRM methods and a list of analyzed proteins 
with peptide, precursor ion, product ion, and fragmentation can be found in Appendix 
Table F1. 
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5.3.5.3. Data analysis 
Chromatograms were analyzed using Skyline software (MacCross Lab Software). All 
peaks were manually inspected and peak areas were used to calculate differences in 
relative protein abundance. The protein tubulin beta chain (UniProt ID P07437) was used 
as an internal standard as its abundance was confirmed to be constant across all three 
conditions using bovine alpha-S1-casein (Sigma-Aldrich) spiked samples. Relative protein 
abundance data was then statistically analyzed using the limma package (Smyth 2005) in 
R (R Core Team 2013).  
5.3.6. Intracellular metabolite analysis 
Cell suspension was collected after three days during exponential growth phase. Sample 
preparation and HPLC-MS/MS analysis to analyze glycolytic, TCA cycle and pentose 
phosphate pathway metabolites was performed according to Dietmair et al. 2010 
(Dietmair, Timmins, Gray, Nielsen & Kromer 2010)  
5.3.7. Metabolic flux analysis 
A detailed description of the metabolic flux analysis is provided in Appendix C. Briefly, 
exchange rates were estimated using a yield approach over the exponential phase (Quek 
et al. 2010). The metabolic model used is a reduced version of the human genome scale 
model Recon 1 (Duarte et al. 2007), generated as described in (Quek & Nielsen 2008b). 
For consistency checking and flux variability analysis constrained weighted quadratic 
programming was used (Antoniewicz, Kelleher & Stephanopoulos 2006). A Monte Carlo 
approach was used to propagate errors in primary data (growth data and extracellular 
nutrient and metabolite data) into the calculated cell-specific rates (Goudar et al. 2009; 
Quek et al. 2014).  The average dry weight was measured to be 515 pg/cell. Estimated 
fluxes were used for estimation of ATP production (Martínez, VS et al. 2013). 
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5.4. Results 
5.4.1. DCA affects cell growth, lactate production and PDC phosphorylation and is 
stable in HEK293F cell culture 
Shake flask experiments were carried out to investigate the effects of different DCA 
concentrations on cell growth, lactate production, and PDC phosphorylation (Figure 5.1). 
Since DCA can be degraded into glyoxylate by glutathione S-transferase ζ1 (Lantum et al. 
2003; Li, WJ et al. 2011), the stability of DCA in HEK293F cell culture was analyzed first 
(Figure 5.1C). Over a culture period of twelve days DCA concentration in all cultures 
decreased by less than 5% of its initial concentration suggesting than HEK293F cells are 
unable to degrade DCA significantly and DCA supplementation is not required during the 
experiments.  
 
Figure 5.1: Growth curve, lactate concentration, DCA concentration, and Western blot analysis. 
HEK293F cells were cultured in shake flask with different DCA concentrations. Growth rate was unaffected 
by DCA up to 5 mM and decreased at higher DCA concentrations (A). Lactate production decreased with 
increasing DCA concentration during exponential growth (B). DCA concentration decreased less than 5% in 
HEK293F cell culture over a 12 day culture period (C) and with increasing DCA concentration PDC E1α 
phosphorylation decreased (D).  
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Growth during exponential phase was unaffected by DCA concentrations up to 5 mM. At 
higher DCA concentrations the growth rate decreased. Lactate production decreased with 
increasing DCA concentration and all cultures except 20 mM DCA culture used lactate as 
a carbon source later during the culture. Western blot analysis showed that PDC 
phosphorylation decreased with increasing DCA concentration indicating PDK inhibition 
and higher PDC activity.  
For further experiments 5 mM and 10 mM DCA concentration were chosen to analyze 
DCA’s effects on metabolism and cell growth. At 5 mM a clear metabolic effect is evident 
without a growth effect, while 10 mM DCA affects both metabolism and cell growth.  
 
5.4.2. DCA reduces lactate production but affects oxidative metabolism only at 
higher concentrations 
 
HEK293F cells were cultivated in duplicates with 5 mM, 10 mM DCA or no DCA (control) 
for 14 days and samples were collected twice a day during exponential and stationary 
growth phase and once a day during death phase. Viable cell density (VCD), viability, 
glucose and lactate concentrations (Figure 5.2) as well as extracellular amino acid 
concentrations were measured.  
The average growth rates during exponential phase were similar between control and 5 
mM DCA cultures, 0.0269 ± 0.0006 h-1 and 0.0254 ± 0.0005 h-1 for control and 5 mM DCA 
respectively (p>0.20 t-test), while the average growth rate of 10 mM DCA culture was 
0.0218 ± 0.0004 h-1 and different compared to the control cultures (p<0.02 t-test). Viability 
was above 95% for all cultures until day 5 and viability as well as VCD decreased faster 
during death phase with increasing DCA concentration.  
Glucose consumption as well as lactate production decreased with increasing DCA 
concentration during exponential growth phase (Figure 5.2 and Table 5.1), with mean 
glucose consumption rates being about 19% lower in 5 mM DCA cultures and about 23% 
lower in 10 mM DCA cultures. Similarly, the lactate production rate was lower in DCA 
cultures, about 27% in 5 mM DCA cultures and about 43% in 10 mM DCA cultures. This 
led to a decreased lactate to glucose yield with increasing DCA concentration; the ratios 
were 1.25 ± 0.02, 1.14 ± 0.02, and 0.94 ± 0.02 for control, 5 mM DCA, and 10 mM DCA, 
respectively. This corresponds to a reduction in lactate to glucose yield of 8.8% at 5 mM 
DCA and 24.8% at 10 mM DCA.  During exponential growth the ammonia concentrations 
were similar for all DCA concentrations (Figure 5.3). However, due to the lower growth rate 
of the 10mM DCA cultures the ammonia production rates were higher (Table 5.1).  
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5.4.2.1. Cell growth and metabolite consumption and production 
 
Figure 5.2: Viable cell density, viability, glucose and lactate concentration profiles. Duplicate cultures 
of HEK293F cells were cultivated with no, 5 mM or 10 mM DCA. DCA reduced glucose consumption (C) and 
lactate production (D) during exponential growth phase. Growth rate was only affected at 10 mM DCA (A) 
however viable cell density and viability decreased faster during death phase with increasing DCA 
concentration (A and B).  
 
Although, several of the amino acid consumption and production rates were significantly 
different in DCA cultures compared to control cultures, the amino acid consumption pattern 
was similar with glutamine being the major consumed amino acid followed by serine, 
leucine, arginine, valine, and isoleucine (Table 5.1).  
The amino acid production pattern differed between the three conditions. In control 
cultures alanine was the major product followed by proline, glutamate, and glycine. In 
cultures treated with 5 mM DCA the major product was glutamate followed by alanine, 
glycine, proline, and asparagine and in cultures treated with 10 mM DCA the major product 
was glutamate followed by glycine, alanine, proline, and asparagine. Major differences 
were observed for lysine and asparagine. In 10 mM DCA cultures, lysine consumption was 
more than 50% lower compared to control cells. Asparagine was consumed in control 
cultures; however it was produced in DCA cultures during exponential growth (Table 5.1). 
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Control cultures started to produce asparagine after 5 days while 10 mM DCA cultures 
mostly consumed asparagine after day 4 (Figure 5.3). 5 mM DCA cultures switched 
between asparagine consumption and production. 
 
Table 5.1: Mean metabolic uptake and production rates during exponential growth. Mean (n = 2) 
metabolic uptake and production rates of control, 5 mM DCA and 10 mM DCA cultures during exponential 
growth. Rates are in µM/(gDW*h), growth rate in h
-1
. Negative rates represent consumption and positive 
rates production. The asterisks indicate rates which were statistically significantly different (p<0.05 t-test) 
compared to the control cultures. Upregulated amino acid transporter in 10 mM DCA cultures identified in 
gene expression analysis. SE = standard error, Y = Yield. 
 No DCA 5 mM DCA 10 mM DCA Upregulated 
transporter in 10 
mM DCA 
Metabolite Rate ± SE Rate ± SE Rate ± SE 
Glucose -297 1 -240* 9 -228* 11  
Lactate 373 5 273* 6 213* 5  
Ylactate/glucose 1.25 0.02 1.14* 0.02 0.94* 0.02  
NH4
+* 12.74 0.41 13.13 0.54 20.43* 1.37  
        
Consumed amino acids        
Asp -4.48 0.12 -4.17 0.07 -4.40 0.04 SLC1A5 
Gln -61.3 0.8 -52.7* 1.4 -62.9 1.6 SLC7A5, SLC3A2, 
SLC1A5 
Ser -28 0.1 -28.2 0.4 -32.0* 0.9 SLC1A5 
Arg -12.04 0.45 -13.76 1.02 -15.77 0.85 SLC7A5, SLC3A2 
Essential amino acids        
Tyr -3.32 0.05 -2.93 0.14 -2.90* 0.05 SLC7A5, SLC3A2, 
SLC1A5 
His -2.41 0.09 -2.21 0.18 -1.95 0.17  
Thr -6.36 0.02 -5.72 0.36 -5.67* 0.07 SLC1A5 
Val -10.17 0.17 -9.46 0.67 -12.02* 0.05 SLC1A5 
Met -3.62 0.16 -3.26 0.10 -3.53 0.30 SLC1A5 
Trp -1.15 0.004 -0.97* 0.001 -1.02 0.04 SLC7A5, SLC3A2, 
SLC1A5 
Phe -4.46 0.13 -3.56 0.21 -3.85* 0.01 SLC7A5, SLC3A2, 
SLC1A5 
Ile -8.92 0.28 -9.25 0.57 -10.89 0.38 SLC1A5 
Leu -13.57 0.32 -14.19 1.30 -15.51 0.98 SLC7A5, SLC3A2, 
SLC1A5 
Lys -7.36 0.28 -6.90 0.25 -3.50* 0.08  
Produced amino acids        
Glu 7.01 0.05 11.7 1.16 14.84* 0.22  
Gly 6.28 0.05 8.28* 0.10 11.91* 0.47 SLC6A9, SLC1A5 
Ala 19.21 0.02 10.16* 0.22 10.43* 0.20 SLC1A5 
Pro 11.53 0.62 6.89* 0.46 7.26* 0.71 SLC1A5 
Consumed or produced 
amino acid 
       
Asn -1.38 0.02 0.79* 0.10 2.99* 0.10  
Growth rate 0.0269 0.0006 0.0254 0.0005 0.0218* 0.0004  
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Figure 5.3: Asparagine and ammonia concentration profile in culture supernatant.  
 
5.4.2.2. Differentially up-regulated amino acid transporters in 10 mM DCA cultures 
A number of amino acid transporters were identified as significantly upregulated in 10 mM 
DCA cultures using gene expression analysis (Table 5.2). Together they cover the 
transport of almost all amino acids (Table 5.1). SLC3A2 is an amino acid transporter and 
binds to SLC7A5 (also upregulated). Together they are involved in sodium-independent 
transport of large neutral amino acids (Elorza et al. 2012; Ganapathy, Thangaraju & 
Prasad 2009). SLC3A2 is also linked to calcium concentrations either by responding to 
fluctuations in intracellular calcium concentrations or by regulating intracellular calcium 
levels (Chang, ACM, Jellinek & Reddel 2003; Jiang, Westberg & Andersson 2012; Nance 
et al. 2012). It was observed that DCA treatment led to lower free cytosolic calcium 
concentration in A549 cells (Bonnet et al. 2007).  SLC1A5 can transport all neutral amino 
acids and mediates the net uptake of glutamine (Ganapathy, Thangaraju & Prasad 2009). 
SLC6A9 is a glycine transporter (Kim, KM et al. 1994) and absolute glycine production rate 
was almost doubled in 10 mM DCA cultures compared to control cultures. Although, amino 
acid transporters were up-regulated, for some amino acids the absolute amino acid 
consumption rate was not increased compared to control cultures. However, when 
metabolic rates are adjusted to growth rate (Appendix E), taking into account the 
significantly lower growth rate of 10 mM DCA cultures, the amino acid consumption rates 
of 10 mM DCA cultures agreed with the upregulation of the amino acid transporters 
suggesting an increased amino acid demand and potentially intracellular amino acid 
limitations.  
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Table 5.2: Up-regulated amino acid transporters in 10 mM DCA cultures compared to control 
cultures. 
Transporter Fold 
change 
Description 
SLC7A5 2.2279 Transport of large neutral amino acids such as phenylalanine, tyrosine, leucine, arginine 
and tryptophan, when associated with SLC3A2. 
SLC3A2 2.2083 Transport of large neutral amino acids such as phenylalanine, tyrosine, leucine, arginine 
and tryptophan. Guiding and targeting of SLC7A5 and LAT2 to the plasma membrane.  
SLC1A5 1.9640 Transport of all neutral amino acids, including glutamine, asparagine, and branched-
chain and aromatic amino acids, excludes methylated amino acids, anionic amino acids, 
and cationic amino acids.  
SLC6A9 1.7642 Sodium- and chloride-dependent glycine transporter 
5.4.2.3. DCA affects several metabolic fluxes in a dose-dependent manner 
Intracellular metabolic fluxes were estimated based on the cell specific consumption and 
production rates during exponential growth (23.25 – 69.5 hours) for all three conditions (n 
= 2). Although the majority of the flux ranges and 95% confidence intervals (CI) 
overlapped, several metabolic flux differences have been observed (Figure 5.4). Glucose 
uptake and glycolytic fluxes were lower in DCA cultures as expected from the reduced 
glucose consumption. Although, 10 mM DCA cultures consumed less glucose compared 
to 5 mM DCA cultures (Figure 5.2), 10 mM DCA glucose consumption rate (Table 5.1) and 
glycolytic fluxes (Figure 5.4) were only slightly lower compared to 5 mM DCA cultures and 
doubling the DCA concentration did not result in an equivalent decrease in absolute 
glycolytic fluxes. Fluxes through lactate dehydrogenase decreased with DCA. Fluxes 
towards biosynthetic precursors (fatty acids, nucleotides, and phosphoglycerolipids) and 
glycogen were similar between control and 5 mM DCA and lower for 10 mM DCA cultures, 
correlating with lower growth rate observed in 10 mM DCA cultures. Conversion of 
pyruvate to acetyl-CoA flux, catalyzed by PDC, was only increased in 10 mM DCA cultures 
and similar in 5 mM DCA cultures compared to control cultures. Correspondingly, fluxes in 
TCA cycle only increased in 10 mM DCA cultures indicating that 10 mM DCA cultures but 
not 5 mM DCA cultures have a more active TCA cycle. Fluxes through the pentose 
phosphate pathway (PPP) were similar in all three conditions. Glutamine uptake and 
conversion into glutamate was reduced for 5 mM DCA, however 10 mM DCA cultures had 
similar fluxes compared to control cultures, suggesting lower glutaminolysis in 5 mM DCA 
cultures. The fluxes through malate/oxoglutarate transport and conversion of aspartate 
and oxoglutarate to glutamate and oxaloacetate were increased in 10 mM DCA cultures. 
The fluxes from aspartate and glutamine to asparagine and glutamate, catalyzed by 
ASNS, increased with increasing DCA concentration which agrees with the observed 
81 
 
difference in asparagine consumption/production during exponential growth (Table 5.1 and 
Figure 5.3). Furthermore, glycine transport out of the cell increased with increasing DCA 
concentration indicating that glycine formation from serine by the one-carbon metabolism 
is increasing with DCA. The reaction from serine to glycine is catalyzed by the serine 
hydroxymethyltransferase (SHMT) which has also increased flux with increasing DCA 
concentrations. The one-carbon metabolism takes place in cytoplasm and mitochondria; 
however the metabolic model does not distinguish between these two pathways but gives 
the sum of both pathways. The formation of serine from glycerate 3-phosphate is lower for 
10 mM DCA and similar for 5 mM DCA concentration compared to control cultures; while 
serine transport into the cell is increased in 10 mM cultures indicating that increased serine 
amount needed in the one-carbon metabolism is not supplied from glycolytic 
intermediates.  
Using estimated metabolic fluxes maximum theoretical ATP production was calculated 
(Figure 5.5). Both DCA cultures derived about 20% less ATP from glycolysis compared to 
control culture correlating with reduced glycolytic fluxes (Figure 5.4) and reduced glucose 
consumption in DCA cultures (Figure 5.2 and Table 5.1). In 10 mM DCA cultures the ATP 
production potential in the TCA cycle was more than doubled compared to the control, in 
line with the increased TCA cycle fluxes observed only for the 10 mM DCA cultures.  
 
 
Figure 5.4: ATP production. Bars show mean optimal ATP production rate and whiskers indicate lower and 
upper optimal production range as estimated by metabolic flux analysis. DCA cultures produced less ATP via 
glycolysis while only 10 mM DCA cultures had increased ATP production from TCA cycle. 
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Figure 5.5: Metabolic flux analysis of HEK293F cultures in 5 mM DCA, 10 mM DCA and control 
cultures during exponential growth. Intracellular fluxes were estimated using metabolic flux analysis. 
Optimum rates are shown as solid bars with 95% confidence intervals shown as vertical lines. C = control, 5 
= 5 mM DCA, 10 = 10 mM DCA. Rates are in µM/(gDW*h). THF = tetrahydrofolate, 5,10MTHF = 5,10-
methylenetetrahydrofolate. 
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5.4.2.4. Intracellular metabolite concentrations 
Samples for intracellular metabolite analysis were taken in triplicates after 3 days resulting 
in 9 samples for cells treated with 5 mM DCA, 10 mM DCA and control cells, respectively. 
53 metabolites were measured using HPLC-MS/MS of which 24 were either not detected, 
not quantifiable due to insufficient calibration, below lower limit of quantification in at least 
one sample or the coefficient of variation of the pooled sample injections was higher than 
25%. The majority of intracellular metabolite concentrations were not significantly different, 
however trends could be detected. Intracellular lactate concentrations decreased 
significantly with increasing DCA concentration correlating with the lower lactate 
production in DCA cultures. However, despite the lower glucose consumption in DCA 
cultures, glucose 6-phosphate (G6P) and fructose 1,6-bisphosphate (F16DP) 
concentrations were higher in DCA cultures; although differences were not significant. 3-
phosphoglycerate and 2-phosphoglycerate (3PG + 2PG) and phosphoenolpyruvate (PEP) 
concentrations decreased with increasing DCA concentrations suggesting an increased 
glycolytic rate in the lower part of glycolysis. Dihydroxyacetone phosphate (DHAP) 
concentration was lower in DCA cultures as well. Concentrations of TCA cycle 
intermediates aconitate, citrate and isocitrate (CIT + ISO) were lower in 10 mM DCA 
cultures, while oxoglutarate (KGA) concentration increased with increasing DCA 
concentration. Succinate (SUC) concentrations were also slightly increased in DCA 
cultures, while fumarate were only lower in 10 mM DCA cultures and malate 
concentrations were similar in all conditions. Erythrose 4-phosphate (E4P) and xylulose 5-
phosphate concentrations were lower in 10 mM DCA cultures. Ribulose 5-phosphate 
(RL5P) concentration decreased with increasing DCA concentration indicating lower 
pentose phosphate pathway activity. Pyruvate concentrations were similar for all 
conditions while acetyl-CoA concentrations increased with increasing DCA concentrations 
indicating a higher PDC activity. NAD+ concentration were increased in DCA cultures while 
NADP concentration was similar in all conditions. 
 
 
84 
 
 
Figure 5.6: Mean intracellular metabolite concentrations in cells treated with DCA and control cells. 
Concentrations are in fmol/cell. N=9 for all three conditions. 3PG and 2PG = 3-phosphoglycerate and 2-
phosphoglycerate, CIT + ISO = citrate and isocitrate, DHAP = dihydroxyacetone phosphate, E4P = erythrose 
4-phosphate, F16DP = fructose 1,6-bisphosphate, G6P = glucose 6-phosphate, KGA = oxoglutarate, PEP = 
phosphoenolpyruvate, PL5P = ribulose 5-phosphate, SUC = succinate, UDPG = UDP glucose, UDPGA = 
UDP glucuronic acid, UDPNAG =  UDP N-acetylglucosamine, X5P = Xylulose 5-phosphate. SE = standard 
error. 0 = control, 5 = 5 mM DCA, 10 = 10 mM DCA 
 
5.4.3. Transcriptomics analysis  
Samples for transcriptomics analysis were collected after 3 days from triplicate cell 
cultures to investigate the differences in gene expression between DCA cultures and 
control cultures. Transcript abundances were analyzed using an Illumina HT12 chip and 
21,569 of the 47,317 entities were expressed. 
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Table 5.3: Significantly regulated genes in 10 mM DCA cultures involved in metabolism according to 
HumanCyc. 
Gene 
name 
Fold 
change 
EC Enzyme Pathway 
HMOX1 2.6297 1.14.99.3 Heme oxygenase 1  heme degradation 
SGSH 2.2129 3.10.1.1  N-sulphoglucosamine sulphohydrolase   
IRAK1 2.1979 2.7.11.1 Interleukin-1 receptor-associated kinase 1  
LPPR2 2.0192 3.1.3.4  Lipid phosphate phosphatase-related 
protein type 2 
 triacylglycerol biosynthesis 
BCAT1 1.9834 2.6.1.42 Branched-chain-amino-acid 
aminotransferase, cytosolic 
 leucine degradation I, valine degradation 
I, isoleucine degradation I 
XYLB 1.9490 2.7.1.17  Xylulose kinase  
PCK2 1.9430 4.1.1.32 Phosphoenolpyruvate carboxykinase [GTP], 
mitochondrial  
 gluconeogenesis 
SRXN1 1.9287 1.8.98.2  Sulfiredoxin-1   
ASNS 1.9173 6.3.5.4  Asparagine synthetase [glutamine-
hydrolyzing] 
 asparagine biosynthesis I, citrulline 
biosynthesis, glutamine degradation I 
CRMP1 1.9153 3.5.2.2  Dihydropyrimidinase-related protein 1   uracil degradation I (reductive), uracil 
degradation I (reductive), thymine 
degradation 
ABCB1 1.8898 3.6.3.44   Multidrug resistance protein 3 ATP-dependent export of organic anions 
and drugs from the cytoplasm 
ISG20 1.8575 3.1.13.1 Interferon-stimulated gene 20 kDa protein  
MTHFD1L 1.8506 6.3.4.3 Monofunctional C1-tetrahydrofolate 
synthase 
 folate polyglutamylation, folate 
transformations 
MARS 1.8290 6.1.1.10 Methionyl-tRNA synthetase, cytoplasmic  tRNA charging 
SPR 1.8118 1.1.1.153  Sepiapterin reductase 2  tetrahydrobiopterin de novo biosynthesis 
CTH 1.7845 4.4.1.1  Cystathionine gamma-lyase 4  cysteine biosynthesis/homocysteine 
degradation, cysteine 
biosynthesis/homocysteine degradation 
MTHFD2 1.7763 3.5.4.9 Methenyltetrahydrofolate cyclohydrolase 2  tetrahydrofolate salvage from 5,10-
methenyltetrahydrofolate, folate 
transformations, histidine degradation III 
TK1 1.7617 2.7.1.21/ 
2.7.1.145 
Thymidine kinase 1   pyrimidine deoxyribonucleosides salvage, 
pyrimidine deoxyribonucleosides salvage 
FADS1 1.7563 1.14.19.- Fatty acid desaturase 1  oleate biosynthesis II  
AGPAT9 1.7173 2.3.1.15 Glycerol-3-phosphate acyltransferase 3   triacylglycerol biosynthesis, CDP-
diacylglycerol biosynthesis 
CBS 1.6837 4.2.1.22  Cystathionine beta-synthase 4  cysteine biosynthesis/homocysteine 
degradation 
PPIF 1.6234 5.2.1.8 Peptidylprolyl isomerase F  
SHMT2 1.5782 2.1.2.1 Serine hydroxymethyltransferase 2   glycine biosynthesis I, dTMP de novo 
biosynthesis (mitochondrial), folate 
polyglutamylation, folate transformations, 
glycine betaine degradation 
TKTL1 -2.3701 2.2.1.1  Transketolase-like protein 1   pentose phosphate pathway (non-
oxidative branch) 
CLYBL -1.7420 4.1.3.6 Citrate lyase subunit beta-like protein, 
mitochondrial 
 
MRPL30 -1.7333 RXN0-
5098 
Lipoyltransferase 1, mitochondrial  lipoate biosynthesis and incorporation II, 
lipoate salvage I 
LHPP -1.6455 3.6.1.1 Phospholysine phosphohistidine inorganic 
pyrophosphate phosphatase 
 
PDK3 -1.6057 2.7.11.2 Pyruvate dehydrogenase kinase 3  
OSGEPL1 -1.5979 3.4.24.57 Probable O-sialoglycoprotein 
endopeptidase 2  
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In 5 mM DCA samples no genes were differentially expressed compared to control 
cultures; however fold changes of up to 2.5 were detected indicating some variation 
between biological triplicates may led to the results being non-significant. In the 10 mM 
DCA samples 164 genes were differentially expressed of which 48 were down-regulated 
and 116 up-regulated (Appendix G). 163 and 51 genes had a fold change greater than 1.5 
and 2, respectively. The complete data set was analyzed for enrichment of up- or down-
regulated genes in metabolic pathways using HumanCyc (http://humancyc.org/). 
Differential expression was observed for 29 genes involved in metabolic reactions (Table 
5.3) with mitochondrial one-carbon metabolism being the only significantly affected 
pathway. Evidently the observed metabolic differences between control and DCA cultures 
are caused mainly by post-transcriptional events rather than alterations in gene 
expression.  
The up-regulated enzymes involved in one-carbon metabolism were monofunctional C1-
tetrahydrofolate synthase (MTHFD1L), bifunctional methylenetetrahydrofolate 
dehydrogenase/cyclohydrolase (MTHFD2) and serine hydroxymethyltransferase (SHMT2). 
One-carbon metabolism takes place in the cytosol as well as in mitochondria (Figure 5.7). 
All three up-regulated enzymes are located in the mitochondria, suggesting that 
mitochondrial but not cytosolic one-carbon metabolism is increased in 10 mM DCA 
cultures.  
Other metabolic enzymes with altered gene expression include asparagine synthetase 
(glutamine-hydrolyzing) (ASNS) which is up-regulated and is responsible for ATP-
dependent synthesis of asparagine and glutamate from glutamine and aspartate. 
Additionally, mitochondrial phosphoenolpyruvate carboxykinase (PCK2) gene expression 
is also increased. This enzyme is used in the pathway of gluconeogenesis and converts 
oxaloacetate into phosphoenolpyruvate and CO2. Somewhat surprising, pyruvate 
dehydrogenase kinase 3 (PDK3) gene expression was down-regulated. PDK3 is one of 
the four isozymes that inhibit PDC activity. As DCA is a PDK inhibitor, rather an up-
regulation, if any, would have been expected to counteract the DCA induced PDK 
inhibition.  
The majority of most up-regulated genes in 10 mM DCA cultures are linked to endoplasmic 
reticulum (ER) stress, oxidative stress, DNA damage or have been found to be associated 
with cancer (Table 5.4).  
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Figure 5.7: Simplified cytosolic and mitochondrial one-carbon metabolism. THF = tetrahydrofolate, 
CH2-THF = 5,10-methylene-THF, CH
+
-THF = 5,10-methenyl-THF, 10-CHO-THF = 10-formyl-THF, Hcys = 
homocysteine, fMet-tRNA
fMet
 = formylmethionyl-tRNA; Reactions: 1 = mitochondrial serine 
hydroxymethyltransferase (SHMT2), 2 & 3  = bifunctional methylenetetrahydrofolate dehydrogenase/ 
cyclohydrolase (MTHFD2), 4 = monofunctional C1-THF synthase (MTHFD1L), 5 = cytoplasmic serine 
hydroxymethyltransferase, 6 & 7 & 8 = trifunctional C1-THF synthase, 9 & 10 = 10-formyl-THF 
dehydrogenase, 11 = glycine cleavage system, 12 = 5,10-methylene-THF reductase, 13 = methionine 
synthase, 14 = thymidylate synthase, 15 = sarcosine dehydrogenase and dimethylglycine dehydrogenase, 
16 = methionyl-tRNA formyl transferase, 17 = glycinamide ribonucleotide transformylase and aminoimidazole 
carboxamide, 18 = formiminotransferase-cyclodeaminase. Enzymes catalyzing reactions 1,2,3, and 4 were 
upregulated in 10 mM DCA cultures (blue circles). 
 
 
Table 5.4: Most significantly up-regulated genes in 10 mM DCA cultures compared to control 
cultures. 
Gene symbol Protein 
Fold 
change 
Up-regulated 
 INHBE Inhibin beta E chain 5.1378 
SESN2 Sestrin-2 3.6613 
ETV5 ETS translocation variant 5 3.2484 
TNFRSF12A  Tumor necrosis factor receptor superfamily 
member 12A 
3.1621 
TNNT1 Troponin T, slow skeletal muscle 2.9702 
DDIT3 DNA damage-inducible transcript 3 protein 2.8866 
ETV4 ETS translocation variant 4 2.8155 
DDIT4 DNA damage-inducible transcript 4 protein 2.7388 
LTBR Tumor necrosis factor receptor superfamily 
member 3 
2.6747 
HMOX1 Heme oxygenase 1 2.6297 
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Inhibin beta E chain (IHNBE) is a peptide hormone and belongs to the growth factor-β 
super family. Treatment of cancer cells with ER stress inducing drugs resulted in increased 
IHNBE expression induced by up-regulation of activating transcription factor 4 (ATF4) 
(Brüning et al. 2012). IHNBE is also up-regulated by insulin in liver cells suggesting that it 
is involved in regulating glucose and energy metabolism (Hashimoto et al. 2009). Sestrin-2 
(SESN2) activates AMP-activated protein kinase (AMPK) and thereby downregulates 
mammalian target of rapamycin (mTOR) which is downregulated in cells to slow down 
their metabolism (Budanov & Karin 2008; Yecies et al. 2011). SESN2 is linked to the 
cellular response to oxidative stress and DNA damage. By regenerating peroxiredoxins, 
SESN2 has a cytoprotective function and plays a role in the antioxidant defense of the cell 
(Essler, Dehne & Brüne 2009). ETS translocation variant 5 (ETV5) has been linked to 
cancer and overexpression increased cell proliferation (Rahim & Üren 2013). It also 
appears to be associated with glucose metabolism and obesity (Gutierrez-Aguilar et al. 
2013). Tumor necrosis factor receptor superfamily member 12A (TNFRSF12A) is the 
receptor for TNF-Related Weak Inducer of Apoptosis (TWEAK). TWEAK has been shown 
to induce cell proliferation in several cell types (Gao et al. 2009; Girgenrath et al. 2006; 
Jakubowski et al. 2005; Sanz et al. 2009; Sugito et al. 2009) and TNFRSF12A gene and 
protein were overexpressed in several solid tumor types (Culp et al. 2010). Troponin T, 
slow skeletal muscle (TNNT1) is a subunit of troponin, a complex that regulates striated 
muscle contraction in response to fluctuations in intracellular calcium concentration 
(Mannherz & Goody 1974). DCA had a lowering effect on free cytosolic calcium 
concentration in A549 cells treated with DCA (Bonnet et al. 2007). DNA damage-inducible 
transcript 3 protein (DDIT3) is a multifunctional transcription factor induced by ER stress, 
oxidative stress, hypoxia and amino acid deprivation and promotes apoptosis 
(Lengwehasatit & Dickson 2002; Oyadomari & Mori 2004; Yamaguchi & Wang 2004). It is 
a negative regulator of ATF4-dependent transcriptional activation of asparagine 
synthetase (Su & Kilberg 2008). Although the adjusted p-value is just above the cut-off of 
0.01 to be considered statistically significant, ATF4 was up-regulated in 10 mM DCA 
cultures with a fold change of 1.58 and could be responsible for increased asparagine 
production in 10 mM DCA cultures as well as increased IHNBE expression (see above). 
ETS translocation variant 4 (ETV4) is a transcriptional activator and linked to several 
cancers (Oh, Shin & Janknecht 2012). DNA damage-inducible transcript 4 protein (DDIT4) 
regulates cell growth, proliferation and survival via inhibition of mammalian target of 
rapamycin complex 1 (mTORC1) in response to cellular energy levels and cellular stress 
such as hypoxia and DNA damage (Corradetti, Inoki & Guan 2005; Ellisen et al. 2002; 
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Shoshani et al. 2002). Tumor necrosis factor receptor superfamily member 3 (LTBR) is 
also involved in promoting apoptosis and is an mTOR inhibitor (Sofer et al. 2005; Wu, MY 
et al. 1999). Heme oxygenase 1 (HMOX1) cleaves free heme to form biliverdin, Fe2+ and 
CO. Excess of free heme, caused by oxidative stress, can produce free radicals 
sensitizing cells to undergo apoptosis and HMOX1 expression is induced by oxidative 
stress (reviewed in (Gozzelino, Jeney & Soares 2010)). 
5.4.4. Targeted proteomics analysis of central carbon metabolic enzyme  
Samples for targeted proteomics were obtained after 3 days while cultures were in 
exponential growth phase (n = 3 for control, 5 mM DCA and 10 mM DCA, respectively). 62 
metabolic proteins, mainly enzymes of glycolysis, TCA cycle and enzymes of connected 
metabolic pathways, were analyzed (Appendix F).  In 5 mM DCA cultures no proteins were 
statistically differentially expressed. However, three proteins had an adjusted p-value of 
0.0559, just above the cut-off of 0.05 (Appendix Table F3). Two proteins were up-
regulated, asparagine synthetase (ASNS) (fold change 1.18) and pyruvate kinase PKLR 
(KPYR) (fold change 1.27). Mitochondrial malate dehydrogenase (MDHM) was 
downregulated (fold change 1.70). MDHM is an enzyme of the TCA cycle and reversibly 
catalyzes the oxidation of malate to oxaloacetate thereby reducing NAD+ to NADH. Five of 
the 62 analyzed proteins were significantly differentially expressed in 10 mM DCA cultures 
compared to control cultures of which four proteins were upregulated and one 
downregulated (Table 5.5 and Appendix Table F2).  
 
Table 5.5: Significantly differentially expressed proteins in 10 mM DCA cultures. Differentially 
expressed proteins in 10 mM DCA cultures compared to control cultures with an adjusted p-value of <0.05. 
Positive fold change indicates up-regulation and negative fold change down-regulation. 
 
UniProt ID Name Fold 
change 
P08243 ASNS_HUMAN Asparagine synthetase [glutamine-hydrolyzing] 1.37 
Q15119 PDK2_HUMAN Pyruvate dehydrogenase kinase isozyme 2, 
mitochondrial 1.41 
P07195 LDHB_HUMAN L-lactate dehydrogenase B chain 1.37 
P30613KPYR_HUMAN Pyruvate kinase PKLR 1.22 
P18669 PGAM1_HUMAN Phosphoglycerate mutase 1 -1.35 
 
ASNS was upregulated with a fold change of 1.36. ASNS converts glutamine and 
aspartate to glutamate and asparagine, using ATP. Pyruvate dehydrogenase 2 (PDK2), 
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which is one of the four PDK isozymes inhibited by DCA, was also upregulated with a fold 
change of 1.36. Lactate dehydrogenase B chain (LDHB) was upregulated with a fold 
change of 1.37 converting pyruvate to lactate. The forth upregulated enzyme was KPYR 
with a fold change of 1.22. It is one of the glycolytic key enzymes, converting 
phosphoenolpyruvate (PEP) to pyruvate generating one ATP. Only one enzyme was 
identified as being differentially downregulated, phosphoglycerate mutase 1 (PGAM1), 
which is also a glycolytic enzyme catalyzing the reversible reaction from 3-
phosphoglycerate to 2-phosphoglycerate via 2,3-bisphosphoglycerate intermediate. The 
majority of the metabolic proteins analyzed were not differentially expressed in 10 mM 
DCA cultures and no proteins were identified as being differentially expressed in 5 mM 
DCA cultures, indicating that the reduced aerobic glycolysis induced by DCA is mainly the 
result of post-translational effects.  
5.5. Discussion 
This study investigated metabolic differences between HEK293F cells cultivated in 
different concentrations of DCA. PDK phosphorylates and thereby inactivates PDC, the 
enzyme complex that converts pyruvate to acetyl-CoA in the mitochondrion. DCA inhibits 
PDK resulting in PDC being less phosphorylated and therefore having higher activity. As 
expected, DCA reduced lactate production in a dose dependent manner (Figure 5.1). Up 
to 5 mM, DCA reduced aerobic glycolysis without affecting growth rate, while 10 mM and 
higher DCA concentrations not only reduced aerobic glycolysis but also affected cell 
growth negatively. In order to better understand the two effects of DCA, cells growing at 
these two conditions were compared and contrasted to control using a range of omics 
technologies, namely transcriptomics, targeted proteomics, fluxomics, and intracellular 
metabolite analysis. 
5.5.1. Lactate production can be reduced without increased TCA cycle flux 
DCA had a clear metabolic effect in HEK293F cells in a dose-dependent manner. The 
metabolic effect was also observed at lower DCA concentration where no growth inhibitory 
effect was evident. At lower DCA concentration, 5 mM, glucose consumption, lactate 
production and lactate to glucose yield were reduced indicating a more energy efficient 
metabolism (Table 5.1).  Correspondingly, glycolytic fluxes were lower in DCA cultures 
indicating a reduced glycolytic rate leading to about 20% lower ATP yield from glycolytic 
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activity. PDC phosphorylation is reduced at 5 mM DCA and intracellular acetyl-CoA was 
increased indicating higher PDC activity. However, TCA cycle fluxes were not increased at 
5 mM DCA and intracellular TCA cycle metabolite concentrations were mostly similar 
compared to control cultures. TCA cycle activity appears unaltered and no increase in 
oxidative metabolism was observed despite the increased acetyl-CoA formation. This has 
been observed before in neuroblastoma cells where glucose consumption and lactate 
production were reduced without increase in oxygen consumption indicating no increase in 
TCA cycle activity (Niewisch et al. 2012) 
In addition to reduced lactate production, alanine formation from pyruvate is reduced as 
well in DCA cultures (Table 5.1 and Figure 5.4) suggesting lower cytosolic pyruvate levels. 
Intracellular pyruvate concentration was similar in DCA cultures compared to control 
(Figure 5.6). However, the measured pyruvate accounts for both, cytosolic and 
mitochondrial fraction. While DCA did not change the overall intracellular pyruvate 
concentration it may have affected the distribution of pyruvate between cytoplasm and 
mitochondrion reducing pyruvate availability for lactate and alanine formation in the 
cytosol.  
It was previously shown that DCA depolarizes mitochondria even at concentrations that 
did not affect cell growth (Stockwin et al. 2010). Depolarization of mitochondria results in 
loss of oxidative phosphorylation capacity and therefore reduced ATP production from 
TCA cycle. However, it is not obvious how mitochondrial depolarization and reduced 
glycolysis can occur simultaneously without affecting cell growth. It appears that metabolic 
flexibility allows cells to adjust their metabolism at moderate PDC activity increase and the 
reduction in ATP production can be tolerated by the cells.  
Furthermore, as no genes or proteins were significantly differentially expressed at 5 mM 
DCA and only a small number of metabolic genes and proteins were differentially 
expressed in 10 mM DCA cultures, the metabolic changes were mostly caused by post-
translational events. Allosteric regulation plays an important role in modulation of the 
glycolytic rate with hexokinase, phosphofructokinase and pyruvate kinase being the three 
main regulatory enzymes. However, concentrations of allosteric regulators together with 
missing increase in TCA cycle activity do not support allosteric regulation. The reduced 
glycolytic activity is not readily explained and further investigations are necessary.  
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5.5.2. High DCA causes metabolic stress 
At higher DCA concentration, 10 mM, the metabolic effect was stronger compared to 
control and 5 mM DCA cultures. Glucose consumption, lactate production and lactate to 
glucose yield were further reduced with peak lactate concentration being almost half 
compared to control cultures (Table 5.1 and Figure 5.2). Despite a strong reduction in 
aerobic glycolysis only a small number of metabolic genes and proteins involved in central 
carbon metabolism were upregulated (Table 5.3 and Table 5.5). Somewhat surprisingly, 
pyruvate dehydrogenase kinase 3 gene expression was downregulated. PDK3 is one of 
the isozymes inhibited by DCA and rather an upregulation, if any, would have been 
expected in order to antagonize the effects of DCA. Phosphoenolpyruvate carboxylase 2 
(PCK2) gene expression was upregulated as well. PCK2 is part of the gluconeogenesis 
pathway converting oxaloacetate to phosphoenolpyruvate. However, PDK3 and PCK2 
were not identified as being differentially expressed in targeted proteomics. In targeted 
proteomics, pyruvate dehydrogenase kinase 2 (PDK2) was upregulated without altered 
gene expression. Lactate dehydrogenase chain B (LDHB) protein was upregulated with a 
fold change of 1.37. LDHB converts pyruvate to lactate; however, no increased LDHB 
gene expression was detected and lactate production was significantly lower in 10 mM 
DCA cultures. Upregulation of PDK2 and LDHB could be the result of the cell 
counteracting PDC activation by DCA. The forth upregulated enzyme was pyruvate kinase 
isozyme L/R (KPYR) with a fold change of 1.22. It is one of the glycolytic key enzymes, 
converting phosphoenolpyruvate (PEP) to pyruvate generating one ATP. Intracellular PEP 
concentrations decreased with increasing DCA concentrations while pyruvate 
concentrations were similar correlating with higher pyruvate kinase activity (Figure 5.6). 
KPYR may be upregulated to provide more pyruvate needed as a substrate for PDC or to 
produce more ATP from glycolysis. PGAM1 was the only glycolytic enzyme identified as 
being downregulated catalyzing the reaction from 3-phosphoglycerate to 2-
phosphoglycerate via 2,3-bisphosphoglycerate intermediate. However, gene expression of 
PGAM1 was not altered. As this reaction is reversible and not a site for major regulation of 
glycolysis the increased PGAM1 protein expression cannot be readily explained. A 
possible explanation for increased protein amount without increase in gene expression 
could be reduced PDK2, LDHB and KPYR protein degradation in response to increased 
PDC activity. Similarly, PGAM1 may be degraded at a higher rate. Taken together, the 
reduction in aerobic glycolysis even at growth inhibiting concentrations is mainly caused by 
post-translational regulation. 
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10 mM DCA significantly reduced exponential cell growth by about 19% in HEK293F 
without reduction in viability. In contrast to 5 mM DCA cultures, higher TCA cycle fluxes 
were estimated for 10 mM DCA cultures indicating increased oxidative metabolism. 
HEK293F cells appear to be unable to adjust their metabolism if PDC activity is increased 
past a threshold leading to higher TCA cycle activity. Due to the increased TCA cycle 
activity, a two-fold increase in theoretical ATP production from TCA was estimated. 
However, DCA can depolarize mitochondria which may reduce the ATP yield considerably 
leading to a “metabolic crisis” in which cells are unable to generate sufficient ATP and fail 
to meet metabolic demands. In gene expression analysis, the majority of the most 
upregulated genes respond to ER stress, oxidative stress, and DNA damage confirming 
cellular stress (Table 5.5). Additionally, four amino acid transporters were found to be 
upregulated together covering the transport of almost all amino acids suggesting 
intracellular amino acid limitation (Table 5.2 and Table 5.1). Correspondingly, ASNS gene 
and protein expression was increased in DCA culture corresponding with increased 
asparagine production during exponential growth. ASNS expression is activated in 
response to either amino acid limitation or cellular stress via pathways involving activating 
transcription factor 4 (ATF 4) which was also upregulated in the 10 mM DCA cultures with 
a fold change of 1.58 (adj. p-value 0.013). In response to amino acid deprivation the 
GCN2-eIF2-ATF4 pathway seems to be the predominant signaling pathway (Siu et al. 
2002; Wek, Jiang & Anthony 2006; Zhang et al. 2002). Via this pathway ASNS mRNA 
expression cannot only be induced by asparagine limitation but also by limitation of other 
amino acids (Gong, Guerrini & Basilico 1991; Hutson & Kilberg 1994). GCN has also been 
linked to various diseases such as cancer and Alzheimer’s disease. In particular the GCN-
eIF2-ATF4 pathway was found to be essential for maintaining metabolic homeostasis in 
tumor cells in response to nutrient deprivation (Ye et al. 2010). It was observed that 
pancreatic tumor cells exposed to low glucose had an increased ASNS gene expression 
which may protect the cells from apoptosis based on the observation that ASNS 
overexpression can suppress JUN NH2-terminal kinase (JNK) activation and reduce 
apoptosis (Cui et al. 2007). The second factor regulating ASNS expression is cellular 
stress. ER stress results in activation of the double-stranded RNA-activated protein 
kinase-like ER kinase (PERK) as part of the unfolded rotein response which can be 
activated in response to various cellular stresses including oxidative stress and 
carbohydrate deprivation (Barbosa-Tessmann, Pineda, et al. 1999; Harding et al. 2000). 
Both, amino acid limitation and cellular stress result in activation of ATF4 either through 
GCN2-eIF2-ATF4 or PERK-eIF2-ATF4 pathway, both leading to transcriptional activation 
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of ATF4 responsive target genes, including ASNS (Barbosa-Tessmann, Chen, et al. 1999; 
Barbosa-Tessmann et al. 2000). However, the exact role that ASNS activation plays in 
response to increased PDC activity and whether amino acid limitations or ER stress are 
responsible need further exploration.  
The only metabolic pathway found to be upregulated was mitochondrial one-carbon 
metabolism. In MFA, serine uptake and glycine production as well as flux through serine 
hydroxymethyltransferase (SHMT) were increased in 10 mM DCA cultures (Figure 5.4). 
The one-carbon metabolism comprises of a parallel cytoplasmic and mitochondrial 
pathway (Figure 5.7). Although the flux is shown in the cytosol, the flux in MFA is the sum 
of both, cytoplasmic and mitochondrial one-carbon metabolism. In gene expression 
analysis, only genes involved in mitochondrial part were upregulated, SHMT2, bifunctional 
methylenetetrahydrofolate dehydrogenase/ cyclohydrolase (MTHFD2), and 
monofunctional C1-tetrahydrofolate synthase (MTHFD1L) (Table 53 and Figure 5.7). The 
mitochondrial one-carbon metabolism and expression of MTHFD2 appear to be critical for 
cancer and knockdown of MTHFD2 results in death of human cancer cells (Nilsson et al. 
2014). SHMT2 and MTHFD1L were also found to be upregulated in tumor cells (Sugiura et 
al. 2004; Tendler, Threadgill & Tisdale 1987) while MTHFD2 has been detected in tumor 
and transformed cells but not adult tissue (Di Pietro, Wang & MacKenzie 2004; Mejia & 
MacKenzie 1985; Peri & MacKenzie 1993; Smith et al. 1990). Folate deficiency or altered 
one-carbon metabolism was linked to several human diseases such as anemias, neural 
tube defects, cardiovascular disease, cancer, and Alzheimer’s disease (Daly et al. 2005; 
Kim, YI 2003; Lucock 2000; Mattson & Shea 2003; Moat et al. 2004). Increased serine 
consumption, glycine production and equilibrium preferences suggest that the reactions 
are shifted towards 10-formyl-THF (Christensen & MacKenzie 2006; Kay et al. 1960; 
Pelletier & MacKenzie 1995). The oxidation of CH2-THF to CH
+-THF and 10-formyl-THF to 
CO2 generate NADH and NADPH respectively and are linked to the electron transport 
chain through Complex I. The exact role of one-carbon metabolism in cancer cell or 
embryonic cell metabolism is yet to be established. It was suggested that MTHFD2 
expression may be necessary for detoxification processes unrelated to normal cell 
metabolism (Linster, Van Schaftingen & Hanson 2013; Nilsson et al. 2014). 
5.6. Conclusions 
Aerobic glycolysis (Warburg effect) is a distinct metabolic phenotype observed in many 
rapid proliferating cells including cancer cells. In this study we used DCA, a known PDK 
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inhibitor, to increase PDC activity and reverse the Warburg effect in HEK293F cells. Use of 
various omics technologies provided information necessary to analyze the cell as a whole 
as often the use of a single technology only gives limited information. A dose-dependent 
reduction of aerobic glycolysis was observed, leading to a more efficient metabolism in 5 
mM DCA cultures. While higher DCA concentration (10 mM) reduced cell growth rate and 
increased TCA cycle activity resulting in increased cellular stress. Additionally, asparagine 
synthetase activity and mitochondrial one-carbon metabolism were increased in DCA 
cultures; however the relationship between reduced aerobic glycolysis and asparagine 
synthetase and one-carbon metabolism needs to be further investigated. 
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Chapter 6  
 
General Discussion and  
Conclusions 
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6.1. Summary and general discussion 
Mammalian cell metabolism is highly complex, organized in different cellular 
compartments and highly regulated. For the generation of energy in the form of ATP the 
cell mainly uses two pathways, glycolysis and TCA cycle. In glycolysis, glucose is 
converted to pyruvate which can be further used in the TCA cycle. However, both 
pathways are not always used as energy generation using TCA cycle (in connection with 
the electron transport chain) requires sufficient oxygen supply, as oxygen is the final 
electron acceptor. Therefore, under aerobic conditions, mammalian cells normally use 
both glycolysis and TCA cycle as it provides them with the maximum ATP yield per 
molecule glucose. Under anaerobic conditions, cells can only use glycolysis and convert 
excess pyruvate into lactate. This results in a lower ATP yield per consumed molecule 
glucose and is characterized by an increased glycolytic rate and lactate production. Otto 
Warburg observed over 80 years ago that cancer cells prefer glycolysis over oxidative 
phosphorylation even when sufficient oxygen is available, called aerobic glycolysis, also 
known as the Warburg effect (Warburg, Wind & Negelein 1927). This phenotype is 
observed in many cancer cells. However, it is not unique to cancer cells and was also 
observed in other rapid proliferating cells such as cell lines used in industrial applications 
indicating that similar metabolic and biosynthetic demands play a role (Hanahan & 
Weinberg 2011). Besides cancer, aerobic glycolysis is also associated with other age-
related diseases such as type-2 diabetes mellitus or neurodegenerative diseases, such as 
Alzheimer’s disease, and was linked to reduced pyruvate dehydrogenase complex (PDC) 
activity (Stacpoole 2012).  
PDC is a crucial link between glycolysis and the TCA cycle as it converts pyruvate to 
acetyl-CoA. The activity of PDC is largely determined by reversible phosphorylation 
catalyzed by two enzymes, pyruvate dehydrogenase kinase (PDK, phosphorylation, 
inactivation) and pyruvate dehydrogenase phosphatase (PDP, dephosphorylation, 
activation) (reviewed in Chapter 2). One approach to reduce the Warburg effect is to 
increase the amount of pyruvate being converted to acetyl-CoA by increasing PDC activity, 
hereby decreasing the amount of pyruvate available for lactate formation. In this thesis, 
dichloroacetate (DCA) was used to inhibit PDK which in turn led to lower PDC 
phosphorylation and higher PDC activity. The majority of research in recent years 
regarding DCA focused on cancer cell apoptosis and growth inhibition as aerobic 
glycolysis is regarded a novel anti cancer target. However, the results regarding efficacy 
and underlying mechanism vary and appear to be highly cell line dependent (Chapter 2).  
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The focus of the main investigations in this thesis was twofold as aerobic glycolysis is an 
undesired phenotype in industrial applications and also associated with various diseases 
in humans. First, the effects of increased PDC activity induced by DCA on culture 
performance and antibody production using an industrial relevant cell line were 
investigated. Chinese hamster ovary cells were cultivated in bioreactor fermentations with 
5 mM DCA improving cell’s metabolism without affecting cell growth (Chapter 4). This was 
followed by an investigation using a human cell line, human embryonic kidney 293 
(HEK293) cells, to obtain a detailed knowledge about the system wide effects of increased 
PDC activity (Chapter5). Specifically, two DCA concentrations were used, 5 mM DCA and 
10 mM DCA. At 5 mM DCA only a metabolic effect was observed while at 10 mM DCA 
growth rate was reduced as well. 
In CHO cell experiments, DCA at 5 mM reduced glucose consumption and lactate 
production in both batch and fed-batch processes (Chapter 4). This resulted in prolonged 
cultivation periods and increased final antibody titers, while growth rate and cell specific 
productivity were unaffected. The strongest effect was observed in fed-batch cultivations 
with glucose feeding to avoid glucose depletion during the cultivation. The cultivation 
period was prolonged by over three days and final antibody titer was doubled in DCA 
cultures. These cultures were not glucose or amino acid depleted suggesting another 
factor being responsible for the culture entering stationary phase and ultimately death 
phase. The data suggested that either lactate concentration or the associated high 
osmolality (due to adding base to the culture to neutralize lactate and keep pH constant) 
are the cause of growth inhibition. Results of sodium lactate and sodium chloride feeding 
experiments showed that high osmolality rather than the lactate concentration per se is 
responsible for the cultures stopping to grow. Due to lower lactate production in DCA 
cultures the increase in osmolality was slower which led to the longer cultivations. We also 
analyzed antibody quality in terms of glycan pattern, charge variants and aggregation 
finding only minor differences which are within run to run variability. MFA and B-DMFA 
were performed showing reduced glycolytic fluxes but similar TCA cycle fluxes in DCA 
cultures compared to control cultures indicating no change in oxidative metabolism. A 
lower one-carbon metabolism flux was observed as well. Combining conventional MFA for 
exponential growth phase and B-DMFA for later growth phases provides a good approach 
for flux analysis over a complete culture period. Additionally, proteomics using SWATH-MS 
analysis showed a lack of changes in core metabolism, thus indicating that reduction of the 
Warburg effect is attributable to post-translational events.  
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The metabolic effect of DCA was further studied in HEK293 cells. Two DCA 
concentrations were chosen; one to induce only a metabolic effect without growth 
inhibition (5 mM) and one to achieve both a metabolic effect and reduced cell growth (10 
mM) (Chapter 5). Both concentrations reduced aerobic glycolysis; glucose consumption 
and lactate production were lower compared to control cultures. Lactate to glucose yield 
was lower as well, meaning that less glucose was converted to lactate. MFA analysis for 
exponential growth phase revealed reduced glycolytic fluxes in DCA cultures. In 10 mM 
DCA cultures an increased TCA cycle flux was observed indicating increased TCA cycle 
activity which would lead to an increase in ATP production. However, DCA was found to 
depolarize mitochondria which may reduce the ATP yield considerably leading to a 
“metabolic crisis” where amounts of generated ATP are insufficient to meet metabolic 
demands leading to cellular stress and reduced cell growth. Gene expression analysis 
revealed that several genes linked to cellular stress were upregulated while similar to the 
CHO cell experiment, only a small number of genes and proteins relating to metabolism 
were differentially expressed.  
Besides reduced Warburg effect, two additional metabolic changes were observed in 
HEK293 cells with DCA: a) increased asparagine synthetase activity (ASNS) and b) 
increased mitochondrial one-carbon metabolism. Asparagine was produced in DCA 
cultures while consumed in control cultures during exponential growth and ASNS gene 
expression and protein expression were upregulated. ASNS catalyzes the ATP dependent 
conversion of aspartate and glutamine to asparagine and glutamate and hereby could also 
affect the glutamine content which is a major energy source. Two mechanisms are known 
to increase ASNS expression: amino acid limitation and cellular stress. Altered ASNS 
activity was also linked to certain cancers and metastasis. However, the exact role of 
higher ASNS activity and the advantage for the cell, especially during ER stress, remain to 
be investigated. Increased mitochondrial one-carbon metabolism was also upregulated. An 
increased flux through the serine hydroxymethyltransferase (SHMT) reaction was 
observed and cultures with DCA consumed more serine and produced more glycine. 
Transcriptomics analysis revealed that the genes for the mitochondrial enzymes involved 
in one-carbon metabolism were upregulated; SHMT2, MTHFD1L and MTHFD2. The flux 
estimated in MFA is the sum of both, cytosolic and mitochondrial, one-carbon metabolism. 
Without gene expression analysis it would not have been identified which pathway was 
upregulated, highlighting the importance of combining different omics technologies. Altered 
one-carbon metabolism was linked to several diseases as well as tumor cells. However, 
similar to upregulated ASNS activity, further investigations are needed as not much is 
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known about the regulation and purpose of increased mitochondrial one-carbon 
metabolism. An overview of expected and oberserved results of central metabolic 
pathways in both cell lines is given in Figure 6.1. 
 
Figure 6.1: Summary of results from HEK293 and CHO-XL99 cells treated with DCA. Blue lines = 
control cell metabolic fluxes, red lines = DCA treatment metabolic fluxes, green circle = upregulated protein 
expression, green diamond = upregulated gene expression.  
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In summary, lower DCA concentrations can lead to a more efficient metabolism by 
reducing aerobic glycolysis resulting in lower glucose consumption and lactate production. 
On the other hand, higher DCA concentrations lead to reduced cell growth. It seems that 
mitochondrial depolarization at higher DCA concentrations may lead to a “metabolic crisis” 
with insufficient ATP production and hereby reduced cell growth.  
Interestingly, while the one-carbon metabolism was lower in CHO DCA cultures it 
increased in HEK DCA cultures. This underlines what has been previously documented in 
literature, that different cell lines and also different culture conditions (different culture 
media with different nutrient concentrations, pH control vs. no pH control) may affect quite 
significantly the specific effects of increased PDC activity induced by DCA. 
In both studies various omics technologies were used to analyze cellular changes in 
response to increased PDC activity as the effects could become apparent at different 
functional levels (gene expression, protein abundance, metabolites and metabolic fluxes). 
Transcriptomics and proteomics are well established and protocols for the analysis of 
intracellular metabolite concentrations are available. Metabolic flux analysis (MFA) can be 
used to estimate fluxes through central metabolic pathways using a limited number of 
extracellular measurements. However, conventional MFA assumes a steady state, which 
is only valid in continuous cultures or during mid exponential phase in batch cultures. In 
order to estimate metabolic fluxes over a complete cultivation period, dynamic MFA 
(DMFA) approaches are necessary. Therefore, an improved DMFA using B-splines (B-
DMFA) was developed based on current DMFA approaches. Fluxes of a temperature shift 
experiment, an approach widely used to extend cultivations and achieve higher antibody 
titers, were estimated using B-DMFA (Chapter 3). Temperature shifted cultures showed a 
reduction in growth rate while control cultures entered death phase earlier. We observed 
an increased final antibody titer in temperature shifted cultures of about 42%. B-DMFA 
revealed that temperature shifted cultures maintained a constant volume specific antibody 
productivity, while productivity of control cultures declined after mid-exponential growth 
phase. The constant productivity together with the longer culture period at higher viability 
in temperature shifted cultures resulted in a higher final antibody titer. B-DMFA was also 
used to estimate fluxes of CHO cell fed-batch cultivations performed to examine DCA’s 
effects in industrial relevant processes (Chapter 4).  
In order to manipulate the cellular metabolism, metabolic engineering is still the most 
widely used approach as the concept of using a specific enzyme inhibitor is not always 
available or desired. However, clonal variation from parental cell line can be a problem; 
especially in system wide investigations in response to a single genetic alteration (Dietmair 
102 
 
et al. 2012). Inducible expression systems have the advantage that only one cell clone is 
used and clonal variation from parental cell line introduced during selection process can be 
avoided. An HEK293 cell line was generated overexpressing resistin like molecule beta 
(RETNLB) in an inducible system (Appendix H). RETNLB was identified as being 
overexpressed in a cell line that had reduced glucose consumption (Dietmair et al. 2012). 
However, overexpression of RETNLB did not result in reduced glucose consumption in 
HEK293 cells, suggesting that increased RETNLB expression may not be the cause but 
rather a result of another factor that led to reduced glucose consumption. This underlines 
the difficulties related to picking successful targets for genetic engineering and further 
investigations are necessary to more effectively identify successful gene targets. 
6.2. Achievements and future work 
The main achievements of this thesis were i) analysis of increased PDC activity on culture 
performance and antibody production using industrial relevant cell line and processes 
(Chapter 4), ii) the comparative analysis of HEK293 cells with increased PDC activity 
induced by DCA using a combination of multiple omics technologies (Chapter 5), and iii) 
development of B-DMFA and analysis of metabolism of temperature shifted cells 
compared to cells maintained at constant temperature (Chapter 3).  
A large amount of information was collected to analyze the system wide effects of 
increased PDC activity induced by DCA. While the aerobic glycolysis reducing effect of 
DCA was confirmed in all experiments there were also differences observed between 
HEK293 cell (Chapter 5) and CHO cell (Chapter 4) experiments. In both cell lines reduced 
aerobic glycolysis without growth inhibition was observed at lower DCA concentrations. It 
appears that the cells become more energy efficient as they produce less ATP without 
negative effects on growth or productivity. The observed reduction in glycolytic rate is not 
readily explained by allosteric regulation of glycolytic enzymes as concentrations of 
allosteric inhibitors such as ATP and citrate are not increased and further investigations 
are necessary. Higher DCA concentrations led to a reduced growth rate. Similarly, the 
mechanisms by which DCA becomes growth inhibitory or apoptotic need further 
explorations. It appears that increased TCA cycle activity leads to cellular stress however it 
is not clear why different cell lines respond very differently to DCA as documented in 
literature.  
Metabolic differences between the two experiments were mainly in ASNS reaction and 
one-carbon metabolism which were both upregulated in HEK293 cultures with DCA but not 
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in CHO cultures with DCA. Apart from being different cell lines, the culture conditions were 
significantly different as well: different medium with different nutrient concentrations, shake 
flask without pH control (HEK293 cultures) or bioreactor with controlled pH and dO (CHO 
cultures), which could have considerably effect on the metabolic phenotypes observed. 
However, the increase in ASNS activity and one- carbon metabolism observed in HEK293 
cells is not easily explained and further investigations are necessary. Genetic engineering 
experiments, preferably in an inducible system to avoid clonal variation, could give further 
insights into the importance of these reaction and pathway, especially during cellular 
stress such as ER and oxidative stress.  
In the CHO cell experiment (Chapter 4) a clear advantage for cell culture performance and 
antibody productivity was observed using DCA without any effects on product quality. It 
would be of interest whether similar effects with regard to reduced aerobic glycolysis and 
unaffected product quality can be achieved using different production cell lines and cell 
lines producing other antibodies or biologics than IgG1. However, a current patent on 
using any PDK inhibitors for industrial applications, including DCA, exists (Follstat 2002) 
leaving only genetic engineering approaches, e.g. knocking-down of PDKs, to be used for 
commercial production processes.  
The current B-DMFA method requires a model with degrees of redundancy to estimate 
metabolic fluxes (Chapter 3). Therefore, B-DMFA is not able to estimate fluxes of the 
pentose phosphate pathway unlike MFA. A method that is able to work with a metabolic 
model with residual degrees of freedom based on flux balance analysis would be required 
(Varma & Palsson 1994b). 
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Appendix A: B-DMFA Supplementary Material 
 
Figure A1: Results of Monte Carlo simulations and heuristic algorithm. The solution of sampling 
100,000 sets of knot sequences. The solutions are organized by the SSR. Each colour represents one of the 
knots of the knot sequence. The solution of the heuristic algorithm is presented with circles, where the 
second and third knot are located in the same time point (green and red).  
 
 
Figure A2: Dynamic intracellular fluxes for cell cultures at 37°C and temperature shifted cells. The 
estimated dynamic fluxes are presented. The cultures at constant 37°C are in pink (37°C-1) and red (37°C-
2), the temperature shifted cultures in cyan (32°C-1) and blue (32°C-2). The fluxes calculated by B-DMFA 
are shown with solid lines and the 95% confidence intervals are shown with dashed lines. 
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Figure A3: Volume specific dynamic intracellular fluxes for cell cultures at 37°C and temperature 
shifted cells. Fluxes in [mmol/gDW/h], time scale in hours. The figure shows the specific dynamic fluxes 
between 60 and 200 hours. The CHO cultures at constant 37°C are in pink (37°C-1) and red (37°C-2), the 
temperature shifted cultures in cyan (32°C-1) and blue (32°C-2). The volume specific fluxes are shown with 
solid lines and their 95% CIs are shown with dashed lines. A difference between fluxes of cells at constant 
temperature and the temperature shifted cultures is observed for biomass precursors' reactions, lactate 
dehydrogenase and serine/glycine metabolism.  
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Algorithm to determine knots sequence 
 
A heuristic algorithm to determine the position and number of knots to describe the 
dynamic of the measured data was developed (Figure A5). In short, the algorithm place a 
new knot in the “knot placement time interval”, which is defined as a continuous segment 
of the time span bounded by two knots but does not contain any knots in-between. The 
knot is initially placed in the middle of the knot placement time interval and then the sum of 
squared residuals (SSR) of this scenario is compared with the SSR of the option of placing 
the knot in the middle of the left or the right half of the knot placement time interval, 
whichever one gives the smallest SSR. The knot placement interval is successively 
reduced by half until the SSR no longer decreases. After the placement of the second and 
subsequent knots, the position of all knots are adjusted again to minimize SSR in order to 
account for the effects of other knots, whereby a better position for the i th knot is checked 
between the time interval defined by i-1th knot and i+1th knot. The process is described as 
follow: 
1. Start with the knot placement time interval defined by the full time span (i.e., with 
three knots in the initial time point and three in the end time point, but no internal 
knots). Stop if SSR is within the 2 cutoff 
2. Calculate SSR with a knot in the middle of the knot placement time interval. 
3. Calculate SSR of adding the knot in the middle of the time interval before or after 
the knot position defined in step 2.  
4. Select the  knot position with the smallest SSR between the SSR calculated in 
steps 2 and 3 (keep that SSR value). If the selected knot is the middle one, go to 
step 7. Otherwise, update the knot placement time interval to the half of the 
previous knot placement time interval which contains the selected knot.  
5. Iteratively perform steps 3 and 4 until the SSR of the knot placed in the middle of 
the knot placement time interval is the smallest, and therefore, it is kept as the first 
inserted knot. 
6. Stop if SSR is within the 2 cutoff. 
7. Calculate SSR for each of the knot placement time intervals. Select the knot 
placement time interval that gives the biggest SSR. Similar to what was done with 
one knot (steps 2 to 4) a second knot is added in the new knot placement time 
interval. 
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8. Relocate one by one the position of the internal knots, starting from the smallest to 
the biggest one. For each of the i knots, select as knot placement time interval, the 
time interval from knot i-1 to knot i+1. Follow the procedure to chose the best 
position of each knot:  
8.1 Calculate SSR of moving the knot in the middle between the previous knot and 
the actual knot position or the middle between the actual knot position and the 
next knot. 
8.2  Find the smallest SSR between the one keeping the position of the knot and the 
calculated in 8.1, keep that solution. If moving the knot position does not reduce 
SSR, keep the knot position and move the next knot. Otherwise, chose as new 
knot placement time interval the half of the knot placement time interval that 
contains the selected knot and go back to 8.1. 
9. Stop if SSR is within the 2 cutoff.  
10. Add iteratively extra knots following steps 7 and 8 until the solution SSR is within 
the 2 cutoff. 
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Figure A4: Initial steps of the knot placement algorithm. 
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Appendix B: Ab2 amino acid composition 
Table B1: Ab2 amino acid composition. The Ab2 amino acids composition was estimated based on the 
sequence of  heavy and light chains by the software ProtParam (from Expasy: 
http://web.expasy.org/protparam/). 
 
Amino 
Acid 
Mass 
fraction 
Molecular  
Weight 
Ala 4.6% 89 
Arg  2.3% 174 
Asn 3.7% 132 
Asp 4.1% 133 
Cys 2.6% 121 
Gln  4.6% 146 
Glu 4.4% 147 
Gly 6.1% 75 
His 1.9% 155 
Ile 2.7% 131 
Leu 7.9% 131 
Lys 6.6% 146 
Met 1.0% 149 
Phe 3.4% 165 
Pro 6.9% 115 
Ser 12.4% 105 
Thr 9.6% 119 
Trp 2.0% 204 
Tyr 4.6% 181 
Val 8.7% 117 
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Appendix C: Metabolic flux analysis method (Quek et al. 2014) 
C.1. Transforming primary data into flux constraints 
Instead of the conventional MFA approach used in consistency checking (Goudar et al. 
2009; van der Heijden et al. 1994; Wang & Stephanopoulos 1983), we used a Monte-Carlo 
approach for error propagation, and quadratic programming for error checking, flux 
calculation and sensitivity analysis. Cell number and cell culture concentrations were 
transformed into rates by a yield approach. Simple linear regression can be used for the 
transformation process by selectively performing MFA on growth phases that show steady-
state metabolic behavior (Quek et al. 2010). A Monte-Carlo approach was used to 
propagate errors in the primary concentration data into the calculated cell-specific rates 
(Goudar et al. 2009). Constrained weighted quadratic programming was used for 
consistency checking and flux variability analysis (Antoniewicz, Kelleher & 
Stephanopoulos 2006). 
C.1.1. Gross growth parameters 
For batch cultures, the accumulation of biomass X  (gDW/ml) and the change in 
metabolite concentrations M  (mol/ml) can be described by a series of differential 
equations shown as Eqs. 1 and 2, where   is the cell specific growth rate (1/hr), and ,xm ir  
is the cell specific productivity of metabolite i (mol/gDW/hr). 
 
dX
X
dt
   (1) 
 
,  for metabolite 
i
xm i
dM
r X i
dt
   (2) 
The calculation for   is different if the loss of viable cells is significant. By distinguishing 
dead and viable cells ( ,  dead viableX X ), the actual growth rate   becomes the sum of cell 
specific death rate dk  (1/hr) and the apparent growth rate apparent  as shown by Eqs. 3, 4 
and 5. It is assumed that dead cells are inert and have negligible effect on the medium 
upon lysis. 
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 viable
apparent viable
dX
X
dt
   (3)
 
 dead
d viable
dX
k X
dt
   (4)
 
 apparent dk     (5) 
The differential equations can be solved directly for parameters apparent , dk  and ,xm ir  by 
regression or optimization approaches (Leighty & Antoniewicz 2011). A simpler process of 
estimating ,xm ir  is to assume that cells are at exponential growth and metabolic steady-
state. This requires that all growth parameters within the growth phase MFA is performed 
are constant. Then ,xm ir  can be estimated using a yield approach and by simple linear 
regression using Eqs. 7, 8 and 9. 
 , , , ,
non growth apparent
xm i xm i xm i xm ir Y r Y 
      (6)
 
where 
 
,
ˆ  for metabolite apparent ixm i
total
M
Y i
X



 (7) 
 0ˆ ˆln lnviable viable apparentX X t   (8) 
 
ˆ
ˆ
d
dead viable
apparent
k
X X

  (9) 
The time-independent yield approach is based on the premise that when cells are at 
steady-state growth, the depletion and accumulation of metabolites in the media is linearly 
correlated with biomass concentration. Eq. 7, however, gives apparent cell-specific yields 
,
apparent
xm iY  (mol/gDW) instead of true yields ,xm iY . As shown in Eq. 6, included in apparent 
yields is a small but potentially significant non-growth associated maintenance term 
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,
non growth
xm ir

 (mol/gDW/hr), which can only be separately estimated by performing a series of 
flux experiments at different growth rates (e.g., chemostat) (Varma & Palsson 1994c). 
For batch cultures, however, it is possible to assume that ,
non growth
xm xm iY r
  since cells are 
growing at the maximum rate ( max  ); this assumption implies that cell metabolism 
mainly serves biosynthesis, and non-growth associated consumption or production is 
negligible. Flux constraints can then be formulated using either ,xm ir  or ,
apparent
xm iY , since both 
parameters are in proportional by the scaling factor  . 
Slow growing or growth arrested ( 0  ) mammalian cells, however, often maintain 
significant productivity and metabolic activity. ,
non growth
xm ir

 is therefore significant and ,
apparent
xm iY  
would over-estimate actual biosynthetic demands. It then becomes necessary to 
separately estimate ,
non growth
xm ir

 (Sheikh, Forster & Nielsen 2005), and to formulate flux 
constraints using ,xm ir . 
C.1.2. Glutamine decomposition 
Free glutamine in the medium can decompose into ammonia and pyrrolidonecarboxylic 
acid. The actual cell-specific consumption of glutamine ,xm GLNr  and production of ammonia 
,NH3xmr  were calculated separately, since apparent glutamine uptake rate can almost double 
the actual consumption rate (Ozturk & Palsson 1990). 
 
,
GLN
GLN xm GLN viable
dM
kM r X
dt
    (10) 
 NH3
,NH3GLN xm viable
dM
kM r X
dt
   (11) 
 0Gln GLNln M ln M kt   (12) 
The rate of glutamine decomposition is taken at first-order with respect to glutamine 
concentration in Eq. 10. A similar adjustment is made to ammonia production as well using 
Eq. 11. The rate constant k  (1/hr) is affected by pH and media composition (Ozturk & 
Palsson 1990), and was separately determined for the blank medium at the same cell 
138 
 
culture condition (e.g., temperature and pH) using Eq. 12. Assuming the parameters  , 
k , ,GLNxmr  and ,NH3xmr  are constant (i.e., cells are at exponential growth and metabolic 
steady-state), integration-by-parts followed by linear regression can be used to estimate 
,GLNxmr  and ,NH3xmr  using Eqs. 13 and 14. Note that ˆ  and 
0ˆ
viableX  were first determined, 
followed by ,GLNxˆmr  and then ,NH3xˆmr . 
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C.1.3. Error propagation by Monte-Carlo 
It is important to gain a sense of accuracy for the MFA results considering the presence of 
experimental errors. Errors for the cell-specific rates ( , ,xm ir ) were therefore calculated 
from the primary data ( X , M ) by a Monte-Carlo approach. Since the system of equations 
is linear under the yield approach (Eq. 7), Monte-Carlo, used in conjunction with linear 
regression, is a fast and convenient technique to propagate errors, especially considering 
that both X and M  contain errors, and the difficulty of processing Eqs. 13 and 14. The 
means and standard deviations were computed from 10,000 simulated samples of   and 
,xm ir  generated by corrupting the primary data with normally distributed random errors. 
There is also the opportunity to generate an error covariance matrix ( CoV ) used for 
subsequent least-square optimization, which accounts for potential biases arising from 
fitting cell-specific rates that are not independent of each other. 
Based on repeated cell counts, a minimum error for cell number of 5% is used. We 
adopted an aggressive error estimate here because the error for all cell-specific rates will 
be at least 5% as well. Errors for metabolite concentrations ( ,e Ms ) determined by HPLC 
were calculated from the respective mean squared errors (
2
es ) obtained from each 
metabolite’s standard (linear) calibration curve (Eqs. 15, 16 and 17). If the number of 
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calibration points ( n ) is large, and that analyte responses are well within the calibration 
range, then Eq. 18 can be used to specify the minimum error 
, sample
min
e M
s for each type of 
metabolite. 
 0 1yˆ b b x    (15) 
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C.1.4. Flux analysis by quadratic programming 
The stoichiometric matrix ( S ) contains a set of reactions, a result of reducing Recon 1. 
The nullspace matrix ( NS ) of matrix S , for which Eq. 19 is satisfied, contains the basis 
vectors spanning the flux solution space  ( v ) (Eq. 20). By arranging reactions in S  such 
that the leading reactions are all the input and output (measured) reactions, two sub-
sections of NS  will appear as shown in Eq. 21. The number of redundant measurements is 
indicated by the number of rows in 1A . Reaction rows spanned by non-zero values of 2I  
and 4A  are underdetermined. 
 ' 0S v    (19)  
 v NS t   (20)  
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Weighted least-square optimization was performed by quadratic programming to calculate 
the optimum flux distribution for the set of mean and variance of   and ,xm ir  generated by 
the Monte-Carlo approach. Cell-specific rates were assumed to be independent, therefore 
only the diagonal elements of CoV were used. During the optimization, irreversible 
reactions were constrained such that their fluxes are zero or positive. The values in the 
boundary vectors ( lb , ub ) for the optimized variables ( t ) was arbitrarily set to -1000 and 
1000 respectively. The optimum flux distribution is calculated using Eq. 20. 
 minimize  ' 't Q t f t c       (22) 
subject to 
lb t ub  , irreversible rxn 0NS t   
where 
'mea meaNS NSQ
CoV
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,
,
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r
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f
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,2 xm i mear NS
c
CoV
      
The 95% confidence intervals of the optimum fluxes were calculated as a form sensitivity 
analysis. This is accomplished by finding the minimum and maximum flux of every reaction 
such that the increase in residual error from the minimum error is less than a certain 
threshold. This threshold is specified by the chi-square value taken at 5% significance and 
with a degrees-of-freedom ( DoF ) equal to the number of redundant measurements. 
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 minimize or maximize  rxn row 'jNS t  (23) 
subject to 
lb t ub  , irreversible rxn 0NS t  ,  
2' ' min  error + 0.05,t Q t f t c DoF       
The optimum ranges of underdetermined reactions were separately calculated using the 
above optimization, except that the residual error threshold is set to zero. 
C.2. Software 
Both linear programming and quadratic programming were performed using Gurobi 
Optimizer (Gurobi Optimization, Inc., Houston TX) in MATLAB R2010a (MathWorks Inc., 
Natick, MA). 
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Appendix D: CHO-XL99 SWATH-MS proteomics 
Table D1: Differentially expressed proteins in 5 mM DCA CHO-XL99 cell cultures compared 
to control cultures. 20 proteins out of 2016 identified protein were differentially expressed. 
Negative fold change indicates downregulation and positive fold change upregulation. 
Gene ID adj. P-
value 
Fold 
change 
Cricetulus griseus (Chinese hamster) predicted protein name (GO biological 
process or function) 
gi|354494438 0.00039 2.11 sulfated glycoprotein 1  
gi|354505255 0.00051 -2.17 ubiquitin-conjugating enzyme E2 D3-like (apoptosis, metabolic process) 
gi|354495660 0.00051 -1.91 calponin-3-like (system process) 
gi|354499660 0.00057 2.10 profilin-2-like (profilin binds to actin and affects the structure of the 
cytoskeleton) 
gi|354475569 0.00336 -1.70 peptidyl-prolyl cis-trans isomerase FKBP1A-like (apoptosis, cell 
communication, cell cycle, cellular process, immune system process, 
metabolic process, response to stimulus, system process) 
(immunoregulation and basic cellular processes involving protein folding 
and trafficking) 
gi|354484974 0.00725 -1.56 60S ribosomal protein L27-like  (metabolic process) 
gi|354500469 0.00894 -1.78 60S ribosomal protein L10-like  (metabolic process) 
gi|354505902 0.00920 -1.58 40S ribosomal protein S15a-like (metabolic process) 
gi|354492481 0.01717 -2.31 LOW QUALITY PROTEIN: deoxyribonucleoside 5'-monophosphate N-
glycosidase-like  
gi|354493803 0.01934 -1.93 SUMO-activating enzyme subunit 1-like (cell communication, cellular 
process, metabolic process) 
gi|354503001 0.01934 -1.54 flap endonuclease 1-like (cell cycle, cellular process, metabolic process)(DNA 
replication, repair , and recombination) 
gi|354492646 0.02102 1.54 integrin beta-1 (cell adhesion, cell communication, cellular process, immune 
system process, response to stimulus) 
gi|354489238 0.02696 2.01 adapter molecule crk-like (cell communication, cellular process) 
gi|354499904 0.02696 2.27 exosome complex component RRP43-like, partial (metabolic process) 
gi|354497793 0.02841 -1.39 heterogeneous nuclear ribonucleoprotein D0-like  
gi|354504522 0.02841 2.02 serine/threonine-protein phosphatase 2A activator-like, partial (metabolic 
process) 
gi|354472305 0.03182 -1.44 heterogeneous nuclear ribonucleoprotein A3-like  
gi|354485024 0.03623 -1.45 synaptic vesicle membrane protein VAT-1 homolog, partial  
gi|354505599 0.04970 -1.41 cytosolic acyl coenzyme A thioester hydrolase  
gi|354473527 0.04970 1.66 hypothetical protein LOC100757682  
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Appendix E: HEK293 cells growth rate adjusted metabolic 
rates (chapter 5) 
Table E1: Growth rate adjusted metabolic rates and differentially expressed amino acid transporters. 
Mean (n = 2) growth rate adjusted nutrient and metabolite production and consumption rates for HEK293F 
cell control, 5 mM DCA, and 10 mM DCA cultures and upregulated amino acid transporters in 10 mM DCA 
cultures. Rates are in mM/(gDW*h), growth rate in h
-1
. Negative rates represent consumption and positive 
rates production. 
  No DCA 5 mM DCA 10 mM DCA Upregulated 
transporter on 10 
mM DCA Metabolite Rate  Rate  Rate  
Glucose -297.47 -254.15 -281.66  
Lactate 373.23 289.09 263.30  
NH4
+ 12.74 13.93 25.26  
      
Consumed amino acids     
Asp -4.48 -4.42 -5.44 SLC1A5 
Gln -61.34 -55.87 -77.80 SLC7A5, SLC3A2, 
SLC1A5 
Ser -27.95 -29.87 -39.62 SLC1A5 
Arg -12.04 -14.59 -19.50 SLC7A5, SLC3A2 
Tyr -3.32 -3.11 -3.59 SLC7A5, SLC3A2, 
SLC1A5 
Essential amino acids     
His -2.41 -2.35 -2.41  
Thr -6.36 -6.06 -7.01 SLC1A5 
Val -10.17 -10.03 -14.86 SLC1A5 
Met  -3.62 -3.46 -4.36 SLC1A5 
Trp -1.15 -1.03 -1.26 SLC7A5, SLC3A2, 
SLC1A5 
Phe -4.46 -3.77 -4.76 SLC7A5, SLC3A2, 
SLC1A5 
Ile -8.92 -9.81 -13.46 SLC1A5 
Leu -13.57 -15.05 -19.18 SLC7A5, SLC3A2, 
SLC1A5 
Lys -7.36 -7.32 -4.33  
Produced amino acids     
Glu 7.01 12.41 18.35  
Gly 6.28 8.79 14.73 SLC6A9, SLC1A5 
Ala 19.21 10.78 12.90 SLC1A5 
Pro  11.53 7.31 8.98 SLC1A5 
Consumed or produced amino acid    
Asn -1.38 0.84 3.70  
      
Growth rate 0.0269 0.0269 0.0269  
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Appendix F: HEK293 cell targeted proteomics (chapter 5) 
Table F1: Proteins, peptides and transitions used in targeted proteomics  
Protein Name Peptide Sequence Precursor Mz Precu
rsor 
Charg
e 
Product Mz Product 
Charge 
Fragme
ntation 
sp|O00757|F16P2_HUMAN GTGELTQLLNSMLTAIK 895.490044 2 1103.649293 1 y10 
sp|O00757|F16P2_HUMAN GTGELTQLLNSMLTAIK 895.490044 2 432.28166 1 y4 
sp|O00757|F16P2_HUMAN YFDAATTEYVQK 718.340632 2 1125.542245 1 y10 
sp|O00757|F16P2_HUMAN YFDAATTEYVQK 718.340632 2 537.303124 1 y4 
sp|O00757|F16P2_HUMAN YFDAATTEYVQK 718.340632 2 568.240189 1 b5 
sp|O43837|IDH3B_HUMAN AAAVPVEFQEHHLSEVQNMASEEK 894.093903 3 823.402086 2 b15 
sp|O43837|IDH3B_HUMAN AAAVPVEFQEHHLSEVQNMASEEK 894.093903 3 872.936293 2 b16 
sp|O43837|IDH3B_HUMAN NIANPTAMLLSASNMLR 908.974038 2 620.318456 1 y5 
sp|O43837|IDH3B_HUMAN NIANPTAMLLSASNMLR 908.974038 2 1039.560478 1 b10 
sp|O75390|CISY_HUMAN DILADLIPK 499.30005 2 656.397753 1 y6 
sp|O75390|CISY_HUMAN DILADLIPK 499.30005 2 244.165568 1 y2 
sp|O75390|CISY_HUMAN DILADLIPK 499.30005 2 229.118283 1 b2 
sp|O75390|CISY_HUMAN GLVYETSVLDPDEGIR 881.946523 2 914.457787 1 y8 
sp|O75390|CISY_HUMAN GLVYETSVLDPDEGIR 881.946523 2 801.373723 1 y7 
sp|O75874|IDHC_HUMAN LVSGWVKPIIIGR 479.969528 3 213.159754 1 b2 
sp|O75874|IDHC_HUMAN LVSGWVKPIIIGR 479.969528 3 642.360973 1 b6 
sp|O75874|IDHC_HUMAN TVEAEAAHGTVTR 671.341497 2 571.283451 2 y11 
sp|O75874|IDHC_HUMAN TVEAEAAHGTVTR 671.341497 2 506.762154 2 y10 
sp|P00338|LDHA_HUMAN DLADELALVDVIEDK 829.430175 2 1001.551353 1 y9 
sp|P00338|LDHA_HUMAN DLADELALVDVIEDK 829.430175 2 930.514239 1 y8 
sp|P00338|LDHA_HUMAN GEMMDLQHGSLFLR 545.265687 3 724.362864 2 y12 
sp|P00338|LDHA_HUMAN GEMMDLQHGSLFLR 545.265687 3 658.842622 2 y11 
sp|P00558|PGK1_HUMAN ALESPERPFLAILGGAK 590.336716 3 792.940847 2 y15 
sp|P00558|PGK1_HUMAN ALESPERPFLAILGGAK 590.336716 3 728.419551 2 y14 
sp|P00558|PGK1_HUMAN VLNNMEIGTSLFDEEGAK 983.974955 2 1153.537159 1 y11 
sp|P00558|PGK1_HUMAN VLNNMEIGTSLFDEEGAK 983.974955 2 1096.515696 1 y10 
sp|P04075|ALDOA_HUMAN GILAADESTGSIAK 666.853906 2 1049.510944 1 y11 
sp|P04075|ALDOA_HUMAN GILAADESTGSIAK 666.853906 2 978.473831 1 y10 
sp|P04075|ALDOA_HUMAN FSHEEIAMATVTALR 838.427247 2 933.518613 1 y9 
sp|P04075|ALDOA_HUMAN FSHEEIAMATVTALR 838.427247 2 721.377025 2 y13 
sp|P04406|G3P_HUMAN LVINGNPITIFQER 807.454122 2 1003.557107 1 y8 
sp|P04406|G3P_HUMAN LVINGNPITIFQER 807.454122 2 579.288536 1 y4 
sp|P04406|G3P_HUMAN GALQNIIPASTGAAK 706.398815 2 815.462144 1 y9 
sp|P04406|G3P_HUMAN GALQNIIPASTGAAK 706.398815 2 597.335487 1 b6 
sp|P05062|ALDOB_HUMAN ELSEIAQSIVANGK 729.893563 2 688.398815 1 y7 
sp|P05062|ALDOB_HUMAN ELSEIAQSIVANGK 729.893563 2 389.214309 1 y4 
sp|P05062|ALDOB_HUMAN ALQASALAAWGGK 622.343312 2 447.235044 1 y4 
sp|P05062|ALDOB_HUMAN ALQASALAAWGGK 622.343312 2 726.414465 1 b8 
sp|P06733|ENOA_HUMAN DATNVGDEGGFAPNILENK 980.965976 2 1159.610599 1 y11 
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sp|P06733|ENOA_HUMAN DATNVGDEGGFAPNILENK 980.965976 2 827.462144 1 y7 
sp|P06733|ENOA_HUMAN YISPDQLADLYK 713.366649 2 1149.57863 1 y10 
sp|P06733|ENOA_HUMAN YISPDQLADLYK 713.366649 2 1062.546602 1 y9 
sp|P06744|G6PI_HUMAN NLVTEDVMR 538.773873 2 306.159436 1 y2 
sp|P06744|G6PI_HUMAN NLVTEDVMR 538.773873 2 228.134267 1 b2 
sp|P06744|G6PI_HUMAN TLAQLNPESSLFIIASK 916.511834 2 1191.661966 1 y11 
sp|P06744|G6PI_HUMAN TLAQLNPESSLFIIASK 916.511834 2 527.318774 1 b5 
sp|P07195|LDHB_HUMAN LIAPVAEEEATVPNNK 847.951609 2 472.251423 1 y4 
sp|P07195|LDHB_HUMAN LIAPVAEEEATVPNNK 847.951609 2 699.348988 2 y13 
sp|P07195|LDHB_HUMAN MVVESAYEVIK 634.333764 2 1037.551353 1 y9 
sp|P07195|LDHB_HUMAN MVVESAYEVIK 634.333764 2 231.116175 1 b2 
sp|P07205|PGK2_HUMAN LGDVYVNDAFGTAHR 545.602232 3 761.357679 2 y14 
sp|P07205|PGK2_HUMAN LGDVYVNDAFGTAHR 545.602232 3 625.799268 2 y11 
sp|P07205|PGK2_HUMAN VSHVSTGGGASLELLEGK 580.975735 3 688.387582 1 y6 
sp|P07205|PGK2_HUMAN VSHVSTGGGASLELLEGK 580.975735 3 559.344989 1 y5 
sp|P07437|TBB5_HUMAN AILVDLEPGTMDSVR 808.42163 2 1219.562328 1 y11 
sp|P07437|TBB5_HUMAN AILVDLEPGTMDSVR 808.42163 2 862.408728 1 y8 
sp|P07437|TBB5_HUMAN GHYTEGAELVDSVLDVVR 653.66545 3 601.366787 1 y5 
sp|P07437|TBB5_HUMAN GHYTEGAELVDSVLDVVR 653.66545 3 488.282723 1 y4 
sp|P07864|LDHC_HUMAN SIIPAIVHYSPDCK 771.902876 2 948.424378 1 y8 
sp|P07864|LDHC_HUMAN SIIPAIVHYSPDCK 771.902876 2 231.604486 2 y4 
sp|P07864|LDHC_HUMAN SIIPAIVHYSPDCK 771.902876 2 994.572029 1 b9 
sp|P07864|LDHC_HUMAN VIGSGCNLDSAR 596.292961 2 546.758754 2 y11 
sp|P07864|LDHC_HUMAN VIGSGCNLDSAR 596.292961 2 490.216722 2 y10 
sp|P07864|LDHC_HUMAN VIGSGCNLDSAR 596.292961 2 213.159754 1 b2 
sp|P07864|LDHC_HUMAN EELFLSIPCVLGR 738.399969 2 1104.623412 1 y10 
sp|P07864|LDHC_HUMAN EELFLSIPCVLGR 738.399969 2 644.354842 1 y6 
sp|P07864|LDHC_HUMAN EELFLSIPCVLGR 738.399969 2 322.681059 2 y6 
sp|P07954|FUMH_HUMAN THTQDAVPLTLGQEFSGYVQQVK 849.434365 3 897.475251 2 y16 
sp|P07954|FUMH_HUMAN THTQDAVPLTLGQEFSGYVQQVK 849.434365 3 1087.03165 2 b20 
sp|P07954|FUMH_HUMAN IYELAAGGTAVGTGLNTR 882.467957 2 817.452642 1 y8 
sp|P07954|FUMH_HUMAN IYELAAGGTAVGTGLNTR 882.467957 2 560.315085 1 y5 
sp|P08237|K6PF_HUMAN SEWSDLLSDLQK 710.851363 2 703.398481 1 y6 
sp|P08237|K6PF_HUMAN SEWSDLLSDLQK 710.851363 2 590.314417 1 y5 
sp|P08237|K6PF_HUMAN DLQANVEHLVQK 697.37534 2 753.425364 1 y6 
sp|P08237|K6PF_HUMAN DLQANVEHLVQK 697.37534 2 624.382771 1 y5 
sp|P08243|ASNS_HUMAN LAVVDPLFGMQPIR 778.436886 2 1173.60849 1 y10 
sp|P08243|ASNS_HUMAN LAVVDPLFGMQPIR 778.436886 2 1058.581547 1 y9 
sp|P08243|ASNS_HUMAN DVPLHALYDNVEK 756.88828 2 880.441074 1 y7 
sp|P08243|ASNS_HUMAN DVPLHALYDNVEK 756.88828 2 649.840602 2 y11 
sp|P08559|ODPA_HUMAN EILAELTGR 1001.562586 1 646.351865 1 y6 
sp|P08559|ODPA_HUMAN EILAELTGR 1001.562586 1 556.297704 1 b5 
sp|P08559|ODPA_HUMAN EILAELTGR 1001.562586 1 827.45091 1 b8 
sp|P08559|ODPA_HUMAN YGMGTSVER 500.231841 2 490.261987 1 y4 
sp|P08559|ODPA_HUMAN YGMGTSVER 500.231841 2 390.189445 2 y7 
sp|P08559|ODPA_HUMAN YGMGTSVER 540.215007 2 570.228318 1 y4 
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sp|P08559|ODPA_HUMAN YGMGTSVER 540.215007 2 430.172611 2 y7 
sp|P08559|ODPA_HUMAN YHGHSMSDPGVSYR 796.849163 2 1098.488435 1 y10 
sp|P08559|ODPA_HUMAN YHGHSMSDPGVSYR 796.849163 2 880.415922 1 y8 
sp|P08559|ODPA_HUMAN YHGHSMSDPGVSYR 796.849163 2 301.129516 1 b2 
sp|P08559|ODPA_HUMAN YHGHSMSDPGVSYR 876.815494 2 660.346385 1 y6 
sp|P08559|ODPA_HUMAN YHGHSMSDPGVSYR 876.815494 2 661.270517 1 y5 
sp|P08559|ODPA_HUMAN YHGHSMSDPGVSYR 876.815494 2 897.330812 1 b8 
sp|P08559|ODPA_HUMAN YHGHSMSDPGVSYR 836.832329 2 1178.454766 1 y10 
sp|P08559|ODPA_HUMAN YHGHSMSDPGVSYR 836.832329 2 758.323281 1 y6 
sp|P08559|ODPA_HUMAN YHGHSMSDPGVSYR 836.832329 2 505.18064 1 y3 
sp|P08559|ODPA_HUMAN YHGHSMSDPGVSYR 836.832329 2 793.383893 1 y7 
sp|P08559|ODPA_HUMAN YHGHSMSDPGVSYR 836.832329 2 678.35695 1 y6 
sp|P08559|ODPA_HUMAN YHGHSMSDPGVSYR 836.832329 2 706.312217 2 y13 
sp|P08559|ODPA_HUMAN YHGHSMSDPGVSYR 836.832329 2 995.307708 1 b8 
sp|P08559|ODPA_HUMAN MVNSNLASVEELK 717.368866 2 1203.621558 1 y11 
sp|P08559|ODPA_HUMAN MVNSNLASVEELK 717.368866 2 775.41961 1 y7 
sp|P08559|ODPA_HUMAN MVNSNLASVEELK 717.368866 2 518.282054 1 y4 
sp|P09104|ENOG_HUMAN IVIGMDVAASEFYR 785.900333 2 701.325316 1 y5 
sp|P09104|ENOG_HUMAN IVIGMDVAASEFYR 785.900333 2 870.475351 1 b9 
sp|P09104|ENOG_HUMAN YITGDQLGALYQDFVR 929.970333 2 827.404629 1 y6 
sp|P09104|ENOG_HUMAN YITGDQLGALYQDFVR 929.970333 2 791.896637 2 y14 
sp|P09467|F16P1_HUMAN YVGSMVADVHR 617.305872 2 597.310334 1 y5 
sp|P09467|F16P1_HUMAN YVGSMVADVHR 617.305872 2 411.246278 1 y3 
sp|P09467|F16P1_HUMAN YVGSMVADVHR 617.305872 2 486.240001 2 y9 
sp|P09467|F16P1_HUMAN TLVYGGIFLYPANK 778.429584 2 965.545479 1 y8 
sp|P09467|F16P1_HUMAN TLVYGGIFLYPANK 778.429584 2 592.308937 1 y5 
sp|P09467|F16P1_HUMAN TLVYGGIFLYPANK 778.429584 2 429.245609 1 y4 
sp|P09467|F16P1_HUMAN APVILGSPDDVLEFLK 856.977095 2 1075.567003 1 y9 
sp|P09467|F16P1_HUMAN APVILGSPDDVLEFLK 856.977095 2 381.249632 1 b4 
sp|P09467|F16P1_HUMAN APVILGSPDDVLEFLK 856.977095 2 551.355159 1 b6 
sp|P09467|F16P1_HUMAN APVILGSPDDVLEFLK 571.653822 3 649.391939 1 y5 
sp|P09467|F16P1_HUMAN APVILGSPDDVLEFLK 571.653822 3 536.307875 1 y4 
sp|P09467|F16P1_HUMAN APVILGSPDDVLEFLK 571.653822 3 538.287139 2 y9 
sp|P09622|DLDH_HUMAN NLGLEELGIELDPR 784.419945 2 799.430844 1 y7 
sp|P09622|DLDH_HUMAN NLGLEELGIELDPR 784.419945 2 272.171716 1 y2 
sp|P09622|DLDH_HUMAN FPFAANSR 909.457727 1 665.336549 1 y6 
sp|P09622|DLDH_HUMAN FPFAANSR 909.457727 1 518.268135 1 y5 
sp|P09972|ALDOC_HUMAN GVVPLAGTDGETTTQGLDGLSER 758.380037 3 846.431572 1 y8 
sp|P09972|ALDOC_HUMAN GVVPLAGTDGETTTQGLDGLSER 758.380037 3 561.299101 1 y5 
sp|P09972|ALDOC_HUMAN TPSALAILENANVLAR 826.970136 2 1112.642233 1 y10 
sp|P09972|ALDOC_HUMAN TPSALAILENANVLAR 826.970136 2 886.474105 1 y8 
sp|P11413|G6PD_HUMAN NSYVAGQYDDAASYQR 904.397729 2 1088.464329 1 y9 
sp|P11413|G6PD_HUMAN NSYVAGQYDDAASYQR 904.397729 2 624.31 1 y5 
sp|P11413|G6PD_HUMAN NSYVAGQYDDAASYQR 904.397729 2 365.14556 1 b3 
sp|P11413|G6PD_HUMAN IFGPIWNR 501.779619 2 475.241192 1 y3 
sp|P11413|G6PD_HUMAN IFGPIWNR 501.779619 2 371.70338 2 y6 
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sp|P11413|G6PD_HUMAN IFGPIWNR 501.779619 2 261.159754 1 b2 
sp|P13929|ENOB_HUMAN TAIQAAGYPDK 567.79312 2 650.314417 1 y6 
sp|P13929|ENOB_HUMAN TAIQAAGYPDK 567.79312 2 481.750724 2 y9 
sp|P13929|ENOB_HUMAN VNQIGSVTESIQACK 526.271495 3 440.21566 2 y8 
sp|P13929|ENOB_HUMAN VNQIGSVTESIQACK 526.271495 3 455.234381 3 y13 
sp|P14618|KPYM_HUMAN LDIDSPPITAR 599.327327 2 856.452307 1 y8 
sp|P14618|KPYM_HUMAN LDIDSPPITAR 599.327327 2 654.393336 1 y6 
sp|P14618|KPYM_HUMAN GADFLVTEVENGGSLGSK 890.441605 2 1177.569522 1 y12 
sp|P14618|KPYM_HUMAN GADFLVTEVENGGSLGSK 890.441605 2 848.410836 1 y9 
sp|P15104|GLNA_HUMAN VQAMYIWIDGTGEGLR 904.953629 2 1216.632063 1 y11 
sp|P15104|GLNA_HUMAN VQAMYIWIDGTGEGLR 904.953629 2 1103.547999 1 y10 
sp|P15104|GLNA_HUMAN VQAMYIWIDGTGEGLR 904.953629 2 804.384622 1 y8 
sp|P15104|GLNA_HUMAN VQAMYIWIDGTGEGLR 904.953629 2 689.357679 1 y7 
sp|P15104|GLNA_HUMAN VQAMYIWIDGTGEGLR 904.953629 2 706.359259 1 b6 
sp|P15104|GLNA_HUMAN VQAMYIWIDGTGEGLR 904.953629 2 1005.522636 1 b8 
sp|P15104|GLNA_HUMAN DIVEAHYR 501.753798 2 475.241192 1 y3 
sp|P15104|GLNA_HUMAN DIVEAHYR 501.753798 2 229.118283 1 b2 
sp|P15104|GLNA_HUMAN LTGFHETSNINDFSAGVANR 1075.516699 2 821.426427 1 y8 
sp|P15104|GLNA_HUMAN LTGFHETSNINDFSAGVANR 1075.516699 2 866.405888 2 y16 
sp|P15259|PGAM2_HUMAN ALPFWNEEIVPQIK 842.458873 2 485.308209 1 y4 
sp|P15259|PGAM2_HUMAN ALPFWNEEIVPQIK 842.458873 2 750.398284 2 y12 
sp|P15259|PGAM2_HUMAN TLWAILDGTDQMWLPVVR 705.374953 3 769.471921 1 y6 
sp|P15259|PGAM2_HUMAN TLWAILDGTDQMWLPVVR 705.374953 3 822.908158 2 b14 
sp|P15259|PGAM2_HUMAN ALPFWNEEIVPQIK 842.458873 2 485.308209 1 y4 
sp|P15259|PGAM2_HUMAN ALPFWNEEIVPQIK 842.458873 2 750.398284 2 y12 
sp|P17858|K6PL_HUMAN SEWGSLLEELVAEGK 823.917235 2 987.535703 1 y9 
sp|P17858|K6PL_HUMAN SEWGSLLEELVAEGK 823.917235 2 874.451639 1 y8 
sp|P17858|K6PL_HUMAN SEWGSLLEELVAEGK 823.917235 2 715.879924 2 y13 
sp|P17858|K6PL_HUMAN TNVLGHLQQGGAPTPFDR 954.489755 2 1173.564711 1 y11 
sp|P17858|K6PL_HUMAN TNVLGHLQQGGAPTPFDR 954.489755 2 534.267073 1 y4 
sp|P17858|K6PL_HUMAN TNVLGHLQQGGAPTPFDR 954.489755 2 735.4148 1 b7 
sp|P18669|PGAM1_HUMAN FSGWYDADLSPAGHEEAK 660.630516 3 838.405357 1 y8 
sp|P18669|PGAM1_HUMAN FSGWYDADLSPAGHEEAK 660.630516 3 419.706317 2 y8 
sp|P18669|PGAM1_HUMAN ALPFWNEEIVPQIK 842.458873 2 485.308209 1 y4 
sp|P18669|PGAM1_HUMAN ALPFWNEEIVPQIK 842.458873 2 750.398284 2 y12 
sp|P18669|PGAM1_HUMAN ALPFWNEEIVPQIK 842.458873 2 485.308209 1 y4 
sp|P18669|PGAM1_HUMAN ALPFWNEEIVPQIK 842.458873 2 750.398284 2 y12 
sp|P19367|HXK1_HUMAN GDFIALDLGGSSFR 727.867348 2 951.489421 1 y9 
sp|P19367|HXK1_HUMAN GDFIALDLGGSSFR 727.867348 2 838.405357 1 y8 
sp|P19367|HXK1_HUMAN GDFIALDLGGSSFR 727.867348 2 610.29435 1 y6 
sp|P19367|HXK1_HUMAN LVDEYSLNAGK 604.81151 2 752.39373 1 y7 
sp|P19367|HXK1_HUMAN LVDEYSLNAGK 604.81151 2 589.330401 1 y6 
sp|P21399|ACOC_HUMAN ANYLASPPLVIAYAIAGTIR 1037.588407 2 864.493778 1 y8 
sp|P21399|ACOC_HUMAN ANYLASPPLVIAYAIAGTIR 1037.588407 2 945.048386 2 y18 
sp|P21399|ACOC_HUMAN YQQAGLPLIVLAGK 735.937576 2 810.544751 1 y8 
sp|P21399|ACOC_HUMAN YQQAGLPLIVLAGK 735.937576 2 292.129182 1 b2 
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sp|P21399|ACOC_HUMAN YQQAGLPLIVLAGK 735.937576 2 661.330401 1 b6 
sp|P21912|DHSB_HUMAN AGDKPHMQTYEVDLNK 615.964842 3 588.335152 1 y5 
sp|P21912|DHSB_HUMAN AGDKPHMQTYEVDLNK 615.964842 3 737.853383 2 y12 
sp|P21912|DHSB_HUMAN AGDKPHMQTYEVDLNK 615.964842 3 606.299435 1 b6 
sp|P21912|DHSB_HUMAN QQYLQSIEER 647.325316 2 761.378808 1 y6 
sp|P21912|DHSB_HUMAN QQYLQSIEER 647.325316 2 433.204138 1 y3 
sp|P23368|MAOM_HUMAN DPFYMGLYQK 631.299724 2 608.340238 1 y5 
sp|P23368|MAOM_HUMAN DPFYMGLYQK 631.299724 2 360.155397 1 b3 
sp|P23368|MAOM_HUMAN ALTSQLTDEELAQGR 816.41539 2 431.236107 1 y4 
sp|P23368|MAOM_HUMAN ALTSQLTDEELAQGR 816.41539 2 360.198993 1 y3 
sp|P24752|THIL_HUMAN TPIGSFLGSLSLLPATK 851.492913 2 729.450516 1 y7 
sp|P24752|THIL_HUMAN TPIGSFLGSLSLLPATK 851.492913 2 529.334424 1 y5 
sp|P24752|THIL_HUMAN TPIGSFLGSLSLLPATK 851.492913 2 416.25036 1 y4 
sp|P24752|THIL_HUMAN EAYMGNVLQGGEGQAPTR 626.631863 3 373.219394 1 y3 
sp|P24752|THIL_HUMAN EAYMGNVLQGGEGQAPTR 626.631863 3 500.743962 2 y10 
sp|P24752|THIL_HUMAN EAYMGNVLQGGEGQAPTR 626.631863 3 753.338097 2 b15 
sp|P30613|KPYR_HUMAN STSIIATIGPASR 637.359159 2 772.431178 1 y8 
sp|P30613|KPYR_HUMAN STSIIATIGPASR 637.359159 2 701.394064 1 y7 
sp|P30613|KPYR_HUMAN STSIIATIGPASR 637.359159 2 487.262322 1 y5 
sp|P30613|KPYR_HUMAN STSIIATIGPASR 637.359159 2 844.477459 1 b9 
sp|P30613|KPYR_HUMAN GSQVLVTVDPAFR 694.880258 2 805.420279 1 y7 
sp|P30613|KPYR_HUMAN GSQVLVTVDPAFR 694.880258 2 584.340238 1 b6 
sp|P30613|KPYR_HUMAN FGVEHGVDIVFASFVR 889.964854 2 1053.572757 1 y9 
sp|P30613|KPYR_HUMAN FGVEHGVDIVFASFVR 889.964854 2 938.545814 1 y8 
sp|P30613|KPYR_HUMAN FGVEHGVDIVFASFVR 889.964854 2 570.267073 1 b5 
sp|P31040|DHSA_HUMAN LGANSLLDLVVFGR 737.424833 2 918.540728 1 y8 
sp|P31040|DHSA_HUMAN LGANSLLDLVVFGR 737.424833 2 805.456664 1 y7 
sp|P31040|DHSA_HUMAN IDEYDYSKPIQGQQK 604.631857 3 727.867348 2 y12 
sp|P31040|DHSA_HUMAN IDEYDYSKPIQGQQK 604.631857 3 646.335684 2 y11 
sp|P35557|HXK4_HUMAN LVDESSANPGQQLYEK 889.43378 2 1076.5371 1 y9 
sp|P35557|HXK4_HUMAN LVDESSANPGQQLYEK 889.43378 2 702.330461 1 b7 
sp|P35557|HXK4_HUMAN LVDESSANPGQQLYEK 889.43378 2 816.373388 1 b8 
sp|P35557|HXK4_HUMAN LVDENLLFHGEASEQLR 657.337444 3 505.26344 3 y13 
sp|P35557|HXK4_HUMAN LVDENLLFHGEASEQLR 657.337444 3 571.272218 1 b5 
sp|P35557|HXK4_HUMAN LVDENLLFHGEASEQLR 657.337444 3 472.758018 2 b8 
sp|P36957|ODO2_HUMAN ASAFALQEQPVVNAVIDDTTK 739.718102 3 791.414525 1 y7 
sp|P36957|ODO2_HUMAN ASAFALQEQPVVNAVIDDTTK 739.718102 3 713.869891 2 b14 
sp|P36957|ODO2_HUMAN GLVVPVIR 852.566549 1 484.324194 1 y4 
sp|P36957|ODO2_HUMAN GLVVPVIR 852.566549 1 466.302396 1 b5 
sp|P40925|MDHC_HUMAN DLDVAILVGSMPR 462.586755 3 547.265692 1 y5 
sp|P40925|MDHC_HUMAN DLDVAILVGSMPR 462.586755 3 490.244229 1 y4 
sp|P40925|MDHC_HUMAN DLDVAILVGSMPR 462.586755 3 627.334818 1 b6 
sp|P40925|MDHC_HUMAN FVEGLPINDFSR 697.359159 2 638.289265 1 y5 
sp|P40925|MDHC_HUMAN FVEGLPINDFSR 697.359159 2 574.290745 2 y10 
sp|P40925|MDHC_HUMAN FVEGLPINDFSR 697.359159 2 546.292225 1 b5 
sp|P40926|MDHM_HUMAN VAVLGASGGIGQPLSLLLK 598.368016 3 783.533852 1 y7 
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sp|P40926|MDHM_HUMAN VAVLGASGGIGQPLSLLLK 598.368016 3 705.919383 2 y15 
sp|P40926|MDHM_HUMAN MISDAIPELK 558.802099 2 872.472374 1 y8 
sp|P40926|MDHM_HUMAN MISDAIPELK 558.802099 2 486.292225 1 y4 
sp|P48163|MAOX_HUMAN DMAAFNERPIIFALSNPTSK 741.380656 3 546.288202 1 y5 
sp|P48163|MAOX_HUMAN DMAAFNERPIIFALSNPTSK 741.380656 3 795.410868 2 b14 
sp|P48163|MAOX_HUMAN QITDNIFLTTAEVIAQQVSDK 778.744428 3 704.357344 1 y6 
sp|P48163|MAOX_HUMAN QITDNIFLTTAEVIAQQVSDK 778.744428 3 1037.046769 2 b19 
sp|P48735|IDHP_HUMAN VAKPVVEMDGDEMTR 838.902747 2 1182.47655 1 y10 
sp|P48735|IDHP_HUMAN VAKPVVEMDGDEMTR 838.902747 2 1083.408136 1 y9 
sp|P48735|IDHP_HUMAN DQTDDQVTIDSALATQK 924.944709 2 1047.568065 1 y10 
sp|P48735|IDHP_HUMAN DQTDDQVTIDSALATQK 924.944709 2 802.321353 1 b7 
sp|P50213|IDH3A_HUMAN TPIAAGHPSMNLLLR 530.964337 3 497.281777 3 y14 
sp|P50213|IDH3A_HUMAN TPIAAGHPSMNLLLR 530.964337 3 464.930856 3 y13 
sp|P50213|IDH3A_HUMAN TPYTDVNIVTIR 696.380091 2 1030.589135 1 y9 
sp|P50213|IDH3A_HUMAN TPYTDVNIVTIR 696.380091 2 715.4461 1 y6 
sp|P51553|IDH3G_HUMAN GNIETNHNLPPSHK 779.392053 2 565.309272 1 y5 
sp|P51553|IDH3G_HUMAN GNIETNHNLPPSHK 779.392053 2 706.339289 2 b13 
sp|P51553|IDH3G_HUMAN DIDILIVR 478.792392 2 500.355494 1 y4 
sp|P51553|IDH3G_HUMAN DIDILIVR 478.792392 2 229.118283 1 b2 
sp|P52789|HXK2_HUMAN GLGATTHPTAAVK 612.340769 2 586.355888 1 y6 
sp|P52789|HXK2_HUMAN GLGATTHPTAAVK 612.340769 2 527.288005 2 y11 
sp|P52789|HXK2_HUMAN NVELVEGEEGR 615.801674 2 547.247065 1 y5 
sp|P52789|HXK2_HUMAN NVELVEGEEGR 615.801674 2 684.356282 1 b6 
sp|P52790|HXK3_HUMAN EQQTLQVAVATGGR 729.388979 2 560.315085 1 y6 
sp|P52790|HXK3_HUMAN EQQTLQVAVATGGR 729.388979 2 461.246672 1 y5 
sp|P52790|HXK3_HUMAN QLGLDQGILLNWTK 799.948672 2 1072.614956 1 y9 
sp|P52790|HXK3_HUMAN QLGLDQGILLNWTK 799.948672 2 944.556378 1 y8 
sp|P53597|SUCA_HUMAN QGTFHSQQALEYGTK 565.609276 3 597.287868 1 y5 
sp|P53597|SUCA_HUMAN QGTFHSQQALEYGTK 565.609276 3 468.245275 1 y4 
sp|P53597|SUCA_HUMAN MGHAGAIIAGGK 541.7924 2 686.419551 1 y8 
sp|P53597|SUCA_HUMAN MGHAGAIIAGGK 541.7924 2 326.128136 1 b3 
sp|P55809|SCOT1_HUMAN QYLSGELEVELTPQGTLAER 745.04974 3 436.235241 2 y8 
sp|P55809|SCOT1_HUMAN QYLSGELEVELTPQGTLAER 745.04974 3 631.319168 2 b11 
sp|P55809|SCOT1_HUMAN QYLSGELEVELTPQGTLAER 745.04974 3 681.843007 2 b12 
sp|P55809|SCOT1_HUMAN GGHVDLTMLGAMQVSK 822.415825 2 720.370886 1 y7 
sp|P55809|SCOT1_HUMAN GGHVDLTMLGAMQVSK 822.415825 2 765.394361 2 y14 
sp|P55809|SCOT1_HUMAN GGHVDLTMLGAMQVSK 822.415825 2 811.3767 1 b8 
sp|P55809|SCOT1_HUMAN GMGGAMDLVSSAK 1223.57587 1 719.393395 1 y7 
sp|P55809|SCOT1_HUMAN GMGGAMDLVSSAK 1223.57587 1 832.369171 1 b9 
sp|P60174|TPIS_HUMAN QSLGELIGTLNAAK 707.898648 2 1086.61535 1 y11 
sp|P60174|TPIS_HUMAN QSLGELIGTLNAAK 707.898648 2 900.551293 1 y9 
sp|P60174|TPIS_HUMAN QSLGELIGTLNAAK 707.898648 2 787.467229 1 y8 
sp|P60174|TPIS_HUMAN QSLGELIGTLNAAK 707.898648 2 674.383165 1 y7 
sp|P60174|TPIS_HUMAN VVLAYEPVWAIGTGK 801.948141 2 1220.631 1 y11 
sp|P60174|TPIS_HUMAN VVLAYEPVWAIGTGK 801.948141 2 928.525078 1 y9 
sp|Q01813|K6PP_HUMAN DLQSNVEHLTEK 706.854437 2 855.457058 1 y7 
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sp|Q01813|K6PP_HUMAN DLQSNVEHLTEK 706.854437 2 756.388644 1 y6 
sp|Q01813|K6PP_HUMAN NVIFQPVAELK 629.363713 2 931.524744 1 y8 
sp|Q01813|K6PP_HUMAN NVIFQPVAELK 629.363713 2 522.808042 2 y9 
sp|Q02218|ODO1_HUMAN SSENGVDYVIMGMPHR 896.411271 2 1103.548867 1 y9 
sp|Q02218|ODO1_HUMAN SSENGVDYVIMGMPHR 896.411271 2 409.230627 1 y3 
sp|Q02218|ODO1_HUMAN LLDTAFDLDVFK 698.871568 2 736.387582 1 y6 
sp|Q02218|ODO1_HUMAN LLDTAFDLDVFK 698.871568 2 508.276575 1 y4 
sp|Q15118|PDK1_HUMAN AIYDFTDTVIR 657.340435 2 851.462144 1 y7 
sp|Q15118|PDK1_HUMAN AIYDFTDTVIR 657.340435 2 488.319108 1 y4 
sp|Q15118|PDK1_HUMAN AIYDFTDTVIR 657.340435 2 565.279846 2 y9 
sp|Q15118|PDK1_HUMAN AVPLAGFGYGLPISR 759.427376 2 862.478128 1 y8 
sp|Q15118|PDK1_HUMAN AVPLAGFGYGLPISR 759.427376 2 674.374612 2 y13 
sp|Q15119|PDK2_HUMAN HNDVVPTMAQGVLEYK 900.951086 2 466.204472 1 b4 
sp|Q15119|PDK2_HUMAN HNDVVPTMAQGVLEYK 900.951086 2 1249.599382 1 b12 
sp|Q15119|PDK2_HUMAN ATVESHESSLILPPIK 860.977627 2 567.38646 1 y5 
sp|Q15119|PDK2_HUMAN ATVESHESSLILPPIK 860.977627 2 454.302396 1 y4 
sp|Q15120|PDK3_HUMAN LFNYMYSTAPRPSLEPTR 715.026213 3 941.959442 2 y16 
sp|Q15120|PDK3_HUMAN LFNYMYSTAPRPSLEPTR 715.026213 3 884.937979 2 y15 
sp|Q15120|PDK3_HUMAN AAPLAGFGYGLPISR 745.411726 2 1066.568006 1 y10 
sp|Q15120|PDK3_HUMAN AAPLAGFGYGLPISR 745.411726 2 642.393336 1 y6 
sp|Q16654|PDK4_HUMAN HHNVVPTMAQGIIEYK 612.985689 3 587.304855 1 b5 
sp|Q16654|PDK4_HUMAN NAPLAGFGYGLPISR 766.914632 2 862.478128 1 y8 
sp|Q16654|PDK4_HUMAN NAPLAGFGYGLPISR 766.914632 2 642.393336 1 y6 
sp|Q16654|PDK4_HUMAN NAPLAGFGYGLPISR 766.914632 2 472.287808 1 y4 
sp|Q16665|HIF1A_HUMAN ITELMGYEPEELLGR 875.44002 2 1034.48631 1 b9 
sp|Q16665|HIF1A_HUMAN ITELMGYEPEELLGR 875.44002 2 1163.528903 1 b10 
sp|Q16665|HIF1A_HUMAN ITELMGYEPEELLGR 875.44002 2 469.220411 2 b8 
sp|Q16665|HIF1A_HUMAN GQVTTGQYR 505.256705 2 824.426093 1 y7 
sp|Q16665|HIF1A_HUMAN GQVTTGQYR 505.256705 2 544.272552 1 b6 
sp|Q16798|MAON_HUMAN GLFITIHDK 522.297841 2 726.414465 1 y6 
sp|Q16798|MAON_HUMAN GLFITIHDK 522.297841 2 437.245078 2 y7 
sp|Q16798|MAON_HUMAN GHLATMLNSWPEDNIK 913.44871 2 724.347934 2 y12 
sp|Q16798|MAON_HUMAN GHLATMLNSWPEDNIK 913.44871 2 1111.535325 1 b10 
sp|Q96I99|SUCB2_HUMAN FFVADTANEALEAAK 798.898845 2 1203.585172 1 y12 
sp|Q96I99|SUCB2_HUMAN FFVADTANEALEAAK 798.898845 2 1132.548058 1 y11 
sp|Q96I99|SUCB2_HUMAN DPNVVGQLAK 520.790381 2 327.12991 1 b3 
sp|Q96I99|SUCB2_HUMAN DPNVVGQLAK 520.790381 2 426.198324 1 b4 
sp|Q99798|ACON_HUMAN IVYGHLDDPASQEIER 921.455047 2 1044.495629 1 y9 
sp|Q99798|ACON_HUMAN IVYGHLDDPASQEIER 921.455047 2 913.441408 1 b8 
sp|Q99798|ACON_HUMAN NAVTQEFGPVPDTAR 801.399543 2 812.426093 1 y8 
sp|Q99798|ACON_HUMAN NAVTQEFGPVPDTAR 801.399543 2 559.283451 1 y5 
sp|Q9NR19|ACSA_HUMAN SAHVPSLQR 994.542854 1 699.4148 1 y6 
sp|Q9NR19|ACSA_HUMAN SAHVPSLQR 994.542854 1 395.203744 1 b4 
sp|Q9NR19|ACSA_HUMAN SAHVPSLQR 994.542854 1 820.431178 1 b8 
sp|Q9NR19|ACSA_HUMAN IGPIATPDYIQNAPGLPK 933.012001 2 847.959237 2 y16 
sp|Q9NR19|ACSA_HUMAN IGPIATPDYIQNAPGLPK 933.012001 2 452.286745 1 b5 
151 
 
sp|Q9NR19|ACSA_HUMAN IGPIATPDYIQNAPGLPK 933.012001 2 553.334424 1 b6 
sp|Q9NUB1|ACS2L_HUMAN GIVHTQAGYLLYAALTHK 652.694903 3 803.441014 1 y7 
sp|Q9NUB1|ACS2L_HUMAN GIVHTQAGYLLYAALTHK 652.694903 3 640.377686 1 y6 
sp|Q9NUB1|ACS2L_HUMAN GIVHTQAGYLLYAALTHK 652.694903 3 562.970256 3 y15 
sp|Q9NUB1|ACS2L_HUMAN MDDVINISGHR 628.806236 2 683.358347 1 y6 
sp|Q9NUB1|ACS2L_HUMAN MDDVINISGHR 628.806236 2 569.31542 1 y5 
sp|Q9NUB1|ACS2L_HUMAN MDDVINISGHR 628.806236 2 456.231356 1 y4 
sp|Q9UI32|GLSL_HUMAN VVQESSSGGLLDR 673.849155 2 1020.495629 1 y10 
sp|Q9UI32|GLSL_HUMAN VVQESSSGGLLDR 673.849155 2 804.421007 1 y8 
sp|Q9UI32|GLSL_HUMAN VVQESSSGGLLDR 673.849155 2 630.35695 1 y6 
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Table F2: Targeted proteomics analysis of 10 mM DCA cultures compared to control cultures 
UniProt ID adj.P.Val Fold 
change 
UniProt ID adj.P.Val Fold 
change 
sp|P08243|ASNS_HUMAN 0.0040 1.37 sp|O43837|IDH3B_HUMAN 0.2459 1.06 
sp|Q15119|PDK2_HUMAN 0.0105 1.41 sp|Q15120|PDK3_HUMAN 0.2556 1.20 
sp|P07195|LDHB_HUMAN 0.0285 1.37 sp|P09104|ENOG_HUMAN 0.2905 1.14 
sp|P18669|PGAM1_HUMAN 0.0349 -1.35 sp|P09622|DLDH_HUMAN 0.3608 1.13 
sp|P30613|KPYR_HUMAN 0.0395 1.22 sp|P06744|G6PI_HUMAN 0.3608 -1.16 
sp|P60174|TPIS_HUMAN 0.0544 -1.43 sp|P00338|LDHA_HUMAN 0.3608 1.13 
sp|P05062|ALDOB_HUMAN 0.0550 1.19 sp|P48735|IDHP_HUMAN 0.3608 1.07 
sp|P04406|G3P_HUMAN 0.0720 -1.42 sp|Q02218|ODO1_HUMAN 0.3629 -1.10 
sp|Q9NR19|ACSA_HUMAN 0.0726 1.55 sp|Q15118|PDK1_HUMAN 0.4310 -1.08 
sp|Q96I99|SUCB2_HUMAN 0.0726 1.38 sp|Q16798|MAON_HUMAN 0.4461 -1.13 
sp|P48163|MAOX_HUMAN 0.0784 -1.63 sp|P24752|THIL_HUMAN 0.4520 1.04 
sp|P00558|PGK1_HUMAN 0.0784 -1.26 sp|P23368|MAOM_HUMAN 0.4538 1.09 
sp|P19367|HXK1_HUMAN 0.1002 1.26 sp|Q16654|PDK4_HUMAN 0.4726 1.18 
sp|P09467|F16P1_HUMAN 0.1076 1.23 sp|P11413|G6PD_HUMAN 0.4761 1.09 
sp|P07205|PGK2_HUMAN 0.1081 1.26 sp|P07954|FUMH_HUMAN 0.4761 1.09 
sp|Q99798|ACON_HUMAN 0.1230 1.23 sp|P08559|ODPA_HUMAN 0.4803 1.09 
sp|P13929|ENOB_HUMAN 0.1230 1.13 sp|P07864|LDHC_HUMAN 0.4815 -1.03 
sp|P15259|PGAM2_HUMAN 0.1230 -1.24 sp|P14618|KPYM_HUMAN 0.4846 1.08 
sp|Q9UI32|GLSL_HUMAN 0.1230 1.12 sp|P36957|ODO2_HUMAN 0.4999 1.07 
sp|P08237|K6PF_HUMAN 0.1427 1.18 sp|P35557|HXK4_HUMAN 0.4999 1.05 
sp|P52790|HXK3_HUMAN 0.1489 1.11 sp|P06733|ENOA_HUMAN 0.5355 -1.16 
sp|Q01813|K6PP_HUMAN 0.1489 1.18 sp|P31040|DHSA_HUMAN 0.5732 1.10 
sp|P40925|MDHC_HUMAN 0.1495 1.26 sp|P50213|IDH3A_HUMAN 0.6132 -1.05 
sp|P15104|GLNA_HUMAN 0.1536 1.23 sp|P52789|HXK2_HUMAN 0.7760 -1.02 
sp|P04075|ALDOA_HUMAN 0.1635 1.35 sp|P51553|IDH3G_HUMAN 0.7814 -1.03 
sp|P17858|K6PL_HUMAN 0.1723 1.20 sp|P53597|SUCA_HUMAN 0.8446 -1.03 
sp|O00757|F16P2_HUMAN 0.1738 1.16 sp|O75874|IDHC_HUMAN 0.8613 1.02 
sp|P55809|SCOT1_HUMAN 0.1875 1.35 sp|P09972|ALDOC_HUMAN 0.8881 -1.04 
sp|P21399|ACOC_HUMAN 0.2293 1.25 sp|Q9NUB1|ACS2L_HUMAN 0.9899 1.00 
sp|O75390|CISY_HUMAN 0.2339 -1.27 sp|P21912|DHSB_HUMAN 0.9899 1.01 
sp|Q16665|HIF1A_HUMAN 0.2361 1.11 sp|P40926|MDHM_HUMAN 1.0000 1.01 
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Table F3: Targeted proteomics analysis of 5 mM DCA cultures compared to control cultures 
UniProt ID adj.P.Va
l 
Fold 
change 
UniProt ID adj.P.Va
l 
Fold 
change 
sp|P08243|ASNS_HUMAN 0.0559 1.18 sp|P00338|LDHA_HUMAN 0.8944 1.08 
sp|P30613|KPYR_HUMAN 0.0559 1.27 sp|Q16654|PDK4_HUMAN 0.8944 1.10 
sp|P40926|MDHM_HUMAN 0.0559 -1.70 sp|P21399|ACOC_HUMAN 0.8944 1.09 
sp|Q15119|PDK2_HUMAN 0.4210 1.21 sp|P36957|ODO2_HUMAN 0.8944 1.05 
sp|O75390|CISY_HUMAN 0.5480 0.65 sp|P06744|G6PI_HUMAN 0.8944 1.03 
sp|P18669|PGAM1_HUMAN 0.5480 -1.09 sp|Q99798|ACON_HUMAN 0.9551 1.05 
sp|P55809|SCOT1_HUMAN 0.5480 1.39 sp|Q16798|MAON_HUMAN 0.9551 -1.07 
sp|P31040|DHSA_HUMAN 0.5705 -1.37 sp|P00558|PGK1_HUMAN 0.9551 -1.05 
sp|P04075|ALDOA_HUMAN 0.6751 1.43 sp|P21912|DHSB_HUMAN 0.9551 1.04 
sp|O43837|IDH3B_HUMAN 0.7705 1.06 sp|P07195|LDHB_HUMAN 0.9566 1.04 
sp|Q96I99|SUCB2_HUMAN 0.7705 1.19 sp|P14618|KPYM_HUMAN 0.9576 1.05 
sp|P48735|IDHP_HUMAN 0.7705 1.09 sp|P50213|IDH3A_HUMAN 0.9576 1.03 
sp|P08237|K6PF_HUMAN 0.7705 1.11 sp|P15104|GLNA_HUMAN 0.9621 1.04 
sp|P09467|F16P1_HUMAN 0.8742 1.11 sp|P07954|FUMH_HUMAN 0.9708 1.03 
sp|P09622|DLDH_HUMAN 0.8944 -1.12 sp|Q02218|ODO1_HUMAN 0.9708 -1.03 
sp|P19367|HXK1_HUMAN 0.8944 1.10 sp|P08559|ODPA_HUMAN 0.9708 -1.03 
sp|P13929|ENOB_HUMAN 0.8944 1.06 sp|P23368|MAOM_HUMAN 0.9708 1.02 
sp|Q16665|HIF1A_HUMAN 0.8944 1.17 sp|P17858|K6PL_HUMAN 0.9708 1.03 
sp|O75874|IDHC_HUMAN 0.8944 -1.04 sp|P24752|THIL_HUMAN 1.0000 1.01 
sp|Q9NR19|ACSA_HUMAN 0.8944 1.17 sp|Q15118|PDK1_HUMAN 1.0000 -1.01 
sp|P60174|TPIS_HUMAN 0.8944 -1.10 sp|P09972|ALDOC_HUMAN 1.0000 1.04 
sp|P53597|SUCA_HUMAN 0.8944 -1.07 sp|P07864|LDHC_HUMAN 1.0000 1.01 
sp|P51553|IDH3G_HUMAN 0.8944 1.05 sp|P35557|HXK4_HUMAN 1.0000 1.01 
sp|P15259|PGAM2_HUMAN 0.8944 -1.04 sp|Q9UI32|GLSL_HUMAN 1.0000 -1.01 
sp|Q15120|PDK3_HUMAN 0.8944 1.11 sp|P52789|HXK2_HUMAN 1.0000 -1.00 
sp|P11413|G6PD_HUMAN 0.8944 1.04 sp|P48163|MAOX_HUMAN 1.0000 -1.01 
sp|P05062|ALDOB_HUMAN 0.8944 1.04 sp|O00757|F16P2_HUMAN 1.0000 1.01 
sp|Q01813|K6PP_HUMAN 0.8944 1.06 sp|P06733|ENOA_HUMAN 1.0000 1.01 
sp|Q9NUB1|ACS2L_HUMAN 0.8944 -1.06 sp|P04406|G3P_HUMAN 1.0000 -1.00 
sp|P07205|PGK2_HUMAN 0.8944 1.06 sp|P52790|HXK3_HUMAN 1.0000 1.00 
sp|P09104|ENOG_HUMAN 0.8944 1.07 sp|P40925|MDHC_HUMAN 1.0000 -1.00 
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Appendix G: Results of HEK293 cell transcriptomics 
Table G1: Differentially regulated genes in 10 mM DCA cultures compared to control cultures. 
Down-regulated 
Gene symbol Protein name 
Adj p-
value 
Fold 
change 
SNORA12 small nucleolar RNA, H/ACA box 12 0.00026 3.6540 
IGFBP5 insulin-like growth factor binding protein 5 0.00003 3.1069 
MYOM2 myomesin (M-protein) 2, 165kDa 0.00013 2.9970 
HS.572495 CDNA clone IMAGE:5268658 0.00012 2.5257 
HS.170035 Transcribed locus 0.00135 2.4412 
HS.335413 Uncharacterized LOC100134361 0.00103 2.4008 
TKTL1 transketolase-like 1 0.00258 2.3701 
HIST1H4K histone cluster 1, H4k 0.00189 2.3352 
HS.192506 Transcribed locus 0.00218 2.3072 
HIST2H2BE histone cluster 2, H2be 0.00256 2.2746 
C10ORF140 chromosome 10 open reading frame 140 0.00384 2.1327 
SNORD13 small nucleolar RNA, C/D box 13 0.00709 2.0989 
HAS2AS HAS2 antisense RNA (non-protein coding) 0.00189 2.0168 
GAS1 growth arrest-specific 1 0.00452 1.9843 
C18ORF56 chromosome 18 open reading frame 56 0.00632 1.9747 
PCDH19 protocadherin 19 0.00189 1.9663 
LOC100134361 Uncharacterized LOC100134361 0.00105 1.9648 
C3ORF31 chromosome 3 open reading frame 31 0.00288 1.9432 
SSPO SCO-spondin homolog (Bos taurus) 0.00560 1.9408 
C7ORF68 Hypoxia Inducible Lipid Droplet-Associated 0.00740 1.9315 
ASB9 ankyrin repeat and SOCS box containing 9 0.00462 1.8770 
HS.444913 Transcribed locus 0.00384 1.8620 
VASH2 vasohibin 2 0.00432 1.8203 
NOL12 nucleolar protein 12 0.00560 1.7881 
C9ORF169 chromosome 9 open reading frame 169 0.00505 1.7871 
LYPD1 LY6/PLAUR domain containing 1 0.00189 1.7704 
ZNF2 zinc finger protein 2 0.00323 1.7560 
SCNN1D sodium channel, non-voltage-gated 1, delta subunit 0.00813 1.7535 
CLYBL citrate lyase beta like 0.00372 1.7420 
GAL3ST4 galactose-3-O-sulfotransferase 4 0.00484 1.7400 
MRPL30 mitochondrial ribosomal protein L30 0.00646 1.7333 
LQK1 putative uncharacterized protein LQK1 0.00396 1.7127 
KIF15 kinesin family member 15 0.00996 1.7071 
LYRM7 Lyrm7 homolog (mouse) 0.00560 1.6829 
CCDC45 centrosomal protein of 95 kDa 0.00973 1.6691 
ARL17P1 ADP-Ribosylation Factor-Like 17A 0.00989 1.6611 
TCEA2 transcription elongation factor A (SII), 2 0.00452 1.6571 
BTBD12 SLX4 Structure-Specific Endonuclease Subunit 0.00996 1.6501 
LOC286467 Family With Sequence Similarity 195, Member A Pseudogene 0.00560 1.6475 
LHPP phospholysine phosphohistidine inorganic pyrophosphate phosphatase 0.00699 1.6455 
C20ORF7 chromosome 20 open reading frame 7 0.00651 1.6348 
IFIT1 interferon-induced protein with tetratricopeptide repeats 1 0.00755 1.6248 
PDK3 pyruvate dehydrogenase kinase, isozyme 3 0.00996 1.6057 
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LOC439949 PRKCQ Antisense RNA 1 0.00989 1.6013 
OSGEPL1 O-sialoglycoprotein endopeptidase-like 1 0.00740 1.5979 
ALDH4A1 aldehyde dehydrogenase 4 family, member A1 0.00997 1.5973 
CTSL2 cathepsin L2 0.00976 1.5805 
FLJ39827 APC membrane recruitment protein 1 0.00996 1.5438 
Up-regulated 
Gene symbol Protein name 
Adj p-
value 
Fold 
change 
INHBE inhibin, beta E 0.00002 5.1378 
SESN2 sestrin 2 0.00189 3.6613 
ETV5 ets variant 5 0.00008 3.2484 
TNFRSF12A tumor necrosis factor receptor superfamily, member 12A 0.00218 3.1621 
TNNT1 troponin T type 1 (skeletal, slow) 0.00560 2.9702 
DDIT3 DNA-damage-inducible transcript 3 0.00065 2.8866 
ETV4 ets variant 4 0.00406 2.8155 
LOC387763 Chromosome 11 open reading frame 96 0.00007 2.7634 
DDIT4 DNA-damage-inducible transcript 4 0.00005 2.7388 
LTBR lymphotoxin beta receptor (TNFR superfamily, member 3) 0.00126 2.6747 
MIR1974 microRNA 1974 0.00168 2.6678 
HMOX1 heme oxygenase (decycling) 1 0.00026 2.6297 
MICALL1 MICAL-like 1 0.00065 2.5090 
SLC4A2 solute carrier family 4, anion exchanger, member 2  0.00972 2.4845 
IRF2BP1 interferon regulatory factor 2 binding protein 1 0.00626 2.4165 
INA internexin neuronal intermediate filament protein, alpha 0.00013 2.4057 
STC2 stanniocalcin 2 0.00026 2.2996 
CHAC1 ChaC, cation transport regulator homolog 1  0.00462 2.2851 
ULBP1 UL16 binding protein 1 0.00168 2.2554 
PLAGL1 pleiomorphic adenoma gene-like 1 0.00679 2.2505 
IRX4 iroquois homeobox 4 0.00084 2.2310 
SLC7A5 solute carrier family 7 (amino acid transporter light chain, L system), 
member 5 0.00042 2.2279 
GDF15 growth differentiation factor 15 0.00505 2.2220 
SGSH N-sulfoglucosamine sulfohydrolase 0.00218 2.2129 
SLC3A2 solute carrier family 3 (activators of dibasic and neutral amino acid 
transport), member 2 0.00084 2.2083 
IRAK1 interleukin-1 receptor-associated kinase 1 0.00189 2.1979 
CEBPB CCAAT/enhancer binding protein (C/EBP), beta 0.00117 2.1597 
LOC392437 Ferritin, Light Polypeptide Pseudogene 0.00158 2.1308 
PLP2 proteolipid protein 2 (colonic epithelium-enriched) 0.00189 2.0884 
CYBASC3 cytochrome b, ascorbate dependent 3 0.00202 2.0738 
KCNK12 potassium channel, subfamily K, member 12 0.00967 2.0733 
TMEM54 transmembrane protein 54 0.00524 2.0527 
GADD45B growth arrest and DNA-damage-inducible, beta 0.00189 2.0473 
ANXA3 annexin A3 0.00318 2.0430 
ORMDL3 ORM1-like 3 (S. cerevisiae) 0.00258 2.0297 
LPPR2 lipid phosphate phosphatase-related protein type 2 0.00772 2.0192 
CHGB chromogranin B (secretogranin 1) 0.00524 2.0126 
SCAMP5 secretory carrier membrane protein 5 0.00452 2.0098 
BCAT1 branched chain amino-acid transaminase 1, cytosolic 0.00228 1.9834 
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EPR1 effector cell peptidase receptor 1 (non-protein coding) 0.00682 1.9806 
CDC42EP1 CDC42 effector protein (Rho GTPase binding) 1 0.00190 1.9794 
XKR8 XK, Kell blood group complex subunit-related family, member 8 0.00276 1.9786 
SLC1A5 solute carrier family 1 (neutral amino acid transporter), member 5 0.00354 1.9640 
XYLB xylulokinase homolog (H. influenzae) 0.00491 1.9490 
PCK2 phosphoenolpyruvate carboxykinase 2 (mitochondrial) 0.00646 1.9430 
LOC143666 Uncharacterized LOC143666 0.00189 1.9316 
SRXN1 sulfiredoxin 1 0.00189 1.9287 
ZNF416 zinc finger protein 416 0.00920 1.9223 
SYP synaptophysin 0.00505 1.9201 
ASNS asparagine synthetase (glutamine-hydrolyzing) 0.00105 1.9173 
MORC2 MORC family CW-type zinc finger 2 0.00258 1.9172 
CRMP1 collapsin response mediator protein 1 0.00189 1.9153 
NPLOC4 nuclear protein localization 4 homolog (S. cerevisiae) 0.00920 1.9009 
IFRD1 interferon-related developmental regulator 1 0.00189 1.8929 
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 0.00709 1.8898 
EMP3 epithelial membrane protein 3 0.00258 1.8806 
NFE2L1 nuclear factor (erythroid-derived 2)-like 1 0.00326 1.8710 
ISG20 interferon stimulated exonuclease gene 20kDa 0.00189 1.8575 
SAPS1 protein phosphatase 6, regulatory subunit 1 0.00632 1.8559 
S100P S100 calcium binding protein P 0.00462 1.8533 
MTHFD1L methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like 0.00168 1.8506 
CHPF2 chondroitin polymerizing factor 2 0.00740 1.8475 
CYTH1 cytohesin 1 0.00646 1.8444 
CORO1B coronin, actin binding protein, 1B 0.00740 1.8313 
MARS methionyl-tRNA synthetase 0.00189 1.8290 
EPCAM epithelial cell adhesion molecule 0.00362 1.8180 
SPR sepiapterin reductase (7,8-dihydrobiopterin:NADP+ oxidoreductase) 0.00920 1.8118 
C19ORF51 chromosome 19 open reading frame 51 0.00524 1.8026 
ZNF766 zinc finger protein 766 0.00920 1.7969 
LOC100132139 similar to methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 1-like 0.00644 1.7945 
CTH cystathionase (cystathionine gamma-lyase) 0.00189 1.7845 
PERP PERP, TP53 apoptosis effector 0.00632 1.7800 
ZNF502 zinc finger protein 502 0.00432 1.7764 
MTHFD2 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase 0.00218 1.7763 
LOC644132 similar to basic-leucine zipper transcription factor MafG 0.00524 1.7714 
SLC6A9 solute carrier family 6 (neurotransmitter transporter, glycine), member 
9 0.00500 1.7642 
TK1 thymidine kinase 1, soluble 0.00452 1.7617 
XBP1 X-box binding protein 1 0.00208 1.7602 
GLIPR1 GLI pathogenesis-related 1 0.00578 1.7578 
FADS1 fatty acid desaturase 1 0.00996 1.7563 
BSPRY B-box and SPRY domain containing 0.00996 1.7531 
MID1IP1 MID1 interacting protein 1 0.00552 1.7521 
TRIB3 tribbles homolog 3 (Drosophila) 0.00475 1.7453 
FKBPL FK506 binding protein like 0.00989 1.7382 
157 
 
GTF3C1 general transcription factor IIIC, polypeptide 1, alpha 220kDa 0.00462 1.7283 
AGPAT9 1-acylglycerol-3-phosphate O-acyltransferase 9 0.00709 1.7173 
SLC35D2 solute carrier family 35, member D2 0.00740 1.7130 
HSD17B14 hydroxysteroid (17-beta) dehydrogenase 14 0.00704 1.6997 
CBS cystathionine-beta-synthase 0.00560 1.6837 
NR0B1 nuclear receptor subfamily 0, group B, member 1 0.00570 1.6819 
ARAP3 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 0.00646 1.6814 
CYR61 cysteine-rich, angiogenic inducer, 61 0.00835 1.6802 
FLNC filamin C, gamma 0.00740 1.6798 
TRIP6 thyroid hormone receptor interactor 6 0.00681 1.6792 
SREBF1 sterol regulatory element binding transcription factor 1 0.00996 1.6694 
STX3 syntaxin 3 0.00975 1.6685 
ZNF134 zinc finger protein 134 0.00646 1.6551 
MTA2 metastasis associated 1 family, member 2 0.00892 1.6515 
CD44 CD44 molecule (Indian blood group) 0.00976 1.6492 
MBD3 methyl-CpG binding domain protein 3 0.00864 1.6487 
TAC1 tachykinin, precursor 1 0.00453 1.6457 
SH2B3 SH2B adaptor protein 3 0.00835 1.6418 
RIMS3 regulating synaptic membrane exocytosis 3 0.00424 1.6351 
LOC645166 lymphocyte-specific protein 1 pseudogene 0.00646 1.6302 
DHRS2 dehydrogenase/reductase (SDR family) member 2 0.00835 1.6255 
SEZ6L2 seizure related 6 homolog (mouse)-like 2 0.00940 1.6235 
PPIF peptidylprolyl isomerase F 0.00989 1.6234 
LOC342979 paralemmin 3 0.00989 1.6204 
ZNF763 zinc finger protein 763 0.00659 1.5933 
ADORA2B adenosine A2b receptor 0.00524 1.5825 
SLC45A3 solute carrier family 45, member 3 0.00975 1.5801 
SHMT2 serine hydroxymethyltransferase 2 (mitochondrial) 0.00644 1.5782 
HERPUD1 homocysteine-inducible, endoplasmic reticulum stress-inducible, 
ubiquitin-like domain member 1 0.00644 1.5630 
SPINT2 serine peptidase inhibitor, Kunitz type, 2 0.00922 1.5417 
ZNF274 zinc finger protein 274 0.00996 1.5175 
KCTD15 potassium channel tetramerisation domain containing 15 0.00996 1.4912 
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Appendix H: Generating a stable HEK293 cell line 
overexpressing resistin-like molecule β using a Tet-On 3G 
inducible expression system 
H.1. Introduction 
Transfection of cells is usually followed first by a selection for cells that incorporated the 
gene of interest (GOI) in their genome and then by a single cell selection to obtain single 
cell clones with desired GOI expression from a pool of transfected cells. In Dietmair et al. 
an HEK293F cell line was transfected to express a recombinant protein and the obtained 
single cell clone showed also reduced glucose consumption. Transcriptomics analysis of 
that clone revealed an about 66 times higher expression of resistin-like molecule beta 
(RETNLB) mRNA (Dietmair et al. 2012). RETNLB belongs to a family of Cysteine rich 
sercreted protein composed of resisitn, resisitn like α and RETNLB (Steppan, Brown, et al. 
2001). These proteins, particularly resisitin, have been linked to insulin resistance and 
diabetes (Kushiyama et al. 2005; Rajala et al. 2003; Schwartz & Lazar 2011; Steppan, 
Bailey, et al. 2001). It was hsown that RETNLB over expression I rate skeletal muscle cells 
reduced glucose uptake (Moon et al. 2003). However, the role of RETNLB in humans or 
human cell lines has been hardly investigated (Neilson et al. 2011; Zheng et al. 2012) and 
further explorations are needed to clearly elucidate RETNLB metabolic role.  
Single cell clone selection can lead to the selection of a clone that is different from the 
parental cell line in addition to the GOI and that can be a problem if the effect of a single 
gene is investigated. One possible approach to avoid the unintended selection for other 
cellular characteristics is to use an inducible expression system. A cell line is first 
transfected with a transactivator protein followed by the transfection of the GOI together 
with the inducible promoter. Using a tetracycline-controlled transcriptional activation 
system only one cell line is generated in which the expression of the GOI can be induced 
by adding doxycycline (Dox) to the cell culture (Figure H1). Here, an HEK293 cell line was 
transfected with a Tet-On 3G transactivator protein followed by the transfection with 
RETNLB that is under the control of a TRE3G promoter (PTRE3G). 
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Figure H1: Tet-On 3G system allows inducible gene expression. Cells constantly express the Tet-On 3G 
transactivator protein. Dox binds to the Tet-On 3G transactivator causing a conformational change allowing it 
to bind to the tet operator sequence located in the TRE3G promoter (PTRE3G) activating the expression of the 
GOI (figure adapted from Tet-On 3G Inducible Expression Systems User Manual (Clontech)).  
 
H.2. Material and methods 
H.2.1. Cell culture, transfection and single cell selection 
HEK293F cells (LifeTechnologies) were cultivated in Freestyle 293 expression medium 
(LifeTechnologies) supplemented with 4 mM GlutaMAX (LifeTechnologies), 0.2% v/v Anti-
Clumping agent (LifeTechnologies) and 5% v/v fetal calf bovine serum (Thermo Scientific). 
Cells were cultivated in vented shake flasks in humidified incubators set to 37°C, 7.5% 
CO2, and 130 rpm. Cells were first transfected with the pCMV-Tet3G plasmid using 
FreeStyle MAX reagent (LifeTechnologies) according to manufacturer’s instructions. 
Geneticin (LifeTechnologies) was used to select for cells that integrated the plasmid. 
Single cell selection was performed using limited dilution and 47 single cell clones were 
obtained of which 18 were tested for Tet-On transactivator mRNA expression using qRT-
PCR. RNA was extracted using the RNA Mini Kit (Qiagen) with on-column DNA digestion 
using the RNase-Free DNase Set (Qiagen). cDNA was synthesized using the ProtoScript 
M-MuLV First Strand cDNA Synthesis Kit (New England BioLabs) and subjected to qRT-
PCR described below.  
GOI P
TRE3G
 
Promoter 
GOI P
TRE3G
 
Promoter 
Tet-On 3G 
Transactivator 
Doxycycline 
No 
Dox 
Dox 
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Five clones with the highest Tet-On transactivator mRNA expression were transiently 
transfected with the pTRE3G-Luc plasmid (Clontech) using FreeStyle MAX reagent. 500 
ng/ml doxycycline (Dox) was added 4 hours after transfection to the cell culture and 
incubated for 24 hours. Cells were harvested and luciferase activity was analyzed using 
the Luciferase Assay System (Promega) according to manufacturer’s instructions. The 
clone with highest fold change in luciferase assay was then transfected with the pTRE3G-
RETNLB plasmid and Linear Puromycin Marker (Clontech) using FreeStyle MAX reagent. 
After 96 hours, puromycin dihydrochloride (LifeTechnologies) was added to the cell culture 
to select for cells with integrated puromycin marker. Before single cell selection, a sample 
from the transfected pool was analyzed for inducible RETNLB mRNA expression. Cells 
were cultivated in a 6-well plate in duplicates and 500 ng/ml Dox was added to one well. 
Cells were incubated for 48 hours, harvested, mRNA was extracted, cDNA was 
synthesized as described before followed by qRT-PCR analysis. This was followed by 
single cell selection using limited dilution and 18 single cell clones were obtained. Single 
cell clones were analyzed for RETNLB mRNA expression as described before. Glucose 
concentration in cell culture supernatant was measured using a Nova Bioprofiler FLEX 
(Nova Biomedical). 
H.2.2. Generation of pTRE3G-RETNLB plasmid 
The RETNLB clone from the lentiviral human ORF expression library (Škalamera et al. 
2012) was obtained from the ARVEC facility at the University of Queensland Diamantina 
Institute. The RETNLB gene was amplified by PCR into a pBluescript vector and 
transformed into E.coli. A white colony containing the vector with insert was selected using 
blue/white screening induced by X-gal and IPTG. The RETNLB gene was than digested 
from the pBluescript clone and ligated into the pTRE3G vector. Clones were screened for 
the presence of the insert by restriction digest. The final construct was submitted to AGRF 
(AGRF Brisbane) for sequencing to ensure that correct RETNLB sequence is present in 
pTRE3G-RETNLB plasmid.  
H.2.3. qRT-PCR 
A Rotor-Gene 3000A (Corbett Research) and SsoAdvanced SYBR Green Supermix (Bio-
Rad) were used according to manufacturer’s instructions for qRT-PCR. The following 
primer pairs were used. 
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Table H1: Primer pairs used for qRT-PCR 
Tet-On 3G F1 5'- CCG TGG GCC ACT TTA CAC -3' 
Tet-On 3G R1 5'- AAA AGG AAG GCA GGT TCG -3' 
Tet-On 3G F2 5'- CAA CGC CAA GTC ATA CCG -3' 
Tet-On 3G R2 5'- ACG CAG CCC AGT GTA AAG -3' 
YWHAZ F 5'- ACT TTT GGT ACA TTG TGG CTT CAA -3' 
YWHAZ R 5'- CCG CCA GGA CAA ACC AGT AT-3' 
RETNLB F1 5’- CCG GGG AGT ACT CAG TGT TCC T -3’ 
RETNLB R1 5’- TGA CAC TAG CAC ACG AGA GCT -3’ 
RETNLB F2 5’- GTC AAA AGC CAA GGC AGA CCG -3’ 
RETNLB R2 5’- ACG AAC CAC AGC CAT AGC CAC -3’ 
 
H.3. Results and discussion 
H.3.1. qRT-PCR of Tet-On transactivator transfected cells 
In total 18 single cell clones were tested for Tet-On transactivator mRNA expression using 
qRT-PCR. The qRT-PCR data was analyzed using the comparative Ct method (also 
known as the 2-ΔΔCt method) comparing Tet-On transactivator single cell clones with the 
Tet-On transactivator cell pool. The five single cell clones with the highest Tet-On 
transactivator mRNA expression compared to the cell pool are shown in Table H2. 
Table H2: Clones with highest relative Tet-On transactivator mRNA expression. Clones with highest 
Tet-On transactivator mRNA expression relative to housekeeping enzyme, YWHAZ, mRNA expression. Two 
primer pairs were used for Tet-On transactivator mRNA and one primer pair for YWHAZ (Tyrosine 3-
Monooxygenase/ Tryptophan 5-Monooxygenase Activation Protein Zeta Polypeptide) mRNA. Ct = cycle 
threshold. 
 
Ct Primer 
Tet-On 1 
Ct Primer 
Tet-On 2 
Ct Primer 
YWHAZ 
Mean Fold 
change (2-ΔΔCt)  
7 10.13 9.86 14.55 2.7962 
46 11.31 11.13 15.19 1.8690 
28 10.68 10.19 13.98 1.3851 
22 10.66 10.35 14.39 1.7559 
34 10.84 10.37 15.07 2.6208 
 
H.3.2. Luciferase assay 
Five clones with high Tet-On transactivator mRNA expression (Table H2) were transiently 
transfected with pTRE3G-Luc plasmid. 500 ng/ml doxycycline (Dox) was added 4 hours 
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after transfection to the cell culture, incubated for 24 hours and luciferase assay was 
performed (Table H3). 
 
Table H3: Luciferase assay results. Five clones with high Tet-On transactivator mRNA expression were 
analyzed using the luciferase assay. Clone 22 had the highest fold change.  RLU = relative light unit.  
 
 
 
 
 
 
 
Although, all clones showed high Tet-On transactivator mRNA expression, the fold 
changes in the luciferase assay were quite different. Clone 22 had the highest fold change 
and was used for transfection with the pTRE3G-RETNLB plasmid and Linear Puromycin 
Marker. 
H.3.3. qRT-PCR and RETNLB sequencing of RETNLB transfected cell pool 
After transfection with the pTRE3G-RETNLB plasmid and Linear Puromycin Marker and 
before single clone selection the cell pool was tested for inducible RETNLB expression. 
Cells were cultivated with 500 ng/ml Dox for 48 hours or without Dox as control. qRT-PCR 
gave good signals for RETNLB mRNA in cells treated Dox whereas only a very week 
signal was obtained from cells cultivated without Dox (Table H4).  
Table H4: Relative mRNA expression of RETNLB with and without Dox. RETNLB transfected cell pool 
was analyzed for RETNLB mRNA expression when cultivated with 500 ng/ml Dox for 48 hours and without 
Dox. Ct = cycle threshold, YWHAZ = Tyrosine 3-Monooxygenase/ Tryptophan 5-Monooxygenase Activation 
Protein Zeta Polypeptide. 
 
 
Ct Primer 
RETNLB 1 
Ct Primer 
RETNLB 2 Ct Primer YWHAZ 
22 33.41 30.3 14.62 
22 + DOX 20.09 20.43 14.98 
 
Due to the slight difference in Ct of untreated clone 22 and the much higher Ct compared 
to the treated cells (22 + DOX), the fold changes for primer RETNLB 1 was 13124.73 and 
for primer pair RETNLB 2 was 1200.98. Therefore, DOX induces RETNLB mRNA 
expression in the transfected pool 22. 
clone +Dox RLU -Dox RLU 
fold 
change 
7 8260000 66654 123.92 
46 9200000 64320 143.04 
28 5660000 103134 54.88 
22 8660000 30789 281.27 
34 4580000 303751 15.08 
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PCR amplified cDNA derived from extracted RNA samples was submitted for sequencing 
to AGRF (AGRF Brisbane) to ensure transfected RETNLB gene sequence is correct. The 
resulting sequence showed a 100% match with the RETNLB sequence confirming that no 
mutations in the RETNLB gene occurred during transfection and subsequent puromycin 
selection. 
A single cell selection followed and 18 clones were obtained and analyzed for RETNLB 
mRNA expression using 500 ng/ml Dox treatment for 48 hours. One clone, clone 18, 
showed inducible RETNLB expression (Table H5) with an average fold change of 4775 
while the remaining clones tested showed no increased RETNLB expression. 
 
Table H5: Relative mRNA expression of RETNLB with and without Dox. RETNLB transfected cell clone 
18 was analyzed for RETNLB mRNA expression when cultivated with 500 ng/ml Dox for 48 hours and 
without Dox. Ct = cycle threshold, YWHAZ = Tyrosine 3-Monooxygenase/ Tryptophan 5-Monooxygenase 
Activation Protein Zeta Polypeptide. 
 
 
Ct Primer 
RETNLB 1 
Ct Primer 
RETNLB 2 Ct Primer YWHAZ 
Clone 18 
+ DOX 
12.53 12.99 13.21 
Clone 18 
no DOX 
25.98 25.94 14.21 
 
However, the RETNLB mRNA expression in non-induced cells is higher than oberserved 
in non-induced cell pool (Table H4) indicating that the TRE3G promoter is leaky in clone 
18 causing a constant low RETNLB mRNA expression. 
H.3.4. Glucose concumption in RETNLB expression induced and non-induced HEK293F 
cell 
Triplcate shake flask cultures of clone 18 with either 500 ng/ml Dox or no Dox (control) 
were analyzed for glucose consumption. The glucose consumption rates between during 
exponential growth (16 – 72 hours) are shown in Table H6. 
 
Table H6: Mean glucose consumption rate of RETNLB expression induced and non-induced cells. 
 
500 ng/ml Dox contol 
- 269.55 ± 15.70 -265.31 ± 14.27 
 
No difference in glucose consumption was oberserved between induced and non-induced 
cells indicating that RETNLB overexpression does not reduce glucose consumption in 
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HEK293F cells. However, as the system is leaky the result is not conclusive. RETNLB 
expression at the constant low level detected in non-induced cells may already reduce 
glucose consumption and further increase in RETNLB expression in induced cells does 
not lower glucose consumption any further. Further explorations are needed, e.g. 
comparing glucose consumption of parental cell line and RETNLB transfected cell line. 
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Appendix I: Summary of studies that investigated DCA’s effects on cancer cells in vitro and in 
vivo 
 
Table I1: Publications investigating DCA’s effects on cancer, DCA concentrations used, cell lines and in vivo models, and major effects of DCA. 
Reference DCA conc. used Cell line used        Major effects of DCA 
Bonnet et al. 2007 0.5-5.0 mM A549, MO59K and MCF-7 cancer 
cells 
Healthy SAEC cells 
- Reduced lactate production 
- Depolarized mitochondria in cancer but not healthy cells 
- DCA is selective for cells with high membrane potential and low K
+
 channel Kv1.5 expression 
- Induced mitochondrial apoptosis in A549 cells 
- Decreased tumor size in rats 
Michelakis et al. 2010 0.5-5.0 mM 
6.25-25 mg/kg 
twice/day 
Glioblastoma cells 
Glioblastoma patients 
- Reversed mitochondrial hyperpolarization 
- Inhibits PDK 2 activity in vivo 
- Inhibited HIF-1α 
- Activated p53 
Cairns et al. 2007 50 mg/kg  RKO and  
RKOShHIF1α tumors in mice 
- Increased oxygen consumption in RKO tumors from mice 
- Delayed tumor growth in combination with tirapazamine 
Niewisch et al. 2012 250 µM -2 mM Neuroblastoma: Kelly, SK-N-SH, and 
LS cells 
- Reduced glucose consumption and lactate production 
- Increased oxygen consumption in Kelly cells 
- Reduced oxygen consumption in SK-N-SH cells 
- Only minor induction of apoptosis at 1mM in LS cells 
McFate et al. 2008 5.0-20.0 mM HNSCC cell lines UM-22A and UM-
22B 
- Decreased PDHα phosphorylation and lactate production only in UM-22A but not in UM-22B cells 
- toxic in UM-22B cells but not UM-22A cells 
Hanberry, Berger & Zastre 2014 0.0001-100 mM SK-N-BE and Panc-1 cancer cell 
lines 
- DCA reduced mitochondrial membrane potential 
- DCA reduced cell proliferation 
Heshe et al. 2010 0.1-50 mM 18 permanent human tumor cell lines - only increased apoptotic rate sparsely at 10mM 
- 80% apoptotic cells at 50mM 
- Dose- and time-dependent reduction of mitochondrial membrane potential in CCRF-CEM cells 
Stockwin et al. 2010 0.5-100 mM 
500 mg/kg/day 
Panel of normal and cancer cell lines 
A549 rat xenografts 
- DCA depolarizes mitochondria of cancer an normal cells  
- DCA is not selective for cancer cells  
- DCA has enhanced activity in cells with defective electron transport chain 
Wong et al. 2008 1-10 mM Panel of endometrial cancer cells - DCA induced apoptosis in most low to moderately invasive but was ineffective in highly invasive cancer 
cell tested  
- Apoptosis was consistent with decreased MMP, decreased Survivin expression, NFAT-Kv1.5-mediated 
pathways and p53-PUMA-mediated mechanism 
Sun et al. 2010 1-5 mM 
23-200 mg/kg/day 
Panel of breast cancer cell lines  
Breast cancer in vivo model 
- Reduced proliferation without increase in cell death 
 
Madhok et al. 2010 10-100 mM Panel of colorectal cancer  - DCA decreased proliferation associated with apoptosis and G2 phase cell cycle arrest in cancerous 
cells but not normal cells 
Cao et al. 2008 0.5-1 mM Prostate cancer cells - DCA increased apoptotic rate, was associated with G1 cell  cycle arrest 
- DCA sensitized cells to irradiation 
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Ohashi et al. 2013 2-10 mM 
25-100 mg/kg/day 
 
Splenocytes and B16 melanoma 
cells 
Panel of mouse strains 
- DCA increased antitumor immunotherapeutic activity in CD8+ T cell- and NK cell-sensitive tumor 
models 
Shahrzad et al. 2010 10 mM 
150 mg/kg/day 
Colorectal cancer cell lines and 
mouse xenografts 
- Induced apoptosis under normoxia 
- DCA acted as a cytoprotective for some colorectal cancer cells under hypoxic conditions 
Sorokina et al. 2011 86 mg/kg Sarcoma 37 cell mouse xenografts - DCA increases the cytotoxic activity of arsenic trioxide which correlates with decreased c-Myc , HIF1-α 
and Bcl-2 expression 
Sun et al. 2011 1-5 mM Panel of breast cancer cells - Combination of DCA and arsenic trioxide was more effective in inhibiting cell proliferation than either 
drug alone 
- DCA alone decreased HIF1α expression but increased ATPβ and Bcl-2 expression 
- DCA increased PDC activity 
Vella et al. 2012 50 mM 
2.5 – 25 
mg/kg/day 
Neuroblastoma cell lines and mouse 
xenografts 
- DCA decreased proliferation without induction of apoptosis in vitro and in vivo 
- DCA was more effective on very malignant and fully proliferating  cells compared to poorly malignant, 
more differentiated cells 
Ayyanathan et al. 2012 1-50 mM A549 and SCC25 cancer cells - DCA enhances killing of cells by anticancer drug Sulindac involving ROS production, mitochondrial 
dysfunction, JNK signalling and induction of apoptosis 
Kumar et al. 2012 1-40 mM Panel of cancer cell lines and  T-cell 
lymphoma cell lines 
Dalton’s lumphoma mouse strain 
- DCA induces apoptosis in tumor cells associated with increased ROS 
- Expression of HIF1-α, HSP70 and Bcl2 were inhibited 
- Expression of PUMA, p53, caspase-3 and CAD was increased 
Kumar A. et al. 2013 112 mg/kg/day Dalton’s lymphoma mouse 
xenografts 
- DCA chemosensitized cells to cisplatin 
- DCA increased survival of mice, reduced tumor volume, increased number of apoptotic cells, increased 
number of Annexin-V and TUNEL positive cells, increased ROS 
Fiebiger et al. 2011 10 mM Lung carcenoid cell lines (UMC-11, 
H727 and H835) 
- DCA inhibited cell growth of UMC-1 cells 
- DCA sensitized UMC-1 cells against novel platinum-based chemotherapeutic drugs 
Hur et al. 2013 10-100 mM Gastric cancer tissues from patients 
Gastric cancer cell lines 
- DCA increased responsiveness to 5-Fluorouracil in cell lines with high expression of PDK-1 
Ishiguro et al. 2012 0.45-1.35 mM 
50mg/kg/day 
HT1080 fibrosarcoma and RKO 
colon cancer cells 
HT1080 mouse xenografts 
- DCA and omeprazole had higher antitumor activity than DCA alone 
- Effect of DCA combined with omeprazole was reversed by vitamin E and caspase inhibitor Z-VAD-FMK 
Shen et al. 2013 0-60 mM 
10-100 mg/kg/day 
Hepatocellular carcinoma cell lines 
and mouse xenografts 
- DCA increased ROS and ATP 
- DCA sensitized sorafenib-resistant cells to sorafenib-induced apoptosis 
- Combination of DCA and sorafenib resulted in better tumor regression in mice than sorafenib alone 
Xie et al. 2011 2-16 mM HeLa cells - DCA increased intracellular H2O2 and pH levels, decrease in MMP, increase of caspase 3 and 9, 
increased Kv1.5 expression  
- Synergistic effect of DCA and Cisplatin 
 
 
 
 
